<SEC-DOCUMENT>0001047469-17-003071.txt : 20170428
<SEC-HEADER>0001047469-17-003071.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170428172102
ACCESSION NUMBER:		0001047469-17-003071
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170629
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170428
EFFECTIVENESS DATE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33277
		FILM NUMBER:		17797200

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231996zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg47801_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> MADRIGAL PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=574655,FOLIO='blank',FILE='DISK106:[17ZBJ1.17ZBJ47801]BA47801A.;3',USER='CHE107324',CD='28-APR-2017;01:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g73532.jpg" ALT="LOGO" WIDTH="300" HEIGHT="67">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;28, 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
Our Stockholders: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the 2017 Annual Meeting of Stockholders of Madrigal Pharmaceuticals,&nbsp;Inc. to be held at 9:00&nbsp;a.m. Eastern Time on Thursday,
June&nbsp;29, 2017, at Philadelphia Marriott West, 111 Crawford Avenue, Conshohocken, Pennsylvania 19428. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details
regarding the meeting, the business to be conducted at the meeting, and information about Madrigal Pharmaceuticals,&nbsp;Inc. that you should consider when you vote your shares
are described in this proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, two persons will be elected to our Board of Directors. In addition, we will ask stockholders to ratify the selection of PricewaterhouseCoopers&nbsp;LLP as our
independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2017, to approve an amendment to our 2015 Stock Plan to increase the total number of shares of our common
stock available for issuance under the 2015 Stock Plan by 1,000,000 shares, and to approve the compensation of our named executive officers, as disclosed in this proxy statement. The Board of
Directors recommends the approval of each of these proposals. Such other business will be transacted as may properly come before the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
hope you will be able to attend the Annual Meeting. </FONT><FONT SIZE=2><B>Your vote is very important, regardless of the number of shares you own</B></FONT><FONT SIZE=2>. Whether
you plan to attend the Annual Meeting or not, it is important that you cast your vote either in person or by proxy. You may vote over the Internet as well as by telephone or by mail. When you have
finished reading the proxy statement, you are urged to vote in accordance with the instructions set forth in this proxy statement. We encourage you to vote by proxy so that your shares will be
represented and voted at the meeting, whether or not you can attend. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thank
you for your continued support of Madrigal Pharmaceuticals,&nbsp;Inc. We look forward to seeing you at the Annual Meeting. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Sincerely,<BR>
/s/&nbsp;PAUL A. FRIEDMAN, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul A. Friedman, M.D.<BR></FONT> <FONT SIZE=2><I>Chairman of the Board and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>YOUR VOTE IS IMPORTANT.<BR>
PLEASE CAST YOUR VOTE PROMPTLY.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=357862,FOLIO='blank',FILE='DISK106:[17ZBJ1.17ZBJ47801]BC47801A.;6',USER='CHE107324',CD='28-APR-2017;01:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g73532.jpg" ALT="GRAPHIC" WIDTH="300" HEIGHT="67">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>MADRIGAL PHARMACEUTICALS,&nbsp;INC.<BR>
NOTICE OF&nbsp;2017 ANNUAL MEETING OF STOCKHOLDERS<BR>
TO BE HELD ON JUNE 29, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>TIME:&nbsp;&nbsp;&nbsp;&nbsp;9:00&nbsp;a.m. ET </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>DATE:&nbsp;&nbsp;&nbsp;&nbsp;Thursday,
June&nbsp;29, 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PLACE:&nbsp;&nbsp;&nbsp;&nbsp;Philadelphia
Marriott West, 111 Crawford Avenue, Conshohocken, Pennsylvania 19428 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PURPOSES:
</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
elect two directors to serve three-year terms expiring in 2020;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2017;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
approve an amendment to our 2015 Stock Plan to increase the total number of shares of our common stock available for issuance under the 2015 Stock Plan by
1,000,000 shares, in the form attached as Annex&nbsp;A to the accompanying proxy statement;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation
disclosure rules of the Securities and Exchange Commission; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
transact such other business that is properly presented at the meeting and any adjournments or postponements thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>WHO
MAY VOTE: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may vote if you were the record owner of our common stock at the close of business on May&nbsp;1, 2017. A list of stockholders of record will be available at the meeting and,
during the 10&nbsp;days prior to the meeting, at our principal executive offices located at 200 Barr Harbor Drive, Suite&nbsp;400, West Conshohocken, Pennsylvania 19428. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
stockholders are cordially invited to attend the Annual Meeting. </FONT><FONT SIZE=2><B>Whether you plan to attend the Annual Meeting or not, we urge you to vote and submit your
proxy by the Internet, telephone or mail in order to ensure the presence of a quorum</B></FONT><FONT SIZE=2>. You may change or revoke your proxy at any time before it is voted at the meeting. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>BY ORDER OF THE BOARD OF DIRECTORS</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;PAUL A. FRIEDMAN, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul A. Friedman, M.D.<BR></FONT> <FONT SIZE=2><I>Chairman of the Board and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>April&nbsp;28,
2017 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=889570,FOLIO='blank',FILE='DISK106:[17ZBJ1.17ZBJ47801]BE47801A.;5',USER='CHE107324',CD='28-APR-2017;01:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg47801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG47801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg47801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG47801_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#INR"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 29,
2017</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#INR"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_important_information___da402386"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_important_information___da402386"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_why_is_the_company_soliciting_my_proxy_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Why is the Company Soliciting My Proxy?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_why_is_the_company_soliciting_my_proxy_"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_who_can_vote_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Who Can Vote?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_who_can_vote_"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_how_many_votes_do_i_have_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>How Many Votes Do I Have?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_how_many_votes_do_i_have_"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_how_do_i_vote_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>How Do I Vote?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_how_do_i_vote_"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_how_does_the_board_of_director__how02885"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>How Does the Board of Directors Recommend That I Vote on the
Proposals?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_how_does_the_board_of_director__how02885"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_may_i_change_or_revoke_my_proxy_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>May I Change or Revoke My Proxy?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_may_i_change_or_revoke_my_proxy_"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_what_if_i_receive_more_than_one_proxy_card_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>What if I Receive More Than One Proxy Card?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_what_if_i_receive_more_than_one_proxy_card_"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_will_my_shares_be_voted_if_i_do_not_vote_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Will My Shares be Voted if I Do Not Vote?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_will_my_shares_be_voted_if_i_do_not_vote_"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_what_vote_is_required_to_appro__wha02998"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>What Vote is Required to Approve Each Proposal and How are Votes
Counted?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_what_vote_is_required_to_appro__wha02998"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_is_voting_confidential_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Is Voting Confidential?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_is_voting_confidential_"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_where_can_i_find_the_v__da402362"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where Can I Find the Voting Results of the Annual Meeting?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_where_can_i_find_the_v__da402362"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_who_is_paying_for_the___da402353"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Who is Paying for the Costs of Soliciting these Proxies?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_who_is_paying_for_the___da402353"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_what_constitutes_a_quorum_for_the_meeting_"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>What Constitutes a Quorum for the Meeting?</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_what_constitutes_a_quorum_for_the_meeting_"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_householding_of_annual_disclosure_documents"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Householding of Annual Disclosure Documents</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_householding_of_annual_disclosure_documents"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da47801_electronic_delivery_of__da402405"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Electronic Delivery of Company Stockholder Communications</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da47801_electronic_delivery_of__da402405"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_security_ownership_of_certain___sec02525"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_security_ownership_of_certain___sec02525"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_management_and_corporate_governance"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MANAGEMENT AND CORPORATE GOVERNANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_management_and_corporate_governance"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_the_board_of_directors"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Board of Directors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_the_board_of_directors"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_director_independence"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director Independence</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_director_independence"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_committees_of_the_board_of_directors_and_meetings"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Committees of the Board of Directors and Meetings</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_committees_of_the_board_of_directors_and_meetings"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_board_leadership_structure"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board Leadership Structure</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_board_leadership_structure"><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_our_board_of_directors__role_in_risk_oversight"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our Board of Directors' Role in Risk Oversight</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_our_board_of_directors__role_in_risk_oversight"><FONT SIZE=2>18</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_stockholder_communications_to_the_board"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Communications to the Board</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_stockholder_communications_to_the_board"><FONT SIZE=2>18</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc47801_executive_officers"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officers</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc47801_executive_officers"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de47801_compensation_discussion_and_analysis"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COMPENSATION DISCUSSION AND ANALYSIS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de47801_compensation_discussion_and_analysis"><FONT SIZE=2>21</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de47801_executive_officer_and_director_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de47801_executive_officer_and_director_compensation"><FONT SIZE=2>25</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg47801_equity_compensation_plan_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EQUITY COMPENSATION PLAN INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg47801_equity_compensation_plan_information"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg47801_compensation_committee_report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COMPENSATION COMMITTEE REPORT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg47801_compensation_committee_report"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg47801_section_16(a)_benefici__dg402030"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg47801_section_16(a)_benefici__dg402030"><FONT SIZE=2>33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg47801_certain_relationships_and_related_party_transactions"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg47801_certain_relationships_and_related_party_transactions"><FONT SIZE=2>33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg47801_policy_for_approval_of_related_person_transactions"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Policy for Approval of Related Person Transactions</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg47801_policy_for_approval_of_related_person_transactions"><FONT SIZE=2>34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di47801_proposal_no._1__election_of_directors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 1: ELECTION OF DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di47801_proposal_no._1__election_of_directors"><FONT SIZE=2>36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di47801_proposal_no._2__ratification_o__pro03631"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di47801_proposal_no._2__ratification_o__pro03631"><FONT SIZE=2>37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#PRO3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 3: APPROVAL OF AMENDMENT TO 2015 STOCK PLAN</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#PRO3"><FONT SIZE=2>41</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk47801_proposal_no._4__advisory_vote___pro04243"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 4: ADVISORY VOTE ON APPROVAL OF EXECUTIVE
COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk47801_proposal_no._4__advisory_vote___pro04243"><FONT SIZE=2>49</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk47801_code_of_conduct_and_ethics"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CODE OF CONDUCT AND ETHICS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk47801_code_of_conduct_and_ethics"><FONT SIZE=2>49</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk47801_other_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OTHER MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk47801_other_matters"><FONT SIZE=2>50</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk47801_stockholder_proposals_and_nominations_for_director"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk47801_stockholder_proposals_and_nominations_for_director"><FONT SIZE=2>50</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=820199,FOLIO='i',FILE='DISK106:[17ZBJ1.17ZBJ47801]BG47801A.;8',USER='SCAVALI',CD='28-APR-2017;13:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da47801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da47801_madrigal_pharmaceuticals,_inc.__mad03106"> </A>
<A NAME="toc_da47801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MADRIGAL PHARMACEUTICALS,&nbsp;INC.<BR>  200 BARR HARBOR DRIVE, SUITE 400<BR>  WEST CONSHOHOCKEN, PENNSYLVANIA 19428<BR>  (484)&nbsp;380-9263    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="INR"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROXY STATEMENT FOR THE MADRIGAL PHARMACEUTICALS,&nbsp;INC.<BR>
2017 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 29, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement, along with the accompanying Notice of 2017 Annual Meeting of Stockholders, contains information about the 2017 Annual
Meeting of Stockholders of Madrigal Pharmaceuticals,&nbsp;Inc., including any adjournments or postponements of the Annual Meeting. We are holding the Annual Meeting at 9:00&nbsp;a.m., Eastern
Time, on Thursday, June&nbsp;29, 2017, at Philadelphia Marriott West, 111 Crawford Avenue, Conshohocken, Pennsylvania 19428. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
proxy statement relates to the solicitation of proxies by our Board of Directors for use at the Annual Meeting. You should rely only on the information contained in or incorporated
by reference into this proxy statement. No one has been authorized to provide you with information that is different from that contained in or incorporated by reference into this proxy statement. This
proxy statement is dated April&nbsp;28, 2017. You should not assume that the information contained in this proxy statement is accurate as of any other date, nor should you assume that the
information incorporated by reference into this proxy statement is accurate as of any date other than the date of such incorporated document. The mailing of this proxy statement to our stockholders
will not create any implication to the contrary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or about May&nbsp;10, 2017, we will begin sending this proxy statement, the attached Notice of Annual Meeting of Stockholders and the enclosed proxy card to all stockholders
entitled to vote at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
not part of this proxy statement, we are also sending, along with this proxy statement, our 2016 Annual Report, which includes our financial statements for the fiscal year ended
December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_note_regarding_our_2016_merger"> </A>
<A NAME="toc_da47801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Note Regarding Our 2016 Merger    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company. On July&nbsp;22, 2016, Synta Pharmaceuticals Corp. completed its business combination with
Private Madrigal, which we refer to in this proxy statement as the Merger, in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of April&nbsp;13, 2016, or the
Merger Agreement. As used in this proxy statement, the term "Private Madrigal" refers to Madrigal Pharmaceuticals,&nbsp;Inc. prior to the consummation of the Merger. The terms "Madrigal", the
"Company", "we", "our" and "us" refer to Private Madrigal, prior to the consummation of the Merger, and Madrigal Pharmaceuticals,&nbsp;Inc. (formerly known as Synta Pharmaceuticals Corp.) and its
subsidiaries upon and following the
consummation of the Merger. The term "Synta" refers to Synta Pharmaceuticals Corp. and its subsidiaries prior to the consummation of the Merger. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 29, 2017</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This proxy statement, the Notice of Annual Meeting of Stockholders and our 2016 Annual Report to security holders are available for viewing, printing and
downloading at the "Investors&#151;Annual Meeting Materials" section of our website at </B></FONT><FONT SIZE=2><B><I>www.madrigalpharma.com</I></B></FONT><FONT SIZE=2><B>.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Additionally, you can find a copy of our Annual Report on Form&nbsp;10-K, which includes our financial statements, for the fiscal year ended December&nbsp;31,
2016, and which provides additional information about us, on the website of the Securities and Exchange Commission, or the SEC, at </B></FONT><FONT SIZE=2><B><I>www.sec.gov</I></B></FONT><FONT SIZE=2><B>, or in
the "Investors&#151;SEC Filings for Madrigal Pharmaceuticals,&nbsp;Inc." section of our  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=437613,FOLIO='1',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> website at </B></FONT><FONT SIZE=2><B><I>www.madrigalpharma.com</I></B></FONT><FONT SIZE=2><B>. You may also obtain a printed copy of our Annual Report on Form&nbsp;10-K, including our financial statements, free
of charge, from us by sending a written request to: Secretary, Madrigal Pharmaceuticals,&nbsp;Inc., 200 Barr Harbor Drive, Suite&nbsp;400, West Conshohocken, Pennsylvania 19428. Exhibits will be
provided upon written request and payment of an appropriate processing fee.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da47801_important_information___da402386"> </A>
<A NAME="toc_da47801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_why_is_the_company_soliciting_my_proxy_"> </A>
<A NAME="toc_da47801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why is the Company Soliciting My Proxy?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors of Madrigal Pharmaceuticals,&nbsp;Inc. is soliciting your proxy to vote at the 2017 Annual Meeting of Stockholders to
be held at 9:00&nbsp;a.m., Eastern Time, on Thursday, June&nbsp;29, 2017, at Philadelphia Marriott West, 111 Crawford Avenue, Conshohocken, Pennsylvania 19428, and any adjournments of the meeting,
which we refer to as the Annual Meeting. The proxy statement along with the accompanying Notice of Annual Meeting of Stockholders summarizes the purposes of the meeting and the information you need to
know to vote at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have made available to you on the Internet or have sent you this proxy statement, the Notice of Annual Meeting of Stockholders, the proxy card and a copy of our Annual Report on
Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 because you owned shares of our common stock on the record date. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_who_can_vote_"> </A>
<A NAME="toc_da47801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders who owned our common stock at the close of business on May&nbsp;1, 2017 are entitled to vote at the Annual Meeting. On this
record date, there were 12,167,405 shares of our common stock outstanding and entitled to vote. Our common stock is our only class of voting stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
do not need to attend the Annual Meeting to vote your shares. Shares represented by valid proxies, received in time for the meeting and not revoked prior to the meeting, will be
voted at the meeting. For instructions on how to change or revoke your proxy, see "May I Change or Revoke My Proxy?" below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_how_many_votes_do_i_have_"> </A>
<A NAME="toc_da47801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Many Votes Do I Have?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of our common stock that you own entitles you to one vote. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_how_do_i_vote_"> </A>
<A NAME="toc_da47801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Do I Vote?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. All shares represented by valid proxies that we receive
through this solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card or as instructed via Internet or telephone. You may specify whether your
shares should be voted for either, both or neither of the nominees for director or withheld from either or both of the nominees for director and whether your shares should be voted for, against or to
abstain with respect to each of the other proposals. If you properly submit a proxy without giving specific voting instructions, your shares will be voted in accordance with the Board of Directors'
recommendations as noted below. Voting by proxy will not affect your right to attend the Annual Meeting. If your shares are registered directly in your name through our stock transfer agent,
Computershare, or you have stock certificates registered in your name, you may vote: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> By mail.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If you received a proxy
card by mail, you can vote by mail by completing, signing, dating and returning the proxy card as instructed on the card. Your proxy will be voted in accordance with your instructions. If you sign the
proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board of Directors below. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=567509,FOLIO='2',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> By Internet or by
telephone.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Follow the instructions on the proxy card to vote by Internet or telephone.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> In person at the meeting.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If you
attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and Internet voting facilities for stockholders of record will be available 24-hours a day and will close at 1:00&nbsp;a.m., Eastern Time, on June&nbsp;29, 2017. If your
shares are held in "street name" (held in the name of a bank, broker or other holder of record), you will receive instructions from the holder of record. You must follow the instructions of the holder
of record in order for your shares to be voted. Telephone and Internet voting also will be offered to stockholders owning shares through certain banks and brokers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are not registered in your own name and you plan to vote your shares in person at the Annual Meeting, you should contact your broker or agent to obtain a legal proxy or
broker's proxy card and bring it to the Annual Meeting in order to vote. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_how_does_the_board_of_director__how02885"> </A>
<A NAME="toc_da47801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Does the Board of Directors Recommend That I Vote on the Proposals?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors recommends that you vote as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the election of the two nominees for director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the ratification of the selection of PricewaterhouseCoopers&nbsp;LLP as our independent
registered public accounting firm for our fiscal year ending December&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the approval of the amendment to our 2015 Stock Plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "</FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the compensation of our named executive officers, as disclosed in this proxy statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any other matter is presented at the Annual Meeting, your proxy provides that your shares will be voted by the proxy holder listed in the proxy in accordance with his best judgment.
At the time this proxy statement was first made available, we knew of no matters that needed to be acted on at the Annual Meeting, other than those discussed in this proxy statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_may_i_change_or_revoke_my_proxy_"> </A>
<A NAME="toc_da47801_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


May I Change or Revoke My Proxy?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you give us your proxy, you may change or revoke it at any time before the meeting. You may change or revoke your proxy in any one of the
following ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if you received a proxy card, by signing a new proxy card with a date later than your previously delivered proxy and submitting it as
instructed above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by re-voting by Internet or by telephone as instructed above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by notifying our Secretary in writing before the Annual Meeting that you have revoked your proxy; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by attending the Annual Meeting in person and voting in person. Attending the meeting in person will not in and of itself revoke a previously
submitted proxy. You must specifically request at the meeting that it be revoked. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
most current vote, whether by telephone, Internet or proxy card is the one that will be counted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=464201,FOLIO='3',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_what_if_i_receive_more_than_one_proxy_card_"> </A>
<A NAME="toc_da47801_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I Receive More Than One Proxy Card?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may receive more than one proxy card if you hold shares of our common stock in more than one account, which may be in registered form or
held in street name. Please vote in the manner described above under "How Do I Vote?" for each account to ensure that all of your shares are voted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_will_my_shares_be_voted_if_i_do_not_vote_"> </A>
<A NAME="toc_da47801_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will My Shares be Voted if I Do Not Vote?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as described above
under "How Do I Vote?" If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above, the bank,
broker or other nominee that holds your shares has the authority to vote your unvoted shares only on the ratification of the appointment of our independent registered public accounting firm (Proposal
2 of this proxy statement) without receiving
instructions from you. Therefore, we encourage you to provide voting instructions to your bank, broker or other nominee. This ensures your shares will be voted at the Annual Meeting and in the manner
you desire. A "broker non-vote" will occur if your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting
authority on that matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Your bank, broker or other nominee does not have the ability to vote your uninstructed shares in the election of directors. Therefore, if you hold your shares in
street name it is critical that you cast your vote if you want your vote to be counted for the election of directors. In addition, your bank, broker or other nominee is prohibited from voting your
uninstructed shares on any matters related to executive compensation. Thus, if you hold your shares in street name and you do not instruct your bank, broker or other nominee how to vote in the
election of directors (Proposal No.&nbsp;1 of this proxy statement) or on matters related to executive compensation (Proposal Nos.&nbsp;3 and No.&nbsp;4 of this proxy statement), no votes will
be cast on these proposals on your behalf.</B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_what_vote_is_required_to_appro__wha02998"> </A>
<A NAME="toc_da47801_12"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Vote is Required to Approve Each Proposal and How are Votes Counted?    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 1: Elect Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The nominees for director who receive the most votes (also known as a "plurality" of the votes cast) will be elected. You may vote either FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD
your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of the directors. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name
for the election of directors. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=937947,FOLIO='4',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 2: Ratify Selection of Independent Registered Public Accounting Firm</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The affirmative vote of a majority of the shares of our common stock present in person or represented by proxy at the Annual Meeting and entitled to vote on
the proposal is required to ratify the selection of our independent registered public accounting firm. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote customers' unvoted shares held by the firms in
street name on this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote. We are not required to obtain the approval of our stockholders to select our independent registered
public accounting firm. However, if our stockholders do not ratify the selection of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the 2017 fiscal year, our Audit Committee will reconsider its
selection.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 3: Approve an Amendment to our 2015 Stock Plan</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The affirmative vote of a majority of the shares of our common stock present in person or represented by proxy at the Annual Meeting and
entitled to vote on the proposal is required to approve the amendment to our 2015 Stock Plan. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in
street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 4: Approve an Advisory Vote on the Compensation of our Named Executive Officers</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on the
proposal is required to approve on an advisory basis the compensation of our named executive officers, as described in this proxy statement. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers' unvoted shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. Although the
advisory vote is non-binding, the Compensation Committee and the Board of Directors will review the voting results and take them into consideration when making future decisions regarding executive compensation.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_is_voting_confidential_"> </A>
<A NAME="toc_da47801_13"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Is Voting Confidential?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will keep all the proxies, ballots and voting tabulations private. We only let our Inspector of Elections examine these documents. Management
will not know how you voted on a specific proposal unless it is necessary to meet legal requirements. We will, however, forward to management any written comments you make, on the proxy card or
elsewhere. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=661068,FOLIO='5',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_where_can_i_find_the_v__da402362"> </A>
<A NAME="toc_da47801_14"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Where Can I Find the Voting Results of the Annual Meeting?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preliminary voting results will be announced at the Annual Meeting, and we will publish preliminary, or final results if available, in a
Current Report on Form&nbsp;8-K within four business days of the Annual Meeting. If final results are unavailable at the time we file the Form&nbsp;8-K, then we will file an amended report on
Form&nbsp;8-K to disclose the final voting results within four business days after the final voting results are known. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_who_is_paying_for_the___da402353"> </A>
<A NAME="toc_da47801_15"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who is Paying for the Costs of Soliciting these Proxies?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy
materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_what_constitutes_a_quorum_for_the_meeting_"> </A>
<A NAME="toc_da47801_16"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Constitutes a Quorum for the Meeting?    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence, in person or by proxy, of the holders of a majority of the voting power of all outstanding shares of our common stock entitled to
vote at the meeting is necessary to constitute a quorum at the meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions, and broker non-votes are
counted for purposes of determining whether a quorum exists. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_householding_of_annual_disclosure_documents"> </A>
<A NAME="toc_da47801_17"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Householding of Annual Disclosure Documents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEC rules concerning the delivery of annual disclosure documents allow us or your broker to send a single set of our annual report and proxy
materials to any household at which two or more of our stockholders reside, if we or your broker believe that the stockholders are members of the same family. This practice, referred to as
"householding," benefits both you and us. It reduces the volume of duplicate information received at your household and helps to reduce our expenses. The rule applies to our annual reports, proxy
statements and information statements. Once you receive notice from your broker or from us that communications to your address will be "householded," the practice will continue until you are otherwise
notified or until you revoke your consent to the practice. Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your household received a single set of proxy materials this year, but you would prefer to receive your own copy, please contact our transfer agent, Computershare, by calling their
toll free number, 1-800-662-7232. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you do not wish to participate in "householding" and would like to receive your own set of our proxy materials in future years, follow the instructions described below. Conversely, if
you share an address with another Madrigal stockholder and together both of you would like to receive only a single set of our proxy materials, follow these
instructions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If your Madrigal shares are registered in your own name, please contact our transfer agent, Computershare, and inform them of your request by
calling them at 1-800-662-7232 or writing them at P.O.&nbsp;Box&nbsp;30170, College Station, Texas 77842. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If a broker or other nominee holds your Madrigal shares, please contact the broker or other nominee directly and inform them of your request.
Be sure to include your name, the name of your brokerage firm and your account number. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=856030,FOLIO='6',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<A NAME="page_da47801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da47801_electronic_delivery_of__da402405"> </A>
<A NAME="toc_da47801_18"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Electronic Delivery of Company Stockholder Communications    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most stockholders can elect to view future proxy materials and annual reports over the Internet instead of receiving paper copies in the mail.
You can choose this option and save Madrigal the cost of producing and mailing these documents by following the instructions provided when you vote over the Internet. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=241889,FOLIO='7',FILE='DISK106:[17ZBJ1.17ZBJ47801]DA47801A.;14',USER='SCAVALI',CD='28-APR-2017;13:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc47801_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc47801_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_dc47801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise noted, the following table sets forth certain information regarding the beneficial ownership of our common stock as of
April&nbsp;21, 2017 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the executive officers named in the Summary Compensation Table on page 25 of this proxy statement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each stockholder known by us to own beneficially more than 5% of our common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Shares of common stock that may be
acquired by an individual or group within 60&nbsp;days of April&nbsp;21, 2017 pursuant to the exercise of options or warrants, are deemed to be outstanding for the purpose of computing the
percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Percentage of
ownership is based on 12,167,405 shares of common stock outstanding on April&nbsp;21, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock
shown to be beneficially owned by them, based on information provided to us by such stockholders. Unless otherwise indicated, the address for each director and executive officer listed is: c/o
Madrigal Pharmaceuticals,&nbsp;Inc., 200 Barr Harbor Drive, Suite&nbsp;400, West Conshohocken, Pennsylvania 19428. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Common Stock<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Directors and Executive Officers</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>958,951</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rebecca Taub, M.D.(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,202,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marc R. Schneebaum(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,144</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chen Schor(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wendy A. Rieder(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth M. Bate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fred B. Craves, Ph.D.(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,953,921</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>48.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith R. Gollust(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,421</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard S. Levy, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Milligan Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (8&nbsp;persons)(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,166,122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Five Percent Stockholders</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities Affiliated with Bay City Capital,&nbsp;LLC(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,657,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SQN&nbsp;LLC(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>729,066</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of the shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
76,564 shares of common stock issuable upon the exercise of options exercisable within sixty days of April&nbsp;21, 2017, 153,128 shares of restricted
common stock (of which 38,282 shares vested within sixty days of April&nbsp;21, 2017), and 729,066 shares of common stock held by SQN,&nbsp;LLC as set forth in footnote 10 below.
Dr.&nbsp;Friedman is a managing member of SQN,&nbsp;LLC and thus may be deemed to share voting and investment power over the shares beneficially owned by SQN,&nbsp;LLC. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=12,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=996194,FOLIO='8',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Friedman
disclaims beneficial ownership of the shares beneficially owned by SQN,&nbsp;LLC except to the extent of his pecuniary interest therein.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
38,282 shares of common stock issuable upon the exercise of options exercisable within sixty days of April&nbsp;21, 2017, 30,626 shares of restricted
common stock (of which 7,657 shares vested within sixty days of April&nbsp;21, 2017) and 729,066 shares of common stock held by SQN,&nbsp;LLC as set forth in footnote 10 below. Dr.&nbsp;Taub is
a managing member of SQN,&nbsp;LLC and thus may be deemed to share voting and investment power over the shares beneficially owned by SQN,&nbsp;LLC. Dr.&nbsp;Taub disclaims beneficial ownership
of the shares beneficially owned by SQN,&nbsp;LLC except to the extent of her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
24,501 shares of common stock issuable upon the exercise of options exercisable within sixty days of April&nbsp;21, 2017, and 24,501 shares of restricted
common stock (of which 6,125 shares vested within sixty days of April&nbsp;21, 2017).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Schor
resigned effective July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;Rieder
resigned effective July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
5,657,854 shares of common stock held by investment entities affiliated with Bay City Capital,&nbsp;LLC, or BCC, as set forth in footnote 9 below.
Dr.&nbsp;Craves is a managing director of BCC and thus may be deemed to share voting and investment power over the shares beneficially owned by these entities. Dr.&nbsp;Craves disclaims beneficial
ownership of the shares beneficially owned by these entities except to the extent of his pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 38,801 shares of common stock owned of record by Wyandanch Partners,&nbsp;L.P. and 8,620&nbsp;shares of common stock owned of record by Keith R.
Gollust Roth IRA. Mr.&nbsp;Gollust is the president and sole stockholder of Gollust Management,&nbsp;Inc., which is the general partner of Wyandanch Partners,&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares of common stock and common stock issuable upon the exercise of options as set forth in footnotes 1 through 3 and 6 through 7.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 5,538,474 shares of common stock held by Bay City Capital Fund IV,&nbsp;L.P., or Fund IV, and 119,380 shares of common stock held by Bay City Capital
Fund IV Co-Investment Fund,&nbsp;L.P., or Co-Invest Fund. Bay City Capital Management IV&nbsp;LLC, or BCC IV, is the general partner of Fund IV and Co-Invest Fund and has sole voting and
investment power over the shares held by Fund IV and Co-Invest Fund. BCC is the manager of BCC IV, and thus has sole voting and investment power over the shares held by Fund IV and Co-Invest Fund.
Dr.&nbsp;Craves is a managing director of BCC and thus may be deemed to share voting and investment power over the shares beneficially owned by these entities. The address for the entities
affiliated with BCC is 750 Battery Street, Suite&nbsp;400, San Francisco, California 94111.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 729,066 shares of common stock held by SQN,&nbsp;LLC. Dr.&nbsp;Friedman and Dr.&nbsp;Taub are the managing members of SQN,&nbsp;LLC and thus may
be deemed to share voting and investment power over the shares beneficially owned by SQN,&nbsp;LLC. Dr.&nbsp;Friedman and Dr.&nbsp;Taub disclaim beneficial ownership of the shares beneficially
owned by SQN,&nbsp;LLC except to the extent of their pecuniary interest therein. The address for SQN,&nbsp;LLC is c/o Madrigal Pharmaceuticals,&nbsp;Inc., 200&nbsp;Barr Harbor Drive,
Suite&nbsp;400, West Conshohocken, Pennsylvania 19428.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=13,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=487239,FOLIO='9',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc47801_management_and_corporate_governance"> </A>
<A NAME="toc_dc47801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_the_board_of_directors"> </A>
<A NAME="toc_dc47801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board of Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws provide that our business is to be managed by or under the direction of our Board
of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each Annual Meeting of Stockholders to serve for a three-year term. Our Board of
Directors, which consists of seven members, is classified into three classes as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors are Paul A. Friedman, M.D. and Kenneth M. Bate, and their terms will expire at the upcoming Annual Meeting of
Stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors are Rebecca Taub, M.D. and Fred B. Craves, Ph.D., and their terms will expire at the Annual Meeting of
Stockholders to be held in 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors are Keith R. Gollust, David Milligan, Ph.D. and Richard S. Levy, M.D., and their terms will expire at the Annual
Meeting of Stockholders to be held in 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;2, 2017, our Board of Directors accepted the recommendation of the Nominating and Governance Committee and voted to nominate Paul A. Friedman, M.D. and Kenneth M. Bate
for
election at the Annual Meeting for a term of three years to serve until the 2020 Annual Meeting of Stockholders, and until their respective successors have been elected and qualified. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth below are the names of the persons nominated as directors and directors whose terms do not expire this year, their ages, their offices in the company, if any, their principal
occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during
the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors' conclusion at the time of filing of this proxy
statement that each person listed below should serve as a director is set forth below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="274pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth M. Bate(1)(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Class&nbsp;I Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fred B. Craves, Ph.D.(2)(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Lead Director and Class&nbsp;II Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chairman of the Board of Directors, Chief Executive Officer and Class&nbsp;I Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith R. Gollust(1)(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Class&nbsp;III Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard S. Levy, M.D.(2)(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Class&nbsp;III Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Milligan, Ph.D.(1)(2)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>76</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Class&nbsp;III Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer, Executive Vice President, Research&nbsp;&amp; Development and Class&nbsp;II Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of our Audit Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of our Compensation Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of our Nominating and Governance Committee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the information presented below regarding each of our director's specific experience, qualifications, attributes and skills that led our Board to the conclusion that he or
she should serve as a director, we also believe that all of our directors have a reputation for integrity, honesty and adherence to high ethical standards. They each have demonstrated business acumen
and an ability to exercise sound judgment, as well as a commitment of service to Madrigal and our Board. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=14,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=767403,FOLIO='10',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Kenneth M. Bate</I></FONT><FONT SIZE=2>, has served on our Board of Directors since July 2016. Mr.&nbsp;Bate currently works as an independent consultant.
Previously, Mr.&nbsp;Bate was the president and chief executive officer of Archemix Corp., a privately held biopharmaceutical company, a position he held from April 2009 through December 2011. From
2006 to April 2009, he served in various positions at NitroMed,&nbsp;Inc., a publicly held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005,
Mr.&nbsp;Bate served as head of commercial operations and chief financial officer at Millennium Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company. Prior to joining Millennium
Pharmaceuticals, Mr.&nbsp;Bate co-founded JSB Partners,&nbsp;LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, Mr.&nbsp;Bate was
employed with Biogen,&nbsp;Inc., a public biotechnology company, first as its chief financial officer and then as head of the commercial organization responsible for launching its multiple sclerosis
business. Mr.&nbsp;Bate currently serves on the board of AVEO Pharmaceuticals,&nbsp;Inc., Catabasis Pharmaceuticals,&nbsp;Inc., Vanda Pharmaceuticals&nbsp;Inc., Genocea
Biosciences,&nbsp;Inc. and Epizyme,&nbsp;Inc., each a public biopharmaceutical company and serves on the board of TransMedics&nbsp;Inc., a privately held medical device company. During the last
five years, Mr.&nbsp;Bate also served as chairman of the board of Cubist Pharmaceuticals,&nbsp;Inc. and as a director of BioMarin Pharmaceutical&nbsp;Inc., each a public biopharmaceutical
company. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe that Mr.&nbsp;Bate's qualifications to serve on our
board of directors include his operating, finance, commercial, transactional and senior management experience in the industry, such as his experience as chief executive officer of Archemix and
NitroMed, as head of commercial operations and chief financial officer at Millennium Pharmaceuticals, and as chief financial officer and vice president of sales and marketing at Biogen, as well as his
experience serving on the board of directors of other public companies in the life sciences industry. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Fred B. Craves, Ph.D.</I></FONT><FONT SIZE=2>, has served on our Board of Directors since July 2016. Dr.&nbsp;Craves served as Chairman of the Board of Private
Madrigal from its inception in September 2011 through the Merger in July 2016. Dr.&nbsp;Craves is a Managing Director and co-founder of Bay City Capital. In the course of his career,
Dr.&nbsp;Craves has founded and managed several biotechnology companies. Dr.&nbsp;Craves previously served on the boards of directors of several privately held and publicly companies.
Dr.&nbsp;Craves currently serves as a member of the board of directors of Dermira,&nbsp;Inc., a publicly-held biopharmaceutical company, where he is the lead director, and as a member of the
boards of directors of Reset Therapeutics,&nbsp;Inc., Grey and White,&nbsp;Inc. and Twist Bioscience,&nbsp;Inc., each a privately held company. Dr.&nbsp;Craves earned a B.S. degree in biology
from Georgetown University, an M.S. in biochemical pharmacology from Wayne State University and a Ph.D. in pharmacology and experimental toxicology from the University of California, San Francisco. We
believe that Dr.&nbsp;Craves is qualified to serve on our board of directors due to his extensive experience with founding, managing and serving on the boards of directors of life sciences
companies, both public and private, and his extensive knowledge of the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Paul A. Friedman, M.D.</I></FONT><FONT SIZE=2>, has served as Chairman of our Board of Directors and Chief Executive Officer since July 2016. Dr.&nbsp;Friedman
served as a member of Synta's board of directors from March 2014 until April 2016. Dr.&nbsp;Friedman served as the Chief Executive Officer and a Director of Incyte Corporation from November 2001
until his retirement in January 2014. From 1994 to 1998, Dr.&nbsp;Friedman served as President of Research&nbsp;&amp; Development for the DuPont-Merck Pharmaceutical Company; and from 1998 to 2001 as
President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior
to his tenures at Merck and DuPont, Dr.&nbsp;Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr.&nbsp;Friedman is a diplomat of the American Board of
Internal Medicine and a member of the American Society of Clinical Investigation. Dr.&nbsp;Friedman currently sits on the board of directors of Cerulean Pharma&nbsp;Inc., a publicly traded
pharmaceutical company, Verastem,&nbsp;Inc., a publicly traded pharmaceutical company, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=15,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=560457,FOLIO='11',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Incyte
Corporation, a publicly traded pharmaceutical company, and Gliknik,&nbsp;Inc. He has previously served on the board of directors of Auxilium Pharmaceuticals&nbsp;Inc., a publicly traded
pharmaceutical company, and Durata Therapeutics,&nbsp;Inc., a publicly traded pharmaceutical company. Dr.&nbsp;Friedman received his A.B. in Biology from Princeton University and his M.D. from
Harvard Medical School. We believe that Dr.&nbsp;Friedman is qualified to serve as Chief Executive Officer and as Chairman of our board of directors due to his research and development and
management experience and his experience as an executive officer and director of life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Keith R. Gollust</I></FONT><FONT SIZE=2>, has served on our Board of Directors since July 2016. Mr.&nbsp;Gollust served on the board of directors of Synta from
July 2002 through the Merger in July 2016 and as Chairman of the Synta board of directors from September 2002 through the Merger in July 2016. Mr.&nbsp;Gollust is a private investor and President of
Gollust Management,&nbsp;Inc., the general partner of Wyandanch Partners, an investment partnership. In the past, Mr.&nbsp;Gollust has served as a director of numerous public and private
companies. Mr.&nbsp;Gollust currently serves as a director of Script Relief,&nbsp;LLC, a discount prescription drug
company. He also is a member of the Board of Trustees of the Julliard School. Mr.&nbsp;Gollust received a B.A. from Princeton University and an M.S.I.A. from Carnegie Mellon University. We believe
that Mr.&nbsp;Gollust is qualified to serve as a member of our board of directors due to his experience as managing general partner of various investment partnerships which have given him the
responsibility for investing over $1&nbsp;billion as a fiduciary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Richard S. Levy, M.D.</I></FONT><FONT SIZE=2>, has been a member of our Board of Directors since August 2016. Dr.&nbsp;Levy serves on the board of directors of
Gliknik Corp., a privately held biotechnology company. Previously, Dr.&nbsp;Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation, a publicly held
biopharmaceutical company, from January 2009 until his retirement in April 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte,
Dr.&nbsp;Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr.&nbsp;Levy served in various
executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy.
Dr.&nbsp;Levy served at Sandoz (now the generic pharmaceuticals division of Novartis) from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs.
Dr.&nbsp;Levy has more than 25&nbsp;years' experience in the pharmaceutical and biotechnology industries through his prior positions at Celgene, DuPont Pharmaceuticals and Novartis, has extensive
clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Prior to joining the pharmaceutical industry, Dr.&nbsp;Levy served as an Assistant
Professor of Medicine at the UCLA School of Medicine. Dr.&nbsp;Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from
the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology
at UCLA. We believe that Dr.&nbsp;Levy is qualified to serve on our board of directors due to his extensive and diverse experience in the pharmaceutical and biotechnology industries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>David Milligan, Ph.D.</I></FONT><FONT SIZE=2>, has been a member of our Board of Directors since July 2016. Dr.&nbsp;Milligan currently works as an independent
consultant. Previously, Dr.&nbsp;Milligan was a partner at Bay City Capital,&nbsp;LLC, a life sciences investment firm, a position he held from 1997 through 2013. From 1979 to 1996,
Dr.&nbsp;Milligan served as Senior Vice President and Chief Scientific Officer at Abbott Laboratories, a publicly-held life sciences company. Dr.&nbsp;Milligan currently serves as a director of
Inspirotech and Xoult, both privately-held life sciences companies. During the past five years, Dr.&nbsp;Milligan has served as a director of Caliper Life Sciences, a publicly-held pharmaceutical
and biotechnology company that was acquired by PerkinElmer Company, and served as a director of WebLOQ,&nbsp;Inc. a privately-held information technology security company. Dr.&nbsp;Milligan also
served as Chairman and a director at Vicuron Pharmaceuticals,&nbsp;Inc., a privately-held biopharmaceutical company acquired by Pfizer, from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=16,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=571722,FOLIO='12',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>1997
to 2005, as a director of Reliant Pharmaceuticals,&nbsp;Inc., a privately-held pharmaceutical company acquired by GlaxoSmithKline, from 1999 to 2007, as a director of Pathway Diagnostics
Corporation, a privately-held diagnostics company acquired by Quest Diagnostics,&nbsp;Inc., from 2002 to 2008, as a director
of ICOS Corporation, a publicly-held pharmaceutical company acquired by Eli Lilly, from 1995 to 2007, and as a director of Maxia Pharmaceuticals,&nbsp;Inc., a privately-held pharmaceutical company
acquired by Incyte Corporation, from 1999 to 2003. Dr.&nbsp;Milligan received an A.B. in Chemistry from Princeton University and an M.S. and Ph.D. in Organic Chemistry from the University of
Illinois. We believe that Dr.&nbsp;Milligan's qualifications to serve on our board of directors include his operating, finance, commercial, transactional and senior management experience in the life
sciences industry, as well as his experience serving on the boards of directors of publicly- and privately-held companies in the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Rebecca Taub, M.D.</I></FONT><FONT SIZE=2>, has been a member of our Board of Directors and has served as our Chief Medical Officer, Executive Vice President,
Research&nbsp;&amp; Development since July 2016. Dr.&nbsp;Taub served on Private Madrigal's board of directors and as Chief Executive Officer of Private Madrigal from its inception in September 2011
through the Merger in July 2016. Prior to joining Private Madrigal, Dr.&nbsp;Taub served as Senior Vice President, Research and Development of VIA Pharmaceuticals from 2008 to 2011 and as Vice
President, Research, Metabolic Diseases at Hoffmann-La Roche from 2004 to 2008. In those positions, Dr.&nbsp;Taub oversaw clinical development and drug discovery programs in cardiovascular and
metabolic diseases including the conduct of a series of Phase&nbsp;I and II proof of conduct clinical trials. Dr.&nbsp;Taub led drug discovery including target identification, lead optimization
and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr.&nbsp;Taub worked at Bristol-Myers Squibb&nbsp;Co. and DuPont Pharmaceutical Company, in a variety
of positions, including Executive Director of CNS and metabolic diseases research. Before becoming a pharmaceutical executive, Dr.&nbsp;Taub was a tenured Professor of Genetics and Medicine at the
University of Pennsylvania, and remains an adjunct professor. Dr.&nbsp;Taub is the author of more than 120 research articles. Before joining the faculty of the University of Pennsylvania,
Dr.&nbsp;Taub served as an Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute.
Dr.&nbsp;Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College. We believe that Dr.&nbsp;Taub is qualified to serve as Chief Medical Officer, Executive Vice
President, Research and Development and a member of our board of directors due to her extensive experience as a pharmaceutical executive heading up major development programs in NASH. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_director_independence"> </A>
<A NAME="toc_dc47801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with Madrigal, either directly or
indirectly. Based on this review, our Board has determined that all of the current members of the Board other than Dr.&nbsp;Friedman and Dr.&nbsp;Taub are "independent directors" as defined by the
Listing Rules of The Nasdaq Stock Market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_committees_of_the_board_of_directors_and_meetings"> </A>
<A NAME="toc_dc47801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors and Meetings    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Meeting Attendance  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the fiscal year ended December&nbsp;31, 2016 there were four meetings of our Board of Directors, and the various committees of the
Board met a total of seven times. No director attended fewer than 75% of the total number of meetings of the Board and of committees of the Board on which he or she served during 2016. The Board has
adopted a policy under which each member of the Board is encouraged, but not required, to attend each Annual Meeting of Stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=17,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=560061,FOLIO='13',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee is composed of Messrs.&nbsp;Bate (chairman) and Gollust and Dr.&nbsp;Milligan, and met three times during fiscal year
2016. All members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by The Nasdaq Stock Market, as such standards apply specifically to members of audit
committees. Our Board of Directors has determined that Mr.&nbsp;Bate is an "audit committee financial expert," as the SEC has defined that term. Please also see the report of the Audit Committee set
forth elsewhere in this proxy statement. Our Audit Committee's role and responsibilities are set forth in the Audit Committee's written charter and include the authority
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve and retain the independent auditors to conduct the annual audit of our consolidated financial statements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review the proposed scope and results of the audit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review and pre-approve the independent auditor's audit and non-audit services rendered; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve the audit fees to be paid; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review accounting and financial controls with the independent auditors and our financial and accounting staff; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review and approve transactions between us and our directors, officers and affiliates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recognize and prevent prohibited non-audit services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish procedures for complaints received by us regarding accounting matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> oversee internal audit functions, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prepare the report of the Audit Committee that the rules of the SEC require to be included in our Annual Meeting proxy statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Audit Committee's written charter is publicly available through the "Investors&#151;Corporate Governance" section of our website at </FONT> <FONT SIZE=2><I>www.madrigalpharma.com</I></FONT><FONT SIZE=2>. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee is composed of Mr.&nbsp;Bate and Drs. Craves, Levy (chairman) and Milligan, and met three times during fiscal year
2016. All members of the Compensation Committee qualify as independent under the current definition promulgated by The Nasdaq Stock Market. Our Compensation Committee's role and responsibilities are
set forth in the Compensation Committee's written charter and include the authority to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review and establish the compensation arrangements for management, including the compensation for our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish and review general compensation policies with the objective to attract and retain superior talent, to reward individual performance
and to achieve our financial goals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> administer our stock incentive plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review the Compensation Discussion and Analysis, or CD&amp;A, prepared by management, discuss the CD&amp;A with management and, based on such review
and discussions, recommend to our Board of Directors that the CD&amp;A be included in our Annual Report on Form&nbsp;10-K, Annual Meeting proxy statement, or any other applicable filing as required by
the SEC; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prepare the report of the Compensation Committee that SEC rules require to be included in our Annual Meeting proxy statement. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=18,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=81654,FOLIO='14',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee is charged with establishing a compensation policy for our executives and directors that is designed to attract and retain the best possible executive talent,
to motivate them to achieve corporate objectives, and reward them for superior performance. Our Compensation Committee is also responsible for establishing and administering our executive compensation
policies and equity compensation plans. The Compensation Committee meets at least twice per year and more often as necessary to review and make decisions with regard to executive compensation matters.
As part of its review of executive compensation matters, the Compensation Committee may delegate any of the powers given to it to a subcommittee of the committee consisting of one or more members of
the Compensation Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee has the authority to directly retain the services of independent consultants and other experts to assist in fulfilling its responsibilities. In October 2016,
the Compensation Committee engaged Compensia,&nbsp;Inc., or Compensia, as its independent compensation consultant. Compensia was engaged to review all aspects of our executive compensation. As
described in the CD&amp;A, Compensia assists the Compensation Committee in defining the appropriate peer companies for executive compensation and practices and in benchmarking our executive compensation
program against the peer group. We use the information we obtain from Compensia primarily for evaluating our executive compensation practices, including measuring the competitiveness of our practices.
We also use information obtained from Compensia to review our cash bonus policy, equity awards, and base salary benchmarks across all levels of the company. The Compensation Committee has assessed the
independence of Compensia pursuant to SEC rules and the corporate governance rules of The Nasdaq Stock Market and concluded that no conflict of interest exists that would prevent Compensia from
independently representing the Compensation Committee. In compliance with the SEC and the corporate governance rules of The Nasdaq Stock Market, Compensia provided the Compensation Committee with a
letter addressing each of the six independence factors. Their responses affirm the independence of Compensia and the partners, consultants, and employees who service the Compensation Committee on
executive compensation matters and governance issues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
also see the CD&amp;A and the report of the Compensation Committee set forth elsewhere in this proxy statement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Compensation Committee's written charter is publicly available through the "Investors&#151;Corporate Governance" section of our website at </FONT> <FONT SIZE=2><I>www.madrigalpharma.com</I></FONT><FONT SIZE=2>. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Governance Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Governance Committee is composed of Drs. Craves and Levy and Mr.&nbsp;Gollust (chairman), and met once in fiscal year 2016.
All members of the Nominating and Governance Committee qualify as independent under the current definition promulgated by The Nasdaq Stock Market. Our Nominating and Governance Committee's role and
responsibilities are set forth in the Nominating and Governance Committee's written charter and include the authority to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identify and nominate members of the Board of Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> develop and recommend to the Board of Directors a set of corporate governance principles applicable to our company; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> oversee the evaluation of the Board of Directors and management. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to nominate a candidate for director who is not to be included in our proxy statement, it must follow the procedures described in our bylaws and in "Stockholder
Proposals and Nominations For Director" at the end of this proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under our current corporate governance policies, the Nominating and Governance Committee may consider candidates recommended by stockholders as well as from other sources
such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=19,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=375771,FOLIO='15',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_16"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>as
other directors or officers, third-party search firms or other appropriate sources. For all potential candidates, our Nominating and Governance Committee may consider all factors it deems relevant,
such as a candidate's personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of the industry in which we operate, possible conflicts of
interest, diversity, the extent to which the candidate would fill a present need on the Board of Directors, and concern for the long-term interests of the stockholders. In general, persons recommended
by stockholders will be considered on the same basis as candidates from other sources. For each Annual Meeting, our Nominating and Governance Committee will consider only one recommended nominee from
any stockholder or group of affiliated stockholders, and such recommending stockholder or group must have held at least 5% of our common stock for at least one year. All stockholder recommendations
for proposed director nominees must be in writing to the Nominating and Governance Committee, care of our Secretary at 200 Barr Harbor Drive, Suite&nbsp;400, West Conshohocken, Pennsylvania 19428,
no later than 120 calendar days prior to the first anniversary of the date of the proxy statement for the prior Annual Meeting of Stockholders or, in certain circumstances, a reasonable time in
advance of the mailing of our proxy statement for the Annual Meeting of Stockholders for the current year. The recommendation must be accompanied by the following information concerning the
recommending stockholder:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> name, address and telephone number of the recommending stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of our common stock owned by the recommending stockholder and the time period for which such shares have been held; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the recommending stockholder is not a stockholder of record, a statement from the record holder verifying the holdings of the recommending
stockholder and a statement from the recommending stockholder of the length of time such shares have been held (alternatively the recommending stockholder may furnish a current Schedule&nbsp;13D,
Schedule&nbsp;13G, Form&nbsp;3, Form&nbsp;4 or Form&nbsp;5 filed with the SEC, together with a statement of the length of time that the shares have been held); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a statement from the recommending stockholder as to a good faith intention to continue to hold such shares through the date of the next Annual
Meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
recommendation must also be accompanied by the following information concerning the proposed nominee:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the information required by Items&nbsp;401, 403 and 404 of Regulation&nbsp;S-K under the Securities Act of 1933, as amended; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of all relationships between the proposed nominee and the recommending stockholder, including any agreements or understandings
regarding the nomination; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of all relationships between the proposed nominee and any of our competitors, customers, suppliers, labor unions or other persons
with special interests regarding Madrigal; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the contact information of the proposed nominee. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
recommending stockholder must also furnish a statement supporting a view that the proposed nominee possesses the minimum qualifications as set forth below for director nominees and
describing
the contributions that the proposed nominee would be expected to make to the Board of Directors and to the governance of Madrigal and must state whether, in its view, the proposed nominee, if elected,
would represent all stockholders and not serve for the purpose of advancing or favoring any particular stockholder or other constituency of Madrigal. The recommendation must also be accompanied by the
written consent of the proposed nominee (1)&nbsp;to be considered by the Nominating and Governance </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=20,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=334046,FOLIO='16',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Committee
and interviewed if the committee chooses to do so in its discretion, and (2)&nbsp;if nominated and elected, to serve as a director. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all potential candidates, the Nominating and Governance Committee may consider all factors it deems relevant, including the following threshold
criteria:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates should possess the highest personal and professional standards of integrity and ethical values; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates must be committed to promoting and enhancing the long-term value of Madrigal for its stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates must be able to represent fairly and equally all stockholders without favoring or advancing any particular stockholder or other
constituency of Madrigal; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates must have demonstrated achievement in one or more fields of business, professional, governmental, community, scientific or
educational endeavor, and possess mature and objective business judgment and expertise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates are expected to have sound judgment, derived from management or policy making experience that demonstrates an ability to function
effectively in an oversight role; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> candidates must have, and be prepared to devote, adequate time to the Board of Directors and its committees. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we do not have a formal policy on diversity, our Nominating and Governance Committee considers diversity of experience as one of the factors it considers in conducting its
assessment of director nominees, along with such other factors as it deems appropriate given the then current needs of the Board and the company, to maintain a balance of knowledge, experience and
capability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Nominating and Governance Committee will also take into account the extent to which the candidate would fill a present need on the Board of Directors, including the
extent to which a candidate meets the independence and experience standards promulgated by the SEC and by The Nasdaq Stock Market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Nominating and Governance Committee's written charter is publicly available through the "Investors&#151;Corporate Governance" section of our website at </FONT> <FONT SIZE=2><I>www.madrigalpharma.com</I></FONT><FONT SIZE=2>. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee is composed of Mr.&nbsp;Bate and Drs. Craves, Levy and Milligan. No member of our Compensation Committee has at any
time been an employee of ours. None of our executive officers serve as a member of the Board of Directors or compensation committee of any entity that has one or more executive officers serving as a
member of our Board of Directors or Compensation Committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_board_leadership_structure"> </A>
<A NAME="toc_dc47801_6"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently, our Chief Executive Officer, Dr.&nbsp;Friedman, serves as Chairman of our Board of Directors. Our Board of Directors believes that
Dr.&nbsp;Friedman is the director best situated to identify strategic opportunities for our company and to focus the activities of our Board of Directors due to his full-time commitment to the
business. Our Board of Directors also believes that Dr.&nbsp;Friedman's dual roles as Chairman of the Board and Chief Executive Officer promotes effective execution of our business strategy and
facilitates information flow between management and our Board of Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has determined that maintaining the independence of a majority of our directors helps maintain the board's independent oversight of management and ensures that the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=21,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=380796,FOLIO='17',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>appropriate
level of independence is applied to all board decisions. Our Audit, Compensation, and Nominating and Governance Committees, each consisting of independent directors, oversee critical
matters such as our accounting policies, financial reporting processes, internal control assessment over financial reporting, executive compensation program, and selection and evaluation of our
directors and director nominees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_our_board_of_directors__role_in_risk_oversight"> </A>
<A NAME="toc_dc47801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Board of Directors' Role in Risk Oversight    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has overall responsibility for risk oversight, including, as part of regular board and committee meetings, general
oversight of our executive officers' management of risks relevant to us. A fundamental part of risk oversight is not only understanding the material risks our company faces and the steps management is
taking to manage those risks, but also understanding what level of risk is appropriate for us. The involvement of our Board of Directors in reviewing our business strategy is an integral aspect of its
assessment of our management's tolerance for risk and also its determination of what constitutes an appropriate level of risk for us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
it has overall responsibility for risk oversight, our Board of Directors has delegated oversight responsibility related to certain risks to committees of the board. Our Audit
Committee is responsible for reviewing our policies with respect to risk assessment and risk management, as well as coordinating our internal control over financial reporting, disclosure controls and
procedures and code of conduct. Our Audit Committee receives regular reports from officers responsible for oversight of particular risks within our company at its regularly scheduled meetings and
other reports as requested by our Audit Committee from time to time. In addition, our Compensation Committee has authority to oversee risks as to our compensation programs and discusses with
management its annual assessment of our employee compensation policies and programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors satisfies its overall responsibility through full reports by each committee chair regarding the committee's considerations and actions, as well as through regular
reports directly from relevant officers within our company. Our Board of Directors believes that full and open communication between management and the board is essential for effective risk management
and oversight. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_stockholder_communications_to_the_board"> </A>
<A NAME="toc_dc47801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications to the Board    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, stockholders who have questions or concerns should contact our Investor Relations department at </FONT> <FONT SIZE=2><I>ir@madrigalpharma.com</I></FONT><FONT SIZE=2>. However,
any stockholders who wish to address questions regarding our business directly with the Board of Directors, or any
individual director, must prepare the communication in written form and mail or hand deliver the same to the following address: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B>ATTN: SECURITY HOLDER COMMUNICATION</B></FONT><FONT SIZE=2><BR>
Board of Directors<BR>
Madrigal Pharmaceuticals,&nbsp;Inc.<BR>
200 Barr Harbor Drive, Suite&nbsp;400<BR>
West Conshohocken, PA 19428 </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
communications should not exceed 500 words in length and must be accompanied by the following information:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a statement of the type and amount of the securities of Madrigal that the person holds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any special interest, meaning an interest not in the capacity as a stockholder of Madrigal, that the person has in the subject matter of the
communication; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the address, telephone number and e-mail address, if any, of the person submitting the communication. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=22,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=826551,FOLIO='18',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following types of communications are not appropriate for delivery to directors under these procedures:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> communications regarding individual grievances or other interests that are personal to the party submitting the communication and could not
reasonably be construed to be of concern to security holders or other constituencies of Madrigal (such as employees, members of the communities in which we operate our businesses, customers and
suppliers) generally; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> communications that advocate engaging in illegal activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> communications that, under community standards, contain offensive, scurrilous or abusive content; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> communications that have no rational relevance to the business or operations of Madrigal. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
will be distributed to the Board of Directors, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the
communications. Items that are unrelated to the duties and responsibilities of the Board of Directors may be excluded, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> junk mail and mass mailings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> r&eacute;sum&eacute;s and other forms of job inquiries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> surveys; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> solicitations or advertisements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any
outside director upon request. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc47801_executive_officers"> </A>
<A NAME="toc_dc47801_9"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding our current executive officers: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="293pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chairman of the Board and Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer, Executive Vice President, Research&nbsp;&amp; Development and Class&nbsp;II Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marc R. Schneebaum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Paul A. Friedman, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Friedman's biographical information is set forth above under "Management and Corporate
Governance&#151;The
Board of Directors." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rebecca Taub, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Taub's biographical information is set forth above under "Management and Corporate Governance&#151;The
Board of
Directors." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Marc R. Schneebaum</I></FONT><FONT SIZE=2> joined us as our Senior Vice President and Chief Financial Officer in July 2016. Mr.&nbsp;Schneebaum served as
Synta's Senior Vice President and Chief Financial Officer from December 2014 through the Merger in July 2016. Mr.&nbsp;Schneebaum has over 25&nbsp;years of experience in the biotechnology and
healthcare sector. Prior to joining Synta, Mr.&nbsp;Schneebaum served as a consultant in the healthcare industry. From 2011 to 2013, Mr.&nbsp;Schneebaum served as President, Chief Executive
Officer and a director of Predictive BioSciences,&nbsp;Inc., a commercial stage cancer diagnostics company. From 1997 to 2010, he served as President, Chief Executive Officer, and a director of
Sensors for Medicine and Science,&nbsp;Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and
Chief Financial Officer </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=23,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=83001,FOLIO='19',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<A NAME="page_dc47801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
Genetic Therapy,&nbsp;Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr.&nbsp;Schneebaum was a Vice President at Alex Brown&nbsp;&amp; Sons Incorporated, a
leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr.&nbsp;Schneebaum began his career in the accounting and
auditing group at KPMG&nbsp;LLP, advancing to Senior Manager in the management consulting group. Mr.&nbsp;Schneebaum has served as a director of GenVec,&nbsp;Inc., a publicly traded
biopharmaceutical company, since 2007. Mr.&nbsp;Schneebaum earned his B.S. in Business Administration, Accounting from the University of Maryland. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=24,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=660725,FOLIO='20',FILE='DISK106:[17ZBJ1.17ZBJ47801]DC47801A.;13',USER='SCAVALI',CD='28-APR-2017;14:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de47801_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de47801_compensation_discussion_and_analysis"> </A>
<A NAME="toc_de47801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION DISCUSSION AND ANALYSIS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Summary  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Compensation Discussion and Analysis explains our executive compensation program as it relates to the following "named executive officers"
whose compensation information is presented in the tables following this discussion in accordance with SEC rules: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Chen Schor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Former President and Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer, Executive Vice President, Research&nbsp;&amp; Development</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Marc R. Schneebaum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Wendy E. Rieder, Esq.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Former Senior Vice President, General Counsel</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Developments  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Merger Transaction  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;22, 2016, Synta completed the Merger with Private Madrigal. Upon consummation of the Merger, Mr.&nbsp;Schor resigned as Synta's
President and Chief Executive Officer and Ms.&nbsp;Rieder resigned as Synta's Senior Vice President and General Counsel. Paul A. Friedman, M.D. became our Chief Executive Officer and Rebecca Taub,
M.D. became our Chief Medical Officer and Executive Vice President, Research&nbsp;&amp; Development. Marc R. Schneebaum, Synta's Senior Vice President and Chief Financial Officer prior to the
consummation of the Merger, remained with us following the Merger as our Senior Vice President and Chief Financial Officer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Developments  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;28, 2016, our Compensation Committee engaged Compensia as our independent compensation consultant. Compensia is a compensation
consulting firm with experience in evaluating public biopharmaceutical companies and will help us collect and analyze data and to compare all components of our compensation program to the practices of
peer companies, as well as data from companies represented in compensation survey data for national and regional companies in the biopharmaceutical industry. Commencing in 2017, our Compensation
Committee, with input from our Board of Directors, senior management team and Compensia, will continue to evaluate and, as
needed, modify our compensation programs for our named executive officers in order to continue offering competitive compensation opportunities that are consistent with our executive compensation
objectives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=443383,FOLIO='21',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_22"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Direct Compensation Components  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of our direct compensation package are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="43%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="43%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Element

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fixed or<BR>
Variable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Compensation Objective </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Base Salary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fixed</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To attract and retain executives by offering fixed compensation that is competitive with market opportunities and that recognizes each executive's position, role, responsibility and experience.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Annual Cash Incentive Bonus</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Variable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To motivate and reward the achievement of annual individual performance objectives and corporate goals.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Equity Awards</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Variable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To align our executives' interests with the interests of stockholders and to promote the long-term retention of our executives and all employees through equity-based compensation in the form of stock options and/or
restricted stock.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee will review base salaries for our named executive officers on an annual basis as part of our compensation program and
may increase such base salaries for merit reasons, based on the executive officer's success in meeting or exceeding individual performance objectives established by our Compensation Committee, with
input from our Board of Directors and senior management term, and an assessment of whether significant corporate goals established by our Compensation Committee, with input from our Board of Directors
and senior management team, were achieved. Additionally, our Compensation Committee may adjust base salaries as warranted throughout the year for changes in the scope or breadth of an executive
officer's role or responsibilities. Our Compensation Committee will also evaluate an executive officer's base salary together with other components of the executive officer's compensation to ensure
that the executive officer's total compensation is in line with our overall compensation philosophy. If necessary, our Compensation Committee will also realign base salaries with market levels for the
same positions if our Compensation Committee identifies significant market changes in its data analysis. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017, our Compensation Committee reviewed the base salaries for our named executive officers and did not make any changes to such base salaries as in effect for the year
ending December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth below is a table describing the base salaries for all of our named executive officers for the year ending December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016<BR>
Base Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chen Schor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>510,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>370,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marc R. Schneebaum</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>365,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wendy E. Rieder</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>306,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Incentive Bonus  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to base salaries, our named executive officers are eligible to receive annual cash incentive bonuses. The annual cash incentive
bonus each named executive officer is eligible to receive is based on the individual's target bonus, as a percentage of base salary, and an assessment of individual </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=436337,FOLIO='22',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2>performance
and achievement of corporate goals by our Compensation Committee, with input from our Board of Directors and senior management team. The target bonus opportunities for our named executive
officers are set forth in their respective employment agreements as described below under
"&#151;Employment Agreements, Severance and Change in Control Arrangements." The following table sets forth the target bonus opportunities for our named executive officers in 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
Percentage<BR>
Opportunity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marc R. Schneebaum</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chen Schor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wendy E. Rieder, Esq.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
its sole discretion, our Compensation Committee may award cash bonuses above or below these targeted amounts on a case-by-case basis based on its review of individual performance and
achievement of corporate goals. Our Compensation Committee may, in its discretion, decide to not award bonus payments at all, notwithstanding the achievement of particular corporate goals or
individual contributions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
our fiscal year ended December&nbsp;31, 2016, we paid Dr.&nbsp;Friedman a pro-rated cash incentive bonus equal to $84,000, Dr.&nbsp;Taub a pro-rated cash incentive bonus equal
to $62,160 and Mr.&nbsp;Schneebaum a pro-rated cash incentive bonus equal to $61,320. These bonuses were paid in March 2017 based upon services rendered by our named executive officers during the
period from the consummation of the Merger through December&nbsp;31, 2016. In addition, Mr.&nbsp;Schneebaum received a cash incentive bonus equal to $85,167 upon consummation of the Merger. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-Term Incentives  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that long-term incentives in the form of equity-based awards are critical to meeting the following
objectives:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> focus all employees, including our named executive officers, on our long-term performance by aligning their interests with those of our
stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> retain our key employees and executives and maintain management continuity through longer-term vesting of our equity-based awards; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> promote an ownership culture through participation in equity-based compensation programs. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
2015 Stock Plan allows the grant of stock options, restricted stock, and other equity-based awards to employees, consultants and directors. We typically make an initial equity award
of stock options to new employees and annual equity grants as part of our overall compensation program. Our Compensation Committee authorized Dr.&nbsp;Friedman to make new hire stock option grants
to our employees, except for our executive officers, within certain parameters, beyond which approval of our Compensation Committee is required. Dr.&nbsp;Friedman may award new hire stock option
grants as of the employee's initial commencement of employment with an exercise price equal to the closing price of our common stock on the date of grant, in accordance with our 2015 Stock Plan.
Annual grants of options to all of our employees and equity awards to our executive officers are approved by our Compensation Committee, the timing of which we intend to be consistent each year with a
regularly scheduled meeting of our Compensation Committee and is not coordinated with the public release of nonpublic material information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=95502,FOLIO='23',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2016, following the consummation of the Merger, we granted Dr.&nbsp;Friedman an option to purchase 306,256 shares of our common stock, with an exercise price of $9.45 per
share, and a restricted stock award representing 153,128 shares of our common stock, we granted Dr.&nbsp;Taub an option to purchase 153,128 shares of our common stock, with an exercise price of
$9.45 per share, and a restricted stock award representing 30,626 shares of our common stock, and we granted Mr.&nbsp;Schneebaum an option to purchase 98,002 shares of our common stock, with an
exercise price of $9.45 per share, and a restricted stock award representing 24,501 shares of our common stock. In each case, we granted the stock options and restricted stock awards under our Amended
2015 Stock Plan, which we assumed in the merger. The foregoing stock options vested as to 25% of the shares on the closing of the Merger and the remainder of the shares will vest in equal annual
installments on the first, second and third anniversaries of the closing of the Merger. The repurchase right relating to the foregoing restricted award lapsed as to 25% of the shares on the closing of
the Merger and the repurchase right on the remaining shares will lapse in equal annual installments on the first, second and third anniversaries of the closing of the Merger. Such stock options and
restricted stock awards are subject to vesting acceleration under certain circumstances, as described below under "&#151;Employment Agreements, Severance and Change in Control Arrangements." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Benefits</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain broad-based benefits that are provided to all employees, including health insurance, life and disability insurance, dental insurance, and a 401(k) plan with
a matching company contribution. Our named executive officers participate in the benefits programs generally on the same basis as all employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=494936,FOLIO='24',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_25"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de47801_executive_officer_and_director_compensation"> </A>
<A NAME="toc_de47801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICER AND DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de47801_summary_compensation_table"> </A>
<A NAME="toc_de47801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows for the fiscal years ended December&nbsp;31, 2016, and December&nbsp;31, 2015 (where applicable), the compensation
awarded to or earned by our principal executive officer, former principal executive officer, and our two other most highly compensated executive officers who were serving as executive officers as of
December&nbsp;31, 2016. The persons listed in the following table are referred to herein as the "named executive officers." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>175,898</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>84,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,447,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,278,545</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3,985,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chen Schor(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
297,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
178,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
351,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
810,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
1,638,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Former President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>471,042</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>306,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>359,985</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,899,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>7,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3,044,877</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
162,705</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
62,160</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
289,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
1,139,272</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
1,654,018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Medical Officer,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Vice President,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Research&nbsp;&amp; Development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Marc R. Schneebaum</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
365,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
146,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
393,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
729,135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
51,247</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
1,685,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Senior Vice President,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>346,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>146,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>169,635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>27,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>690,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Wendy E. Rieder, Esq.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
178,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
71,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
162,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
330,817</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
742,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Senior Vice President,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>303,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>122,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>486,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>7,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>901,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>These
amounts represent the aggregate grant date fair value of stock awards and option awards, respectively, granted in each year presented calculated in accordance
with Financial Accounting Standards Board Accounting Standards Certifications, or the FASB ASC, Topic 718. See our discussion of "Stock-Based Compensation" under Notes&nbsp;2, 3 and 9 to our audited
consolidated financial statements included in our Annual Report on Form&nbsp;10-K filed on March&nbsp;31, 2017, or the Annual Report, for a discussion of all assumptions made by us in determining
the grant date fair values of our equity awards. See also our discussion of stock-based compensation under Item&nbsp;7 "Management's Discussion and Analysis of Financial Condition and Results of
Operations&#151;Critical Accounting Policies and Estimates" of the Annual Report.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Mr.&nbsp;Schor
resigned as President and Chief Executive Officer of Synta effective upon the consummation of the Merger on July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
a cash bonus for performance in 2015, which was paid in March 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
matching contributions made under our 401(k) plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Reflects
a cash award paid in 2016 for performance in 2015 under our prior annual incentive bonus program.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
a relocation allowance of $20,000 and matching contributions of $7,950 made under our 401(k) plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
a cash bonus for performance in 2015, which was paid in March 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Ms.&nbsp;Rieder
resigned as Senior Vice President and General Counsel of Synta effective upon the consummation of the Merger on July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
an accrued paid time off payment of $37,268, matching contributions of $7,950 made under our 401(k) plan and a severance payment of $765,000.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
an accrued paid time off payment of $42,289 and matching contributions of $7,950 made under our 401(k) plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
an accrued paid time off payment of $22,361, matching contributions of $1,913 made under our 401(k) plan and a severance payment of $306,000. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=196295,FOLIO='25',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_26"> </A>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de47801_outstanding_equity_awards_at_fiscal_year_end"> </A>
<A NAME="toc_de47801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Fiscal Year End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows stock options and shares of unvested stock held by each of our named executive officers as of December&nbsp;31,
2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
Grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Paul A. Friedman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>07/22/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>76,564</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>229,692</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>07/22/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>114,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,711,205</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Rebecca Taub, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
07/22/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
38,282</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
114,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
9.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
07/22/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
22,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
342,238</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Executive Vice President,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Research&nbsp;&amp; Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Marc R. Schneebaum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
07/22/16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
24,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
73,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
9.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
07/22/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
18,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
273,787</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Senior Vice President,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10/02/15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,093</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10/02/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/08/14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,214</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,214</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>99.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12/08/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,071</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
market value of the stock awards was determined by multiplying the number of shares by $14.90, the closing price of our common stock on The Nasdaq Global Market
on December&nbsp;30, 2016, the last trading day of our fiscal year.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
stock option vests as to 25% of the underlying shares on the grant date and as to 25% of the remaining shares on each of the first, second and third
anniversaries of the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
restricted stock grant vests as to a lapsing repurchase right as to 25% of the shares on the grant date and as to 25% of the remaining shares on each of the
first, second and third anniversaries of the grant date. </FONT></DD></DL>
 </DIV>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de47801_employment_agreements,_severan__emp02667"> </A>
<A NAME="toc_de47801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Paul A. Friedman, M.D.  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;13, 2016, Private Madrigal entered into a contingent employment agreement, or the Friedman Letter Agreement, with
Dr.&nbsp;Friedman, for the position of Chairman and Chief Executive Officer of our company following the completion of the Merger. We assumed the Friedman Letter Agreement upon completion of the
Merger. Under the terms of the Friedman Letter Agreement, Dr.&nbsp;Friedman will receive an annual base salary of $400,000 and an annual performance-based bonus of up to 50% of his base salary. In
addition, upon the consummation of the Merger, Dr.&nbsp;Friedman received equity awards, including stock options to purchase 306,256 shares of our common stock and a restricted stock award
representing 153,128 shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing stock options vested as to 25% of the shares on the grant date and the remainder of the shares will vest in equal annual installments on the first, second and third
anniversaries of the grant date. The repurchase right relating to the foregoing restricted award lapsed as to 25% of the shares on the grant date and the repurchase right on the remaining shares will
lapse in equal annual installments on the first, second and third anniversaries of the grant date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Friedman
is also entitled to severance benefits if we terminate his employment without "Cause" or if Dr.&nbsp;Friedman voluntarily resigns for "Good Reason," each as defined
in the applicable employment agreement, which we refer to herein collectively as a "Qualifying Separation," consisting of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a severance payment equal to 12&nbsp;months of Dr.&nbsp;Friedman's then-current base salary and target bonus, payable (i)&nbsp;in a lump
sum for a Qualifying Separation, if such Qualifying Separation </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=30,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=694530,FOLIO='26',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_27"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>occurs
following a change of control of our company and (ii)&nbsp;in 12 equal monthly payments if such Qualifying Separation does not occur following a change of control of our company; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> full vesting of restricted stock and stock options held by Dr.&nbsp;Friedman upon a Qualifying Separation (the mere occurrence of a change of
control of our company is not enough to trigger this acceleration; a Qualifying Separation must occur); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reimbursement of continuation of medical benefits for 12&nbsp;months following a Qualifying Separation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Friedman
has also entered into a customary indemnification agreement with us with respect to his service as an officer and director of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rebecca Taub, M.D.  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;13, 2016, Private Madrigal entered into a contingent employment agreement, or the Taub Letter Agreement, with Rebecca Taub, M.D.
for the position of Chief Medical Officer and Executive Vice President, Research&nbsp;&amp; Development, of our company following the completion of the Merger. We assumed the Taub Letter Agreement upon
completion of the Merger. Under the terms of the Taub Letter Agreement, Dr.&nbsp;Taub will receive an annual base salary of $370,000 and an annual performance based bonus of up to 40% of her base
salary. In addition, upon the consummation of the Merger, Dr.&nbsp;Taub received equity awards, including stock options to purchase 153,128 shares of our common stock and a restricted stock award
representing 30,626 shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing stock options vested as to 25% of the shares on the grant date and the remainder of the shares will vest in equal annual installments on the first, second and third
anniversaries of the grant date. The repurchase right relating to the foregoing restricted award lapsed as to 25% of the shares on the grant date and the repurchase right on the remaining shares will
lapse in equal annual installments on the first, second and third anniversaries of the grant date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Taub
is also entitled to severance benefits upon a Qualifying Separation consisting of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a severance payment equal to 12&nbsp;months of Dr.&nbsp;Taub's then-current base salary and target bonus, payable (i)&nbsp;in a lump sum
for a Qualifying Separation, if such Qualifying Separation occurs following a change of control of our company and (ii)&nbsp;in 12 equal monthly payments if such Qualifying Separation does not occur
following a change of control of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> full vesting of restricted stock and stock options held by Dr.&nbsp;Taub upon a Qualifying Separation (the mere occurrence of a change of
control of our company is not enough to trigger this acceleration; a Qualifying Separation must occur); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reimbursement of continuation of medical benefits for 12&nbsp;months following a Qualifying Separation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Taub
has also entered into a customary indemnification agreement with us with respect to her service as an officer and director of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marc R. Schneebaum  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to a letter agreement dated November&nbsp;24, 2014, with Mr.&nbsp;Schneebaum, Mr.&nbsp;Schneebaum will receive an annual base
salary of $365,000. Under our bonus policy,
Mr.&nbsp;Schneebaum is eligible to receive an annual performance-based bonus of up to 40% of his base salary. In addition, upon the consummation of the Merger, Mr.&nbsp;Schneebaum received equity
awards, including stock options to purchase 98,002 shares of our common stock and a restricted stock award representing 24,501 shares of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=31,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=210209,FOLIO='27',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<A NAME="page_de47801_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing stock options vested as to 25% of the shares on the grant date and the remainder of the shares will vest in equal annual installments on the first, second and third
anniversaries of the grant date. The repurchase right relating to the foregoing restricted award lapsed as to 25% of the shares on the grant date and the repurchase right on the remaining shares will
lapse in equal annual installments on the first, second and third anniversaries of the grant date. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of a severance and change of control agreement entered into with Mr.&nbsp;Schneebaum, he is also entitled to severance benefits upon a Qualifying Separation
consisting of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a severance payment equal to 12&nbsp;months of Mr.&nbsp;Schneebaum's then-current base salary and target bonus, payable (i)&nbsp;in a
lump sum if such Qualifying Separation occurs following a change of control of our company, and (ii)&nbsp;in 12 equal monthly payments if such Qualifying Separation does not occur following a change
of control of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> (i) full vesting of restricted stock and stock options held by Mr.&nbsp;Schneebaum upon a Qualifying Separation, if such Qualifying
Separation occurs following a change in control of our company, and (ii)&nbsp;six months' vesting of restricted stock and stock options held by Mr.&nbsp;Schneebaum upon a Qualifying Separation, if
such Qualifying Separation does not occur following a change of control of our company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reimbursement of continuation of medical benefits for 12&nbsp;months following a Qualifying Separation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Schneebaum
has also entered into a customary indemnification agreement with us with respect to his service as an officer of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de47801_director_compensation"> </A>
<A NAME="toc_de47801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Director Compensation Program  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A non-employee director is a director who is not employed by us and who does not receive compensation from us or have a business relationship
with us that would require disclosure under certain SEC rules. Our Board of Directors approves the form and amount of non-employee director compensation. Our Compensation Committee makes
recommendations on the form and amount of non-employee director compensation. In July 2016, we adopted a non-employee director compensation program that became effective upon its adoption. The terms
of our non-employee director compensation program are described below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Initial Stock Option Grant Upon Appointment or Election  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each new non-employee director automatically receives a stock option to purchase 20,000 shares of our common stock upon his or her initial
appointment or election to our Board of Directors, to be granted on or as soon as reasonably practicable after the date of such non-employee director's initial appointment or election, as applicable.
Each such stock option has an exercise price equal to the fair market value of our common stock on the date of grant and vests as to 25% of the underlying shares on the first anniversary of the grant
date and as to an additional 6.25% of the underlying shares on the last calendar day of each successive quarterly period thereafter, subject to the non-employee director's continued service as a
director. Each such stock option will terminate on the earlier of ten years from the date of grant and three months after the recipient ceases to serve as a director, except in the case of death or
disability, in which event the option will terminate one year from the date of the non-employee director's death or disability. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=32,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=871394,FOLIO='28',FILE='DISK106:[17ZBJ1.17ZBJ47801]DE47801A.;13',USER='HYUNG',CD='28-APR-2017;16:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg47801_1_29"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Stock Option Awards  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each non-employee director automatically receives an annual stock option on the date of each annual meeting of our stockholders, or the Annual
Grant Date, to purchase 10,000 shares of our common stock. Each such stock option has an exercise price equal to the fair market value of our common stock on the Annual Grant Date and vests in full on
the first anniversary of the Annual Grant Date, subject to the non-employee director's continued service as a director on such date. Each such stock option will terminate on the earlier of ten years
from the date of grant and three months after the recipient ceases to serve as a director, except in the case of death or disability, in which event the option will terminate one year from the date of
the non-employee director's death or disability. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to stock options, each non-employee director is eligible to receive for his or her service on our Board of Directors or committees
thereof annual cash retainers (payable quarterly, in arrears), as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Retainer ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board Member</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Governance Committee Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee Member</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee Member</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Governance Committee Member</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally, we reimburse our non-employee directors for their reasonable out-of-pocket expenses incurred in attending meetings of our Board of
Directors and committee meetings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg47801_director_compensation_table"> </A>
<A NAME="toc_dg47801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information about the compensation paid to the non-employee members of our Board of Directors who served as a
director during the year ended December&nbsp;31, 2016. Other than as set forth in the table and described more fully below, during the year ended December&nbsp;31, 2016, we did not pay any fees
to, make any equity awards to or pay any other compensation to the non-employee members of our Board of Directors. The stock options granted in 2016 and disclosed in the table below were granted under
our Amended 2015 Stock Plan. Neither Dr.&nbsp;Friedman, our Chief Executive Officer and Chairman of our Board of Directors, nor Dr.&nbsp;Taub, our Chief Medical Officer, Executive Vice President,
Research&nbsp;&amp; Development and a member of our Board of Directors, nor Mr.&nbsp;Schor, our former Chief Executive Officer and a member of our Board of Directors prior to the consummation of the
Merger, received any compensation from us in 2016 for service as a director and they are not included in the table below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=33,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=390013,FOLIO='29',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
SEC rules require us to disclose this information as of the end of our last fiscal year, and because we consummated the Merger in July 2016, at which time our board composition
changed, some of the individuals listed in the table below were no longer serving on our board at December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned or<BR>
Paid in Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(3)(6) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth M. Bate*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>176,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fred B. Craves, Ph.D.*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>171,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith R. Gollust*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>180,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard S. Levy, M.D.**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>114,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>137,552</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Milligan, Ph.D.*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>171,213</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bruce Kovner***</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald W. Kufe, M.D.***</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott Morenstein***</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,367</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,367</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William S. Reardon, C.P.A.***</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert N. Wilson***</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,521</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,521</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul A. Friedman, M.D.****</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Messrs.&nbsp;Bate
and Gollust and Drs. Craves and Milligan joined our Board of Directors effective July&nbsp;22, 2016. Mr.&nbsp;Gollust served on the board of
directors of Synta until the consummation of the Merger on July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Levy
joined our Board of Directors effective August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>***</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Messrs.&nbsp;Kovner,
Morenstein, Reardon and Wilson and Dr.&nbsp;Kufe resigned as members of the board of directors of Synta effective upon the consummation of
the Merger on July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>****</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Friedman
resigned as a member of the board of directors of Synta effective April&nbsp;13, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$6,631 paid to Mr.&nbsp;Gollust in connection with his service as a member of the board of directors of Synta prior to the consummation of the Merger.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
fees earned or paid in cash to Messrs.&nbsp;Kovner, Morenstein, Reardon and Wilson and Dr.&nbsp;Kufe in connection with their service as members of
the board of directors of Synta prior to the consummation of the Merger.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in this column represent the aggregate grant date fair value of option awards granted to or earned by the applicable director in our fiscal year 2016
computed in accordance with FASB ASC Topic 718. See our discussion of "Stock-Based Compensation" under Notes&nbsp;2, 3 and 9 to our audited consolidated financial statements included in our Annual
Report on Form&nbsp;10-K filed on March&nbsp;31, 2017, or the Annual Report, for a discussion of all assumptions made by us in determining the grant date fair values of our equity awards. See also
our discussion of stock-based compensation under Item&nbsp;7 "Management's Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical Accounting Policies and
Estimates" of the Annual Report.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the grant date fair value of an option grant to purchase 20,000 shares of our common stock, at an exercise price of $9.45 per share, granted on
July&nbsp;22, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the grant date fair value of an option grant to purchase 20,000 shares of our common stock, at an exercise price of $7.36 per share, granted on
August&nbsp;11, 2016. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=34,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=999211,FOLIO='30',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
following table shows the total number of outstanding and vested stock options, and shares of restricted common stock as of December&nbsp;31, 2016, the last
day of our fiscal year, that have been issued as director compensation.  </FONT></DD></DL>
 </DIV>

 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B># of Stock<BR>
Options<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B># of Stock<BR>
Options<BR>
Vested </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth M. Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fred B. Craves, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith R. Gollust</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard S. Levy, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Milligan, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bruce Kovner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald W. Kufe, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott Morenstein</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William S. Reardon, C.P.A.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert N. Wilson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=35,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=534481,FOLIO='31',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg47801_equity_compensation_plan_information"> </A>
<A NAME="toc_dg47801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EQUITY COMPENSATION PLAN INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides certain aggregate information with respect to all of our equity compensation plans in effect as of
December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="124pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="100pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="136pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan Category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(a)<BR>
Number of Securities to be<BR>
Issued Upon Exercise of<BR>
Outstanding Options,<BR>
Warrants and Rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(b)<BR>
Weighted Average<BR>
Exercise Price of<BR>
Outstanding Options,<BR>
Warrants and Rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(c)<BR>
Number of Securities<BR>
Remaining Available for<BR>
Future Issuance Under<BR>
Equity Compensation Plans<BR>
(excluding securities reflected<BR>
in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Compensation Plans Approved by Security Holders(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>941,273</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>651,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>941,273</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>651,261 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
plans consist of our Amended 2015 Stock Plan and Amended and Restated 2006 Stock Plan, or our 2006 Stock Plan. In connection with the adoption of our Amended
2015 Stock Plan in June 2015, our 2006 Stock Plan was terminated and thereafter no further stock options were granted under the 2006 Stock Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of common stock available for future issuance under our Amended 2015 Stock Plan.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg47801_compensation_committee_report"> </A>
<A NAME="toc_dg47801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of our Board of Directors has reviewed and discussed the Compensation Discussion and Analysis required by
Item&nbsp;402(b) of Regulation&nbsp;S-K, which appears elsewhere in this proxy statement, with our management. Based on this review and discussion, the Compensation Committee has recommended to
the Board of Directors that the Compensation Discussion and Analysis be included in our proxy statement and incorporated by reference in our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="327pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>MEMBERS OF THE COMPENSATION COMMITTEE:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard S. Levy, M.D. (Chairman)<BR>
Kenneth M. Bate<BR>
Fred B. Craves, Ph.D.<BR>
David Milligan, Ph.D.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=36,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=215195,FOLIO='32',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg47801_section_16(a)_benefici__dg402030"> </A>
<A NAME="toc_dg47801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our records reflect that all reports which were required to be filed pursuant to Section&nbsp;16(a) of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, were filed on a timely basis except that, due to an administrative error, the initial Section&nbsp;16 filings made for Drs. Friedman, Taub, Craves, Milligan and Levy,
and Messrs.&nbsp;Schneebaum, Bate and Gollust, were filed late. We received either a written statement from our directors, officers and 10% stockholders or know from other means that any required
Forms&nbsp;5 were filed or that no Forms&nbsp;5 were required to be filed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg47801_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dg47801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than compensation arrangements for our named executive officers and directors, we describe below each transaction or series of similar
transactions, since January&nbsp;1, 2016, to which we were a party or will be a party, in which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts involved exceeded or will exceed $120,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the
foregoing persons, had or will have a direct or indirect material interest. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation
for our named executive officers and directors is described in the section entitled "Compensation Discussion and Analysis." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg47801_merger,_financing_and_change_of_control_bonus_plan"> </A>
<A NAME="toc_dg47801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Merger, Financing and Change of Control Bonus Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;22, 2016, Synta completed the Merger with Private Madrigal in accordance with the terms of the Merger Agreement, pursuant to
which Saffron Merger Sub,&nbsp;Inc., a wholly-owned subsidiary of Synta, merged with and into Private Madrigal, with Private Madrigal surviving as a wholly-owned subsidiary of Synta. Also on
July&nbsp;22, 2016, in connection with, and prior to completion of, the Merger, Synta effected a 1-for-35 reverse stock split of its common stock and, following the Merger, changed its name from
"Synta Pharmaceuticals Corp." to "Madrigal Pharmaceuticals,&nbsp;Inc." Following the completion of the Merger, Private Madrigal changed its name to "Canticle Pharmaceuticals,&nbsp;Inc." Under the
terms of the Merger Agreement, at the effective time of the Merger, Synta issued an aggregate of 7,253,655 shares of its common stock to Private Madrigal stockholders, at an exchange rate of 0.1593
shares of common stock, after taking into account the reverse stock split, in exchange for each share of Private Madrigal common stock outstanding immediately prior to the Merger. The exchange rate
was calculated by a formula that was determined through arms-length negotiations between Synta and Private Madrigal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;13, 2016, concurrently with the execution of the Merger Agreement, Private Madrigal entered into a Restated Note Purchase Agreement, or the Purchase Agreement, with
certain funds associated with Bay City Capital, or the Bay City Funds, Private Madrigal's largest stockholder and a holder of more than 5% of our capital stock, Dr.&nbsp;Craves, a director of our
company and an affiliate of the Bay City Funds, and SQN&nbsp;LLC, an investment entity affiliated with Dr.&nbsp;Taub and Dr.&nbsp;Friedman, pursuant to which such investors irrevocably committed
to provide Private Madrigal with $9,000,000 of funding during the pendency of the Merger in the form of convertible promissory notes. Upon the consummation of the Merger, the principal amount
outstanding under these convertible notes automatically converted into shares of common stock of Synta in accordance with the exchange ratio described above, whereupon the Bay City Funds received an
aggregate of 5,657,854 shares of Synta common stock, Dr.&nbsp;Craves received 296,067 shares of Synta common stock and SQN&nbsp;LLC received 729,066 shares of Synta common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, Private Madrigal adopted a Change in Control Bonus Plan, or the Madrigal CoC Bonus Plan, prior to the consummation of the Merger pursuant to which certain key service
providers </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=37,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=315155,FOLIO='33',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
Private Madrigal would receive bonuses upon the consummation of a change of control transaction such as the Merger. The purpose of the Madrigal CoC Bonus Plan was to compensate such key service
providers for past services, and secure, to a limited extent, their continued services to Private Madrigal through the consummation of the Merger. In accordance with the Madrigal CoC Bonus Plan, up to
10% of the net proceeds from the Merger were paid to eligible participants based upon their participation agreement, which was funded out of the consideration paid to certain stockholders of Private
Madrigal in connection with the Merger. Upon consummation of the Merger, an aggregate of 570,668 shares of Synta common stock were issued to participants in the Madrigal CoC Bonus Plan, including
404,132 shares of Synta common stock issued to Dr.&nbsp;Taub. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg47801_indemnification_agreements"> </A>
<A NAME="toc_dg47801_7"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into indemnification agreements with each of our directors and executive officers and certain other key employees. The
indemnification agreements will provide that we indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive
officer, or other key employee because of his or her status as one of our directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, our restated
certificate of incorporation and our amended and restated bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, we will advance all
expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg47801_policy_for_approval_of_related_person_transactions"> </A>
<A NAME="toc_dg47801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy for Approval of Related Person Transactions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the written charter of our Audit Committee, the Audit Committee is responsible for reviewing and approving, prior to our entry into
any such transaction, all transactions in
which we are a participant and in which any of the following persons has or will have a direct or indirect material interest:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the beneficial owners of more than 5% of our securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the immediate family members of any of the foregoing persons; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other persons whom the Board of Directors determines may be considered related persons. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of these procedures, "immediate family members" means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, and any person (other than a tenant or employee) sharing the household with the executive officer, director or 5% beneficial owner. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
reviewing and approving such transactions, the Audit Committee shall obtain, or shall direct our management to obtain on its behalf, all information that the committee believes to be
relevant and important to a review of the transaction prior to its approval. Following receipt of the necessary information, a discussion shall be held of the relevant factors if deemed to be
necessary by the committee prior to approval. If a discussion is not deemed to be necessary, approval may be given by written consent of the committee. This approval authority may also be delegated to
the chairman of the Audit Committee in some circumstances. No related person transaction shall be entered into prior to the completion of these procedures. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee or its chairman, as the case may be, shall approve only those related person transactions that are determined to be in, or not inconsistent with, the best interests
of us and our stockholders, taking into account all available facts and circumstances as the committee or the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=38,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=172816,FOLIO='34',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<A NAME="page_dg47801_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>chairman
determines in good faith to be necessary. These facts and circumstances will typically include, but not be limited to, the benefits of the transaction to Madrigal; the impact on a director's
independence in the event the related person is a director, an immediate family member of a director or an entity in which a director is a partner, stockholder or executive officer; the availability
of other sources for comparable products or services; the terms of the transaction; and the terms of comparable transactions that would be available to unrelated third parties or to employees
generally. No member of the Audit Committee shall participate in any review, consideration or approval of any related person transaction with respect to which the member or any of his or her immediate
family members is the related person. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=39,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=430812,FOLIO='35',FILE='DISK106:[17ZBJ1.17ZBJ47801]DG47801A.;8',USER='SCAVALI',CD='28-APR-2017;14:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di47801_1_36"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di47801_proposal_no._1__election_of_directors"> </A>
<A NAME="toc_di47801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1:<BR>  ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_summary"> </A>
<A NAME="toc_di47801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors currently consists of seven members, classified into three classes as follows: Paul A. Friedman, M.D. and Kenneth M. Bate
are the Class&nbsp;I directors with a term ending at the upcoming 2017 Annual Meeting of Stockholders. Rebecca Taub, M.D. and Fred B. Craves, Ph.D. constitute the Class&nbsp;II directors with a
term ending at the 2018 Annual Meeting of
Stockholders; and Keith R. Gollust, David Milligan, Ph.D. and Richard S. Levy, M.D. are the Class&nbsp;III directors with a term ending at the 2019 Annual Meeting of Stockholders. At each Annual
Meeting of Stockholders, directors are elected for a full term of three years to succeed those directors whose terms are expiring. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;2, 2017, the Board of Directors accepted the recommendation of the Nominating and Governance Committee and voted to nominate Paul A. Friedman, M.D. and Kenneth M. Bate
for election at the Annual Meeting for a term of three years to serve until the 2020 Annual Meeting of Stockholders, and until their respective successors have been elected and qualified, or until
their earlier death, resignation, retirement or removal. Unless authority to vote for any of these nominees is withheld, the shares represented by a validly executed proxy will be voted FOR the
election as directors of Dr.&nbsp;Friedman and Mr.&nbsp;Bate. In the event that either nominee should become unable or unwilling to serve, the shares represented by a validly executed proxy will
be voted for the election of such other person as the Board of Directors may recommend in his place, unless the Board of Directors chooses to reduce the number of directors serving on the Board of
Directors. We have no reason to believe that either nominee will be unable or unwilling to serve as a director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_vote_required"> </A>
<A NAME="toc_di47801_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors are elected by a plurality of the affirmative votes cast by those shares present in person, or represented by proxy, and entitled to
vote at the Annual Meeting. The nominees for director receiving the highest number of affirmative votes will be elected. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_recommendation_of_the_board_of_directors"> </A>
<A NAME="toc_di47801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" THE ELECTION OF DR. FRIEDMAN AND MR. BATE
AS DIRECTORS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN ACCORDANCE WITH THE BOARD'S RECOMMENDATION UNLESS A STOCKHOLDER HAS INDICATED OTHERWISE ON THE PROXY.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=340596,FOLIO='36',FILE='DISK106:[17ZBJ1.17ZBJ47801]DI47801A.;6',USER='SCAVALI',CD='28-APR-2017;14:09' -->
<A NAME="page_di47801_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di47801_proposal_no._2__ratification_o__pro03631"> </A>
<A NAME="toc_di47801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2:<BR>  RATIFICATION OF APPOINTMENT OF<BR>  INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_summary_1"> </A>
<A NAME="toc_di47801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has appointed PricewaterhouseCoopers&nbsp;LLP, independent registered public accounting firm, to audit our financial
statements for the fiscal year ending December&nbsp;31, 2017. PricewaterhouseCoopers&nbsp;LLP audited our financial statements for the fiscal year ended December&nbsp;31, 2016. The Board of
Directors proposes that our stockholders ratify this appointment. In the event our stockholders do not ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public
accounting firm, the Audit Committee will reconsider its appointment. We expect that a representative of PricewaterhouseCoopers&nbsp;LLP will be present at the Annual Meeting, will be able to make a
statement if they so desire, and will be available to respond to appropriate questions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
July&nbsp;22, 2016, the Audit Committee approved the dismissal of Ernst&nbsp;&amp; Young&nbsp;LLP, Synta's independent registered public accounting firm, as our independent
registered public accounting firm, effective as of such date. Subsequently, the Audit Committee conducted a competitive process to determine our independent registered public accounting firm for the
fiscal year ended December&nbsp;31, 2016. As a result of this process, on September&nbsp;26, 2016, the Audit Committee approved, on our behalf, the engagement of PricewaterhouseCoopers&nbsp;LLP
as our independent registered public accounting firm for the fiscal year ended December&nbsp;31, 2016. On September&nbsp;28, 2016, the Audit Committee formally engaged
PricewaterhouseCoopers&nbsp;LLP. In deciding to appoint PricewaterhouseCoopers&nbsp;LLP, the Audit Committee reviewed auditor independence issues and existing relationships with
PricewaterhouseCoopers&nbsp;LLP and concluded that PricewaterhouseCoopers&nbsp;LLP has no relationship with the Company that would impair its independence for the fiscal year ending
December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp;
Young&nbsp;LLP's audit reports on Synta's financial statements as of and for each of the two fiscal years ended December&nbsp;31, 2015 and December&nbsp;31, 2014,
contained no adverse opinion or disclaimer of
opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles. During the two fiscal years ended December&nbsp;31, 2015 and December&nbsp;31, 2014, and the
subsequent interim period through July&nbsp;22, 2016, the date of the dismissal of Ernst&nbsp;&amp; Young&nbsp;LLP, there were no disagreements (as defined in Item&nbsp;304(a)(1)(iv) of
Regulation&nbsp;S-K and the related instructions to Item&nbsp;304 of Regulation&nbsp;S-K) between Synta and Ernst&nbsp;&amp; Young&nbsp;LLP on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure which, if not resolved to Ernst&nbsp;&amp; Young&nbsp;LLP's satisfaction, would have caused Ernst&nbsp;&amp; Young&nbsp;LLP to make
reference to the subject matter of the disagreement in connection with its report for such periods. In addition, during the periods identified above, there were no reportable events (as that term is
defined in Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
previously reported the Audit Committee's determination to dismiss Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm on a Current Report on
Form&nbsp;8-K filed by us with the SEC on July&nbsp;22, 2016. We provided Ernst&nbsp;&amp; Young&nbsp;LLP with a copy of the foregoing disclosures and requested that Ernst&nbsp;&amp;
Young&nbsp;LLP furnish us with a letter addressed to the SEC stating whether it agreed with the foregoing disclosures and, if not, stating the respects in which it did not agree. A copy of the
letter from Ernst&nbsp;&amp; Young&nbsp;LLP was filed as Exhibit&nbsp;16.1 to our Form&nbsp;8-K filed on July&nbsp;22, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the two fiscal years ended December&nbsp;31, 2015 and December&nbsp;31, 2014, and the subsequent interim period through September&nbsp;28, 2016, the date of our engagement
of PricewaterhouseCoopers&nbsp;LLP, neither we nor anyone on our behalf consulted with PricewaterhouseCoopers&nbsp;LLP regarding (i)&nbsp;the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided to us
that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=369038,FOLIO='37',FILE='DISK106:[17ZBJ1.17ZBJ47801]DI47801A.;6',USER='SCAVALI',CD='28-APR-2017;14:09' -->
<A NAME="page_di47801_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>PricewaterhouseCoopers&nbsp;LLP
concluded was an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii)&nbsp;any matter that
was either the subject of a disagreement (as defined in Item&nbsp;304(a)(1)(iv) of SEC Regulation&nbsp;S-K and the instructions to Item&nbsp;304) or a reportable event (as defined in
Item&nbsp;304(a)(1)(v) of SEC Regulation&nbsp;S-K). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_accounting_fees_and_services"> </A>
<A NAME="toc_di47801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounting Fees and Services    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the aggregate fees for professional services rendered by PricewaterhouseCoopers&nbsp;LLP to us for the year
ended December&nbsp;31, 2016, Friedman&nbsp;LLP,
Private Madrigal's independent accounting firm, for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016, and Ernst&nbsp;&amp; Young&nbsp;LLP, Synta's independent registered public
accounting firm, for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016. The Audit Committee pre-approved all services fees described below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>763,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>575,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-related fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All other fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>799,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>594,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Fees  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit services were comprised of services associated with the quarterly reviews and annual audits of our financial statements. Audit services in
2016 and 2015 also include services in connection with our at-the-market offerings. In addition, audit services in 2016 include services rendered in connection with the Merger. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Fees  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax fees for 2016 and 2015 included the services of PricewaterhouseCoopers&nbsp;LLP and Ernst&nbsp;&amp; Young&nbsp;LLP in connection with tax
compliance, tax planning and tax advice. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_policy_on_audit_committee_pre-__pol04236"> </A>
<A NAME="toc_di47801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent  Auditors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with policies of the SEC regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation
and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and
permissible non-audit services provided by our independent registered public accounting firm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement of an independent registered public accounting firm for the next year's audit, management will submit an aggregate of services expected to be rendered during that
year for each of four categories of services to the Audit Committee for approval. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Audit</I></B></FONT><FONT SIZE=2> services include audit work performed in the preparation of financial statements, as well as work that generally
only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial
accounting and/or reporting standards. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=406259,FOLIO='38',FILE='DISK106:[17ZBJ1.17ZBJ47801]DI47801A.;6',USER='SCAVALI',CD='28-APR-2017;14:09' -->
<A NAME="page_di47801_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Audit-Related</I></B></FONT><FONT SIZE=2> services are for assurance and related services that are traditionally performed by an independent
registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Tax</I></B></FONT><FONT SIZE=2> services include all services performed by an independent registered public accounting firm's tax personnel except
those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Other Fees</I></B></FONT><FONT SIZE=2> are those associated with services not captured in the other categories. We generally do not request such
services from our independent registered public accounting firm. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement, the Audit Committee pre-approves these services by category of service. The fees are budgeted and the Audit Committee requires our independent registered public
accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become necessary to
engage our independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit Committee requires specific pre-approval
before engaging our independent registered public accounting firm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any
pre-approval decisions to the Audit Committee at its next scheduled meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_report_of_audit_committee"> </A>
<A NAME="toc_di47801_9"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Report of Audit Committee    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee, which consists entirely of directors who meet the independence and experience requirements of The Nasdaq Stock Market, has
furnished the following report: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee assists the Board of Directors in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and
the quality of internal and external audit processes. The Audit Committee's role and responsibilities are set forth in a charter adopted by the Board of Directors, which is publicly available through
the "Investors&#151;Corporate Governance" section of our website at </FONT><FONT SIZE=2><I>www.madrigalpharma.com</I></FONT><FONT SIZE=2>. The Audit Committee reviews and reassesses its
charter annually and recommends any changes to the Board of Directors for approval. The Audit Committee is responsible for overseeing our overall financial reporting process, and for the appointment,
compensation, retention, and oversight of the work of our independent registered public accounting firm. In fulfilling its responsibilities for the financial statements for the fiscal year ended
December&nbsp;31, 2016, the Audit Committee took the following actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2016 with management and
PricewaterhouseCoopers&nbsp;LLP, our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Discussed with PricewaterhouseCoopers&nbsp;LLP the matters required to be discussed in accordance with Auditing Standard No
16-</FONT><FONT SIZE=2><I>Communications with Audit Committees</I></FONT><FONT SIZE=2>; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Received written disclosures and the letter from PricewaterhouseCoopers&nbsp;LLP regarding its independence as required by the applicable
requirements of the Public Company Accounting Oversight Board regarding PricewaterhouseCoopers&nbsp;LLP's communications with the Audit Committee and the Audit Committee further discussed with
PricewaterhouseCoopers&nbsp;LLP their independence. The Audit Committee also considered the status of taxation matters and other areas of oversight relating to the financial reporting and audit
process that the committee determined appropriate. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=202247,FOLIO='39',FILE='DISK106:[17ZBJ1.17ZBJ47801]DI47801A.;6',USER='SCAVALI',CD='28-APR-2017;14:09' -->
<A NAME="page_di47801_1_40"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Audit Committee's review of the audited financial statements and discussions with management and PricewaterhouseCoopers&nbsp;LLP, the Audit Committee recommended to the
Board that the audited financial statements be included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 for filing with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>MEMBERS OF THE AUDIT COMMITTEE</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Kenneth M. Bate (Chairman)<BR>
Keith R. Gollust<BR>
David Milligan, Ph.D.<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_vote_required_1"> </A>
<A NAME="toc_di47801_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of the shares of our common stock present in person or represented by proxy at the Annual Meeting and
entitled to vote on the proposal is required to ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our stockholders ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm, the Audit Committee may still, in its discretion,
decide to appoint a different independent registered public accounting firm at any time during the year ending December&nbsp;31, 2017, if it concludes that such a change would be in the best
interests of Madrigal and our stockholders. If our stockholders fail to ratify the appointment, the Audit Committee will reconsider, but not necessarily rescind, the appointment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di47801_recommendation_of_the_board_of_directors_1"> </A>
<A NAME="toc_di47801_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" RATIFICATION OF THE APPOINTMENT OF
PRICEWATERHOUSECOOPERS&nbsp;LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN ACCORDANCE WITH THE BOARD'S RECOMMENDATION UNLESS A
STOCKHOLDER INDICATES OTHERWISE ON THE PROXY.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=380514,FOLIO='40',FILE='DISK106:[17ZBJ1.17ZBJ47801]DI47801A.;6',USER='SCAVALI',CD='28-APR-2017;14:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk47801_1_41"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="PRO3"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROPOSAL NO. 3:<BR>
APPROVAL OF AMENDMENT TO 2015 STOCK PLAN  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_summary"> </A>
<A NAME="toc_dk47801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our 2015 Stock Plan currently authorizes the grant of stock options and other stock-based awards to employees, non-employee directors,
consultants and advisors of our company and our affiliates. Currently, 1,392,600 shares of common stock are reserved for issuance pursuant to awards granted under the 2015 Stock Plan. As of
April&nbsp;28, 2017, approximately 510,261 shares were available
for grant under the 2015 Stock Plan. Our Board of Directors has approved an amendment to the 2015 Stock Plan (we refer herein to the 2015 Stock Plan and the proposed amendment to the 2015 Stock Plan
as the Amended 2015 Stock Plan), subject to stockholder approval, to increase the aggregate number of shares authorized for issuance under the 2015 Stock Plan by 1,000,000 shares of common stock
(subject to appropriate adjustment in the event of any stock dividend, stock split or other similar event affecting our common stock). We are also asking for stockholder approval to increase the
amount of awards that a participant will be entitled to receive in any fiscal year from 571,429 shares of common stock to 750,000 shares of common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of the proposed increase in the 2015 Stock Plan is to provide us with appropriate capacity to issue equity compensation to new, existing and key employees of, and key service
providers to, our company. We believe that stock options and other stock-based awards are a critical part of the compensation package offered to new, existing and key employees, and other key service
providers, and is an important tool in our ability to attract and retain talented personnel. Our Board of Directors believes that the 1,000,000 share increase is appropriate for this purpose.
Stockholder approval of the Amended 2015 Stock Plan will also serve as re-approval of the performance goals under Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code,
as described further below, such that additional approval of such goals will not be required for another five years after such approval. In the event that the Amended 2015 Stock Plan is not approved
by stockholders, the 2015 Stock Plan will continue in effect without the amendment described herein. The shares issuable by us under the Amended 2015 Stock Plan will be authorized but unissued shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801__best_practices__integrated_in___be03377"> </A>
<A NAME="toc_dk47801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Best Practices" Integrated Into Our Equity Compensation Program and the 2015 Stock Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation practices include a number of features that the Board of Directors believes reflect responsible compensation and governance
practices and promote the interests of stockholders. Approval of the amendment to our 2015 Stock Plan will position us to continue and expand these "best practices," including the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Limitation on Shares
Issued.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Assuming the approval of the Amended 2015 Stock Plan, the maximum aggregate number of shares of common stock that we may issue pursuant
to awards granted under the Amended 2015 Stock Plan may not exceed the sum of (a)&nbsp;2,392,600 shares, plus (b)&nbsp;any shares subject to an award granted under the 2006 Stock Plan, which award
is forfeited, canceled, terminated, expires or lapses for any reason (subject to adjustment for anti-dilution purposes). The Amended 2015 Stock Plan also imposes limitations on the amount of
participant awards. See "Shares Available for Issuance," below.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> No Discounted Stock Options or SARs and Limit on Option and SAR
Terms.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Under the Amended 2015 Stock Plan, stock options and stock appreciation rights, or SARs, must have an exercise price or base price, as
applicable, equal to or greater than the fair market value of our common stock on the date of grant. In addition, the term of an option or SAR is limited to 10&nbsp;years.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> No "Evergreen" Provision.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The
Amended 2015 Stock Plan continues to require stockholder approval of any additional authorization of shares (other than adjustments for anti-dilution </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1008352,FOLIO='41',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_42"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>purposes),
rather than permitting an annual "replenishment" of shares under a plan "evergreen" provision.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> No Stock Option or SAR
Repricings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended 2015 Stock Plan continues to prohibit the repricing of stock options or SARs without the approval of stockholders. This
Amended 2015 Stock Plan provision applies to (i)&nbsp;direct repricings (lowering the exercise price of an option or the base price of an SAR), (ii)&nbsp;indirect repricings (exchanging an
outstanding option or SAR that is underwater for cash, for options or SARs with an option price or base price less than that applicable to the original option or SAR, or for another equity award), and
(iii)&nbsp;any other action that would be treated as a repricing under applicable stock exchange rules (subject to anti-dilution adjustments).  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Prudent Change of Control
Provisions.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended 2015 Stock Plan continues to include prudent "change of control" triggers: a change of control is deemed to have occurred
only upon a change in beneficial ownership of 50% or more of our voting stock, completion (rather than stockholder approval) of a significant merger or other transaction, or a change in a majority of
the our Board of Directors. In addition, the Amended 2015 Stock Plan generally provides that awards will vest upon a change of control only if (i)&nbsp;awards are not assumed, substituted or
continued, or (ii)&nbsp;even if such awards are assumed, substituted or continued, a participant's employment is terminated without cause or, if provided by the participant's award agreement, for
good reason within specified time periods related to the change of control.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Forfeiture and Recoupment
Policies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended 2015 Stock Plan also authorizes the Compensation Committee or the Board of Directors to require forfeiture and/or
recoupment of plan benefits if a participant engages in certain types of detrimental conduct and to require that a participant be subject to any compensation recovery policy or similar policies that
may apply to the participant or be imposed under applicable laws.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Administered by Independent
Committee.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended 2015 Stock Plan will continue be administered by the Compensation Committee. All members of the Compensation Committee are
intended to qualify as "independent" under The Nasdaq Stock Market listing standards, "non-employee directors" under Rule&nbsp;16b-3 under the Exchange Act and "outside directors" under Code
Section&nbsp;162(m) to the extent required.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> No Dividends or Dividend Equivalents on Unearned Performance
Awards.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Dividends and dividend equivalents on performance-based awards issued under the Amended 2015 Stock Plan may only be paid if and to the
extent the award has vested or been earned. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of the Amended 2015 Stock Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description of certain material features of the Amended 2015 Stock Plan is intended to be a summary only. This summary is
qualified in its entirety by the full text of the Amended 2015 Stock Plan that is attached hereto as Annex&nbsp;A. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term of the Plan</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan was initially adopted by the Synta board of directors and approved by the
stockholders of Synta in 2015. We assumed the 2015 Stock Plan upon consummation of the Merger in July 2016. The Amended 2015 Stock Plan will terminate on April&nbsp;23, 2025. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares Available for Issuance</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan provides for the issuance of up to 2,392,600 shares of common
stock plus a number of additional shares of common stock to be issued if awards outstanding under the 2006 Stock Plan are forfeited, terminated, cancelled or expire on or after the date of the Annual
Meeting. Generally, shares of common stock reserved for awards under the Amended 2015 Stock Plan or the 2006 Stock Plan that lapse, or expire or are forfeited or canceled will be added back to the
share reserve available for future awards under the Amended 2015 Stock Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=107292,FOLIO='42',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>However,
shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The Amended 2015 Stock Plan provides that no
participant may receive awards for more than 750,000 shares of common stock in any fiscal year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan requires the administrator to make appropriate adjustments to the number of
shares of common stock that are subject to the Amended 2015 Stock Plan, to certain limits in the Amended 2015 Stock Plan, and to any outstanding awards to reflect stock dividends, stock splits,
extraordinary cash dividends and similar events. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Plan Administration</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee has full power and authority, subject to the provisions of the Amended
2015 Stock Plan and applicable law, to select the participants to whom awards will be granted, to make any combination of awards to participants, to determine the number of shares of common stock to
be covered by awards, to accelerate the exercisability or vesting of any award and to determine the specific terms and conditions of each award, including but not limited to, whether the vesting or
payment of all or any portion of any award may be subject to one or more performance goals. To the extent permitted under applicable law, our Compensation Committee may delegate to any person all or
part of the Compensation Committee's authority and duties with respect to the granting of awards to employees who are not subject to the reporting and other provisions of Section&nbsp;16 of the
Exchange Act or are Covered Employees (as defined in Section&nbsp;162(m) of the Code, generally the executive officers named in the Summary Compensation Table). Covered Employees include the Chief
Executive Officer, and the three most highly compensated officers (other than the Chief Financial Officer) whose compensation is reported to stockholders under the Exchange Act for the taxable year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our Compensation Committee may, in its discretion, amend any term or condition of an outstanding award provided (i)&nbsp;such term or condition as amended is permitted by
the Amended 2015 Stock Plan, and (ii)&nbsp;any such amendment shall be made only with the consent of the participant to whom such award was made, if the amendment is adverse to the participant; and
provided, further, that, without the prior approval of our stockholders, options will not be repriced, replaced or regranted
through cancellation or by lowering the exercise price of a previously granted award and will not be exchanged for cash. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Eligibility</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Persons eligible to participate in the Amended 2015 Stock Plan will be our and our subsidiaries' officers,
employees, directors and consultants and prospective employees as selected from time to time by our Compensation Committee, including our directors and executive officers. The granting of awards under
the Amended 2015 Stock Plan is discretionary, and we cannot now determine the number or type of awards to be granted in the future to any particular person or group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Types of Awards</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan permits us to make grants of incentive stock options, non-qualified stock
options, stock appreciation rights, restricted stock awards, unrestricted stock awards, stock units (including restricted stock units), performance awards, cash-based awards and awards that are
convertible into or otherwise based on stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance-Based Compensation</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In order for us to have the ability to grant awards under the Amended 2015 Stock Plan
that qualify as "performance-based compensation" under Section&nbsp;162(m) of the Code, the Amended 2015 Stock Plan provides that our Compensation Committee may require that the vesting of certain
awards be conditioned on the satisfaction of performance criteria related to objectives of our company, an affiliate of our company or a division or strategic business unit of our company in which the
relevant participant is employed, such as: (i)&nbsp;pre-tax income or after-tax income; (ii)&nbsp;income or earnings including operating income, earnings before or after taxes, interest,
depreciation, amortization, and/or extraordinary or special items; (iii)&nbsp;net income excluding amortization of intangible assets, depreciation and impairment of goodwill and intangible assets
and/or excluding charges attributable to the adoption of new accounting pronouncements; (iv)&nbsp;earnings or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=47,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=86453,FOLIO='43',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>book
value per share (basic or diluted); (v)&nbsp;return on assets (gross or net), return on investment, return on capital, return on invested capital or return on equity; (vi)&nbsp;return on
revenues; (vii)&nbsp;cash flow, free cash flow, cash flow return on investment (discounted or otherwise), net cash provided by operations, or cash flow in excess of cost of capital;
(viii)&nbsp;economic value created; (ix)&nbsp;operating margin or profit margin; (x)&nbsp;stock price or total stockholder return; (xi)&nbsp;income or earnings from continuing operations;
(xii)&nbsp;cost targets, reductions and savings, expense management, productivity and efficiencies; (xiii)&nbsp;operational objectives, consisting of one or more objectives based on achieving
progress in research and development programs or achieving regulatory milestones related to development and or approval of products; or (xiv)&nbsp;strategic business criteria, consisting of one or
more objectives based on meeting
specified market penetration or market share of one or more products or customers, geographic business expansion, customer satisfaction, employee satisfaction, human resources management, supervision
of litigation, information technology, and goals relating to acquisitions, divestitures, joint ventures and similar transactions. As discussed above, if we determine to make awards under the Amended
2015 Stock Plan subject to the attainment of these performance goals, the Compensation Committee intends that compensation paid under the Amended 2015 Stock Plan will not be subject to the
deductibility limitation imposed under Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Options</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock options granted under the Amended 2015 Stock Plan may either be incentive stock options, which are
intended to satisfy the requirements of Section&nbsp;422 of the Code, or non-qualified stock options, which are not intended to meet those requirements. Incentive Stock Options may be granted to
employees of our company and our affiliates. Non-qualified options may be granted to employees, directors and consultants of our company and our affiliates. The exercise price of a stock option may
not be less than 100% of the fair market value of our common stock on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of
all classes of our capital stock, the exercise price may not be less than 110% of the fair market value of our common stock on the date of grant and the term of the incentive stock option may not be
longer than five years. Non-qualified options may not have a term longer than ten years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Award
agreements for stock options include rules for exercise of the stock options after termination of service. Options may not be exercised unless they are vested, and no option may be
exercised after the end of the term set forth in the award agreement. Generally, stock options will be exercisable for three months after termination of service for any reason other than death or
total and permanent disability, and for 12&nbsp;months after termination of service on account of death or total and permanent disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restricted Stock</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is common stock that is subject to restrictions, including a prohibition against
transfer and a substantial risk of forfeiture, until the end of a "restricted period" during which the grantee must satisfy certain vesting conditions. If the grantee does not satisfy the vesting
conditions by the end of the restricted period, the restricted stock is forfeited. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the restricted period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that the restrictions set forth in the applicable award
agreement apply. For example, the holder of restricted stock may vote and receive dividends on the restricted shares; but he or she may not sell the shares until the restrictions are lifted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Stock-Based Awards</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan also authorizes the grant of other types of stock-based
compensation including, but not limited to phantom stock awards, and stock unit awards. Our Compensation Committee may award such stock-based awards subject to such conditions and
restrictions as it may determine. These conditions and restrictions may include continued employment with us through a specified restricted period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=48,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=642291,FOLIO='44',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Withholding</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Participants in the Amended 2015 Stock Plan are responsible for the payment of any Federal, state or
local income taxes, employment taxes or other amounts that we are required by law to withhold upon any option exercise or vesting of awards. We may withhold from the participant's compensation, if
any, or may require that the participant make a cash payment to us for the statutory minimum amount of such withholdings, or subject to approval by our Compensation Committee, by transferring to us
shares or a promissory note having a value equal to the amount of such taxes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Dividends and Stock Splits</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If our common stock shall be subdivided or combined into a greater or smaller number
of shares or if we issue any shares of common stock as a stock dividend, the number of shares of our common stock deliverable upon exercise of an option issued or upon issuance of an award shall be
appropriately increased or decreased proportionately, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or stock dividend. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change in Control Provisions</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan provides that upon a merger or other reorganization event, our
board of directors, may, in its sole discretion, take any one or more of the following actions, as to some or all outstanding awards under the plan: (i)&nbsp;provide that all options shall be
assumed or substituted by the successor corporation; (ii)&nbsp;upon written notice to a participant, provide that the participant's unexercised options will become exercisable in full and will
terminate immediately prior to the consummation of such transaction unless exercised by the participant; (iii)&nbsp;in the event of a merger pursuant to which holders of our common stock will
receive a cash payment for each share surrendered in the merger, make or provide for a cash payment to the participants equal to the difference between the merger price times the number of shares of
our common stock subject to such outstanding options (at prices not in excess of the merger price), and the aggregate exercise price of all such outstanding options (all options being made fully
vested and immediately exercisable prior to their termination), in exchange for the termination of such options; and (iv)&nbsp;provide that outstanding awards shall be assumed or substituted by the
successor corporation, become realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon the merger or reorganization event. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Amended 2015 Stock Plan provides that in the event of a change in control where outstanding options are assumed or substituted or in the event of a change in control
that does not constitute a corporate transaction under Amended 2015 Stock Plan, options will become immediately exercisable in full if on or prior to the date that is six months after the date of the
change in control (i)&nbsp;an option holder's service with our company or our succeeding corporation is terminated by us or the succeeding corporation without cause, as defined in the Amended 2015
Stock Plan; (ii)&nbsp;a participant terminates his or her service with us as a result of being required to change the principal location where he or she renders services to a location more than 50
miles from his or her location of service immediately prior to the change in control; or (iii)&nbsp;the participant terminates his or her service after there occurs a material adverse change in a
participant's duties, authority or responsibilities which cause such participant's position with us to become of significantly less responsibility or authority than such participant's position was
immediately prior to the change in control. The Amended 2015 Stock Plan provides similar change in control vesting provisions for restricted stock under the plan and allows our Board of Directors to
make appropriate adjustments for other stock-based awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments and Termination</U>.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended 2015 Stock Plan may be amended by our stockholders. It may also be amended by
our Board of Directors, provided that any amendment approved by our Board of Directors which is of a scope that requires stockholder approval as required by the rules of The Nasdaq Stock Market, in
order to ensure favorable federal income tax treatment for any incentive stock options under Code Section&nbsp;422, or for any other reason, is subject to obtaining such stockholder approval.
However, no such action may adversely affect any rights under any outstanding award without the holder's consent. Additionally, any amendments that materially change </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=49,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=843945,FOLIO='45',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
terms of the Amended 2015 Stock Plan, including any amendments that increase the number of shares reserved for issuance under the Amended 2015 Stock Plan, expand the types of awards available,
materially expand the eligibility to participate in, or materially extend the term of, the Amended 2015 Stock Plan, or materially change the method of determining the fair market value of our common
stock, will be subject to approval by our stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_new_plan_benefits"> </A>
<A NAME="toc_dk47801_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No grants have been issued with respect to the additional shares to be reserved for issuance under the Amended 2015 Stock Plan. The number of
shares that may be granted to our executive officers, non-employee directors and non-executive officers under the Amended 2015 Stock
Plan is not determinable at this time, as such grants are subject to the discretion of the Compensation Committee. In 2016, we granted equity awards under the Amended 2015 Stock Plan to our named
executive officers, non-employee directors and certain other eligible employees and consultants. The 2016 grants to the named executive officers are reflected in the Outstanding Equity Awards at
Fiscal Year End. See "Executive Officer and Director Compensation&#151;Outstanding Equity Awards at Fiscal Year End." The equity grants for our non-employee directors are described under the
section entitled "Executive Officer and Director Compensation&#151;Director Compensation." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_federal_income_tax_considerations"> </A>
<A NAME="toc_dk47801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Income Tax Considerations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The material federal income tax consequences of the issuance and exercise of stock options and other awards under the Amended 2015 Stock Plan,
based on the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described below. This summary assumes that all awards granted under
the Amended 2015 Stock Plan are exempt from or comply with, the rules under Section&nbsp;409A of the Code related to nonqualified deferred compensation. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incentive Stock Options:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Incentive stock options are intended to qualify for treatment under Section&nbsp;422 of the Code. An incentive stock option does not result in taxable income to the optionee or deduction to us at the time it is granted or
exercised, provided that no disposition is made by the optionee of the shares acquired pursuant to the option within two years after the date of grant of the option nor within one year after the date of issuance of shares to the optionee (referred to
as the "ISO holding period"). However, the difference between the fair market value of the shares on the date of exercise and the option price will be an item of tax preference includible in "alternative minimum taxable income" of the optionee. Upon
disposition of the shares after the expiration of the ISO holding period, the optionee will generally recognize long term capital gain or loss based on the difference between the disposition proceeds and the option price paid for the shares. If the
shares are disposed of prior to the expiration of the ISO holding period, the optionee generally will recognize taxable compensation, and we will have a corresponding deduction, in the year of the disposition, equal to the excess of the fair market
value of the shares on the date of exercise of the option over the option price. Any additional gain realized on the disposition will normally constitute capital gain. If the amount realized upon such a disqualifying disposition is less than fair
market value of the shares on the date of exercise, the amount of compensation income will be limited to the excess of the amount realized over the optionee's adjusted basis in the shares.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=50,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=984386,FOLIO='46',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Qualified Options:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options otherwise qualifying as incentive stock options, to the extent the aggregate fair market value of shares with respect to which such options are
first exercisable by an individual in any calendar year exceeds $100,000, and options designated as non-qualified options will be treated as options that are not incentive stock options.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>A non-qualified option ordinarily will not result in income to the optionee or deduction to us at the time of grant. The optionee will
recognize compensation income at the time of exercise of such non-qualified option in an amount equal to the excess of the then value of the shares over the option price per share. Such compensation income of optionees may be subject to withholding
taxes, and a deduction may then be allowable to us in an amount equal to the optionee's compensation income.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>An optionee's initial basis in shares so acquired will be the amount paid on exercise of the non-qualified option plus the amount of any
corresponding compensation income. Any gain or loss as a result of a subsequent disposition of the shares so acquired will be capital gain or loss.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock Grants:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>With respect to stock grants under the Amended 2015 Stock Plan that result in the issuance of shares that are either not restricted as to
transferability or not subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of shares received. Thus, deferral of the time of issuance will generally result in the deferral
of the time the grantee will be liable for income taxes with respect to such issuance. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>With respect to stock grants involving the issuance of shares that are restricted as to transferability and subject to a substantial risk of
forfeiture, the grantee must generally recognize ordinary income equal to the fair market value of the shares received at the first time the shares become transferable or are not subject to a substantial risk of forfeiture, whichever occurs earlier.
A grantee may elect to be taxed at the time of receipt of shares rather than upon lapse of restrictions on transferability or substantial risk of forfeiture, but if the grantee subsequently forfeits such shares, the grantee would not be entitled to
any tax deduction, including as a capital loss, for the value of the shares on which the grantee previously paid tax. The grantee must file such election with the Internal Revenue Service within 30&nbsp;days of the receipt of the shares. We generally
will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock Units:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The grantee recognizes no income until the issuance of the shares. At that time, the grantee must generally recognize ordinary income equal
to the fair market value of the shares received. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_limitation_on_deductions"> </A>
<A NAME="toc_dk47801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on Deductions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of Section&nbsp;162(m) of the Code, our deduction for certain awards under the Amended 2015 Stock Plan may be limited to the
extent that a Covered Employee receives compensation in excess of $1,000,000 a year (other than for performance-based compensation that otherwise meets the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=51,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=408833,FOLIO='47',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>requirements
of Section&nbsp;162(m) of the Code). If our stockholders approve the amendment to the Amended 2015 Stock Plan, certain grants under our Amended 2015 Stock Plan, may qualify as
performance-based compensation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_vote_required"> </A>
<A NAME="toc_dk47801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of the shares of our common stock present in person or represented by proxy at the Annual Meeting and
entitled to vote on the proposal is required to approve the amendment to the Amended 2015 Stock Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_recommendation_of_the_board_of_directors"> </A>
<A NAME="toc_dk47801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT AN AMENDMENT TO THE 2015 STOCK PLAN TO, AMONG OTHER THINGS,
INCREASE THE NUMBER OF SHARES OF OUR COMMON STOCK CURRENTLY ISSUABLE UNDER THE 2015 STOCK PLAN BY 1,000,000 SHARES IS ADVISABLE TO, AND IN THE BEST INTERESTS OF,
MADRIGAL AND OUR STOCKHOLDERS AND HAS APPROVED SUCH AMENDMENT. THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" PROPOSAL NO. 3 TO APPROVE AN AMENDMENT TO THE 2015 STOCK
PLAN.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=52,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=740325,FOLIO='48',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk47801_proposal_no._4__advisory_vote___pro04243"> </A>
<A NAME="toc_dk47801_8"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 4:<BR>  ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION<BR>  AS DISCLOSED IN THIS PROXY STATEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As required by Section&nbsp;14A of the Exchange Act, we are providing our stockholders with an opportunity to approve, on an advisory basis,
the compensation of our named executive officers (as defined in Item&nbsp;402 of Regulation&nbsp;S-K of the Exchange Act) as disclosed in this proxy statement in accordance with the compensation
disclosure rules of the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to casting your vote on this proposal, you are encouraged to read the sections entitled "Compensation Discussion and Analysis" and "Executive Officer and Director Compensation"
beginning on page&nbsp;21 for a detailed discussion of our policies and practices relating to the compensation of our named executive officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee believes that the objectives of our executive compensation program, as it relates to our named executive officers, are appropriate for a company of our size
and stage of development and that our compensation policies and practices help meet those objectives. In addition, our Compensation Committee believes that our executive compensation program, as it
relates to our named executive officers, achieves an appropriate balance between fixed compensation and variable incentive compensation, pays for performance and promotes an alignment between the
interests of our named executive officers and our stockholders. Accordingly, we are asking our stockholders to approve the compensation of our named executive officers. This advisory vote is not
intended to be limited or specific to any particular element of compensation, but rather to cover the overall compensation of our named executive officers and the compensation policies and practices
described in this proxy statement as it relates to our named executive officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors unanimously recommends that our stockholders vote "FOR" the following resolution at the Annual Meeting: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>"RESOLVED,
that the compensation paid to the named executive officers of Madrigal Pharmaceuticals,&nbsp;Inc., as disclosed pursuant to the compensation disclosure rules of the Securities and
Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED." </FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_vote_required_1"> </A>
<A NAME="toc_dk47801_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing resolution will be approved on an advisory basis by the affirmative vote of a majority of the shares present in person or
represented by proxy at the Annual Meeting and entitled to vote on the proposal. Because this proposal is advisory, the results of the vote will not be binding on us, our Board of Directors or our
Compensation Committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk47801_recommendation_of_the_board_of_directors_1"> </A>
<A NAME="toc_dk47801_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS VOTE "FOR" THE APPROVAL ON AN ADVISORY BASIS OF THE
COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN ACCORDANCE WITH THE BOARD'S RECOMMENDATION UNLESS A STOCKHOLDER INDICATES OTHERWISE ON THE
PROXY.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk47801_code_of_conduct_and_ethics"> </A>
<A NAME="toc_dk47801_11"> </A>
<BR></FONT><FONT SIZE=2><B>  CODE OF CONDUCT AND ETHICS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of conduct and ethics that applies to all of our directors and employees, including our chief executive officer and chief
financial and accounting officer. The text of the code of conduct and ethics is posted on the "Investors&#151;Corporate Governance" section of our website at </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=53,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=476532,FOLIO='49',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<A NAME="page_dk47801_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> www.madrigalpharma.com</I></FONT><FONT SIZE=2>. Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive
and financial officers will be included in a Current Report on Form&nbsp;8-K within four business days following the date of the amendment or waiver, unless website posting or the issuance of a
press release of such amendments or waivers is then permitted by the rules of The Nasdaq Stock Market. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk47801_other_matters"> </A>
<A NAME="toc_dk47801_12"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors knows of no other business which will be presented at the Annual Meeting. If any other business is properly brought
before the Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the persons named therein. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk47801_stockholder_proposals_and_nominations_for_director"> </A>
<A NAME="toc_dk47801_13"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be considered for inclusion in the proxy statement relating to our 2018 Annual Meeting of Stockholders, we must receive stockholder proposals
no later than January&nbsp;10, 2018. To be considered for presentation at the 2018 Annual Meeting, although not included in the proxy statement, proposals must be received no earlier than
February&nbsp;23, 2018 and no later than March&nbsp;26, 2018; provided, however, that in the event that the date of the 2018 Annual Meeting is more than thirty (30)&nbsp;days before or more than
thirty (30)&nbsp;days after the anniversary date of the preceding year's Annual Meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the
ninetieth (90th) day prior to such Annual Meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such Annual Meeting or the tenth (10th) day following the
day on which we make a public announcement of the date of such meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposals
that are not received in a timely manner will not be voted on at the 2018 Annual Meeting. If a proposal is received on time, the proxies that management solicits for the
meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. All stockholder proposals should be marked for the attention
of Secretary, Madrigal Pharmaceuticals,&nbsp;Inc., 200&nbsp;Barr Harbor Drive, Suite&nbsp;400, West Conshohocken, Pennsylvania&nbsp;19428. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>West
Conshohocken, Pennsylvania<BR>
April&nbsp;28, 2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=54,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=531731,FOLIO='50',FILE='DISK106:[17ZBJ1.17ZBJ47801]DK47801A.;12',USER='SCAVALI',CD='28-APR-2017;14:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq47801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="dq47801_annex_a"> </A>
<A NAME="toc_dq47801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Annex&nbsp;A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq47801_madrigal_pharmaceutica__dq401828"> </A>
<A NAME="toc_dq47801_2"> </A></FONT> <FONT SIZE=2><B>  MADRIGAL PHARMACEUTICALS,&nbsp;INC.<BR>  <BR>    AMENDED 2015 STOCK PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>DEFINITIONS</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise specified or unless the context otherwise requires, the following terms, as used in this Madrigal Pharmaceuticals,&nbsp;Inc. Amended 2015 Stock Plan, have the
following meanings: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I>Administrator</I></FONT><FONT SIZE=2> means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means
the Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Affiliate</I></FONT><FONT SIZE=2> means a corporation which, for purposes of Section&nbsp;424 of the Code, is a parent or subsidiary of the Company, direct or indirect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>Agreement</I></FONT><FONT SIZE=2> means an agreement between the Company and a Participant pertaining to a Stock Right delivered pursuant to the Plan, in such form as the
Administrator shall approve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Board of Directors</I></FONT><FONT SIZE=2> means the Board of Directors of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Cause</I></FONT><FONT SIZE=2> means, with respect to a Participant (a)&nbsp;dishonesty with respect to the Company or any Affiliate, (b)&nbsp;insubordination, substantial
malfeasance or non-feasance of duty, (c)&nbsp;unauthorized disclosure of confidential information, (d)&nbsp;breach by a Participant of any provision of any employment, consulting, advisory,
nondisclosure, non-competition or similar agreement between the Participant and the Company or any Affiliate, and (e)&nbsp;conduct substantially prejudicial to the business of the Company or any
Affiliate; provided, however, that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition of Cause for termination and which is in
effect at the time of such termination, shall supersede this definition with respect to that Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the
Participant and the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Change of Control</I></FONT><FONT SIZE=2> means the occurrence of any of the following events: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;Ownership.
Any "Person" (as such term is used in Sections&nbsp;13(d) and 14(d) of the Exchange Act) becomes the "Beneficial Owner" (as defined in Rule&nbsp;13d-3
under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company's then outstanding voting securities
(excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions which the Board of Directors does not approve; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;Merger/Sale
of Assets. (A)&nbsp;A merger or consolidation of the Company whether or not approved by the Board of Directors, other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation,
as the case may be, outstanding immediately after such merger or consolidation; or (B)&nbsp;the sale or disposition by the Company of all or substantially all of the Company's assets in a
transaction requiring shareholder approval; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;Change
in Board Composition. A change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are Incumbent
Directors. "Incumbent Directors" shall mean directors who either (A)&nbsp;are directors of the Company as of the date of adoption of the Plan, or (B)&nbsp;are elected, or nominated for election,
to the Board of Directors with </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=886542,FOLIO='A-1',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>the
affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection
with an actual or threatened proxy contest relating to the election of directors to the Company). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>provided,
that if any payment or benefit payable hereunder upon or following a Change of Control would be required to comply with the limitations of Section&nbsp;409A(a)(2)(A)(v) of the Code in
order to avoid an additional tax under Section&nbsp;409A of the Code, such payment or benefit shall be made only if such Change in Control constitutes a change in ownership or control of the
Company, or a change in ownership of the Company's assets in accordance with Section&nbsp;409A of the Code </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Code</I></FONT><FONT SIZE=2> means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>Committee</I></FONT><FONT SIZE=2> means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or pursuant to the provisions
of the Plan, the composition of which shall at all times satisfy the provisions of Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Common Stock</I></FONT><FONT SIZE=2> means shares of the Company's common stock, $.0001 par value per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2> means Madrigal Pharmaceuticals,&nbsp;Inc., a Delaware corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Consultant</I></FONT><FONT SIZE=2> means any natural person who is an advisor or consultant that provides bona fide services to the Company or its Affiliates, provided that
such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly promote or maintain a market for the Company's or its
Affiliates' securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Disability</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>Disabled</I></FONT><FONT SIZE=2> means permanent and total disability as defined in Section&nbsp;22(e)(3) of the
Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Employee</I></FONT><FONT SIZE=2> means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or director
of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Exchange Act</I></FONT><FONT SIZE=2> means the Securities Exchange Act of 1934, as amended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Fair Market Value</I></FONT><FONT SIZE=2> of a Share of Common Stock means: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;If
the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock,
the closing or, if not applicable, the last price of the Common Stock on the composite tape or other comparable reporting system for the trading day on the applicable date and if such applicable date
is not a trading day, the last market trading day prior to such date; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;If
the Common Stock is not traded on a national securities exchange but is traded on the over-the-counter market, if sales prices are not regularly reported for the
Common Stock for the trading day referred to in clause&nbsp;(1), and if bid and asked prices for the Common Stock are regularly reported, the mean between the bid and the asked price for the Common
Stock at the close of trading in the over-the-counter market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day, the last
market trading day prior to such date; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;If
the Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the Administrator, in good faith, shall
determine in compliance with applicable laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>ISO</I></FONT><FONT SIZE=2> means an option intended to qualify as an incentive stock option under Section&nbsp;422 of the Code. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=799855,FOLIO='A-2',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I>Non-Qualified Option</I></FONT><FONT SIZE=2> means an option which is not intended to qualify as an ISO. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Option</I></FONT><FONT SIZE=2> means an ISO or Non-Qualified Option granted under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Participant</I></FONT><FONT SIZE=2> means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock Rights are granted under the Plan. As
used herein, "Participant" shall include "Participant's Survivors" where the context requires. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>Performance-Based Award</I></FONT><FONT SIZE=2> means a Stock Grant or Stock-Based Award which vests based on the attainment of written Performance Goals as set forth in
Paragraph&nbsp;9 hereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Performance Goals</I></FONT><FONT SIZE=2> means performance goals based on one or more of the following criteria: (i)&nbsp;pre-tax income or after-tax income;
(ii)&nbsp;income or earnings including operating income, earnings before or after taxes, interest, depreciation, amortization, and/or extraordinary or special items; (iii)&nbsp;net income
excluding amortization of intangible assets, depreciation and impairment of goodwill and intangible assets and/or excluding charges attributable to the adoption of new accounting pronouncements;
(iv)&nbsp;earnings or book value per share (basic or diluted); (v)&nbsp;return on assets (gross or net), return on investment, return on capital, return on invested capital or return on equity;
(vi)&nbsp;return on revenues; (vii)&nbsp;cash flow, free cash flow, cash flow return on investment (discounted or otherwise), net cash provided by operations, or cash flow in excess of cost of
capital; (viii)&nbsp;economic value created; (ix)&nbsp;operating margin or profit margin; (x)&nbsp;stock price or total shareholder return; (xi)&nbsp;income or earnings from continuing
operations; (xii)&nbsp;cost targets, reductions and savings, expense management, productivity and efficiencies; (xiii)&nbsp;operational objectives, consisting of one or more objectives based on
achieving progress in research and development programs or achieving regulatory milestones related to development and/or approval of products; and (xiv)&nbsp;strategic business criteria, consisting
of one or more objectives based on meeting specified market penetration or market share of one or more products or customers, geographic business expansion, customer satisfaction, employee
satisfaction, human resources management, supervision of litigation, information technology, and goals relating to acquisitions, divestitures, joint ventures and similar transactions. Where
applicable, the Performance Goals may be expressed in terms of a relative measure against a set of identified peer group companies, attaining a specified level of the particular criterion or the
attainment of a percentage increase or decrease in the particular criterion, and may be applied to one or more of the Company or an Affiliate of the Company, or a division or strategic business unit
of the Company, all as determined
by the Committee. The Performance Goals may include a threshold level of performance below which no Performance-Based Award will be issued or no vesting will occur, levels of performance at which
Performance-Based Awards will be issued or specified vesting will occur, and a maximum level of performance above which no additional issuances will be made or at which full vesting will occur. Each
of the foregoing Performance Goals shall be evaluated in an objectively determinable manner in accordance with Section&nbsp;162(m) of the Code and in accordance with generally accepted accounting
principles, where applicable, unless otherwise specified by the Committee, and shall be subject to certification by the Committee. The Committee shall have the authority to make equitable adjustments
to the Performance Goals in recognition of unusual or non-recurring events affecting the Company or any Affiliate or the financial statements of the Company or any Affiliate, in response to changes in
applicable laws or regulations, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment
of a business or related to a change in accounting principles provided that any such change shall at all times satisfy the provisions of Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Plan</I></FONT><FONT SIZE=2> means this Madrigal Pharmaceuticals,&nbsp;Inc. Amended 2015 Stock Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Securities Act</I></FONT><FONT SIZE=2> means the Securities Act of 1933, as amended. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=963281,FOLIO='A-3',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I>Shares</I></FONT><FONT SIZE=2> means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock into which
the Shares are changed or for which they are exchanged within the provisions of Paragraph&nbsp;3 of the Plan. The Shares issued under the Plan may be authorized and unissued shares or shares held by
the Company in its treasury, or both. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Stock-Based Award</I></FONT><FONT SIZE=2> means a grant by the Company under the Plan of an equity award or an equity based award which is not an Option or a Stock Grant, which
the Committee may, in its sole discretion, structure to qualify in whole or in part as "performance-based compensation" under Section&nbsp;162(m) of the Code. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>Stock Grant</I></FONT><FONT SIZE=2> means a grant by the Company of Shares under the Plan, which the Committee may, in its sole discretion, structure to qualify in whole or in
part as "performance-based compensation" under Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Stock Right</I></FONT><FONT SIZE=2> means a right to Shares or the value of Shares of the Company granted pursuant to the Plan&#151;an ISO, a Non-Qualified Option, a
Stock Grant or a Stock-Based Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Survivor</I></FONT><FONT SIZE=2> means a deceased Participant's legal representatives and/or any person or persons who acquired the Participant's rights to a Stock Right by
will or by the laws of descent and distribution. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>PURPOSES OF THE PLAN</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan is intended to encourage ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates in order to attract and retain such people,
to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to promote the success of the Company or of an Affiliate. The Plan provides for
the granting of ISOs, Non-Qualified Options, Stock Grants and Stock-Based Awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>SHARES SUBJECT TO THE PLAN</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i)&nbsp;2,392,600 shares of Common Stock or the equivalent of
such number of Shares after the Administrator, in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction in accordance
with Paragraph&nbsp;25 of this Plan and (ii)&nbsp;any shares of Common Stock that are represented by awards granted under the Company's 2006 Amended and Restated Stock Plan that are forfeited,
expire or are cancelled without delivery of shares of Common Stock or which result in the forfeiture of shares of Common Stock back to the Company on or after the date of adoption of the Plan;
provided, however, that no more than 257,000 Shares shall be added to the Plan pursuant to this subsection&nbsp;(ii). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;If
an Option ceases to be outstanding, in whole or in part (other than by exercise), or if the Company shall reacquire (at not more than its original issuance price) any
Shares issued pursuant to a Stock Grant or Stock-Based Award, or if any Stock Right expires or is forfeited, cancelled, or otherwise terminated or results in any Shares not being issued, the unissued
or reacquired Shares which were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing, if a Stock Right is exercised,
in whole or in part, by tender of Shares or if the Company or an Affiliate's tax withholding obligation is satisfied by withholding Shares, the number of Shares deemed to have been issued under the
Plan for purposes of the limitation set forth in Paragraph&nbsp;3(a) above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the net number of Shares
actually issued. However, in the case of ISOs, the foregoing provisions shall be subject to any limitations under the Code. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=740410,FOLIO='A-4',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ADMINISTRATION OF THE PLAN</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator of the Plan will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the Committee shall be
the Administrator. Notwithstanding the foregoing, the Board of Directors may not take any action that would cause any outstanding Stock Right that would otherwise qualify as performance-based
compensation under Section&nbsp;162(m) of the Code to fail to so qualify. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisions of the Plan, the Administrator is authorized to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Interpret
the provisions of the Plan and all Stock Rights and to make all rules and determinations which it deems necessary or advisable for the administration of the
Plan;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Determine
which Employees, directors and Consultants shall be granted Stock Rights;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Determine
the number of Shares for which a Stock Right or Stock Rights shall be granted; provided, however, that in no event shall Stock Rights with respect to more
than 750,000 Shares be granted to any Participant in any fiscal year;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Specify
the terms and conditions upon which a Stock Right or Stock Rights may be granted;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>e.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Determine
Performance Goals no later than such time as required to ensure that a Performance-Based Award which is intended to comply with the requirements of
Section&nbsp;162(m) of the Code so complies;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>f.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amend
any term or condition of any outstanding Stock Right, other than reducing the exercise price or purchase price, provided that (i)&nbsp;such term or condition
as amended is not prohibited by the Plan; (ii)&nbsp;any such amendment shall not impair the rights of a Participant under any Stock Right previously granted without such Participant's consent or in
the event of death of the Participant the Participant's Survivors; and (iii)&nbsp;any such amendment shall be made only after the Administrator determines whether such amendment would cause any
adverse tax consequences to the Participant, including, but not limited to, the annual vesting limitation contained in Section&nbsp;422(d) of the Code and described in Paragraph&nbsp;6(b)(iv)
below with respect to ISOs and pursuant to Section&nbsp;409A of the Code;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>g.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Make
any adjustments in the Performance Goals included in any Performance-Based Awards provided that such adjustments comply with the requirements of
Section&nbsp;162(m) of the Code; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>h.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Adopt
any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax or
other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate the administration of the Plan, which sub-plans may include additional restrictions or conditions
applicable to Stock Rights or Shares issuable pursuant to a Stock Right; </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>provided,
however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of not causing any adverse tax consequences under
Section&nbsp;409A of the Code and preserving the tax status under Section&nbsp;422 of the Code of those Options which are designated as ISOs and in accordance with Section&nbsp;162(m) of the
Code for all other Stock Rights to which the Committee has determined Section&nbsp;162(m) is applicable. Subject to the foregoing, the interpretation and construction by the Administrator of any
provisions of the Plan or of any Stock Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In addition, if the
Administrator is the Committee, the Board of Directors may take any action under the Plan that would otherwise be the responsibility of the Committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=59,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=879157,FOLIO='A-5',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_6"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent permitted under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members
and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The Board of Directors or the Committee may revoke any such allocation or delegation at any
time. Notwithstanding the foregoing, only the Board of Directors or the Committee shall be authorized to grant a Stock Right to any director of the Company or to any "officer" of the Company as
defined by Rule&nbsp;16a-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ELIGIBILITY FOR PARTICIPATION</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator will, in its sole discretion, name the Participants in the Plan, provided, however, that each Participant must be an Employee, director or Consultant of the Company or
of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize the grant of a Stock Right to a person not then an Employee, director or Consultant
of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or prior to the time
of the execution of the Agreement evidencing such Stock Right. ISOs may be granted only to Employees who are deemed to be residents of the United States for tax purposes. Non-Qualified Options, Stock
Grants and Stock-Based Awards may be granted to any Employee, director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that
individual to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under any other benefit plan established by the Company or any Affiliate for Employees,
directors or Consultants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>TERMS AND CONDITIONS OF OPTIONS</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Option shall be set forth in writing in an Option Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The
Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions specifically required under this Plan, as the Administrator may deem
appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the
following terms and conditions: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Non-Qualified Options:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Option intended to be a Non-Qualified Option shall be subject to the terms and
conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified Option: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Exercise
Price</U>:&nbsp;&nbsp;&nbsp;&nbsp;Each Option Agreement shall state the exercise price (per share) of the Shares covered by each Option, which
exercise price shall be determined by the Administrator and shall be at least equal to the Fair Market Value per share of Common Stock on the date of the grant of the Option.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Number
of Shares</U>:&nbsp;&nbsp;&nbsp;&nbsp;Each Option Agreement shall state the number of Shares to which it pertains.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Vesting</U>:&nbsp;&nbsp;&nbsp;&nbsp;Each
Option Agreement shall state the date or dates on which it first is exercisable and the date after which it
may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain performance
conditions or the attainment of stated goals or events.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Additional
Conditions</U>:&nbsp;&nbsp;&nbsp;&nbsp;Exercise of any Option may be conditioned upon the Participant's execution of a Share purchase
agreement in form satisfactory to the </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=60,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=79533,FOLIO='A-6',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Administrator
providing for certain protections for the Company and its other shareholders, including requirements that: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>i.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Participant's or the Participant's Survivors' right to sell or transfer the Shares may be restricted; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>ii.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Participant or the Participant's Survivors may be required to execute letters of investment intent and must also acknowledge that the Shares will bear legends
noting any applicable restrictions.
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>e.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Term
of Option</U>:&nbsp;&nbsp;&nbsp;&nbsp;Each Option shall terminate not more than ten years from the date of the grant or at such earlier time as
the Option Agreement may provide. </FONT></DD></DL>
</UL>
</UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>ISOs:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Option intended to be an ISO shall be issued only to an Employee who is deemed to be a resident of
the United States for tax purposes, and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator determines are appropriate but not in
conflict with Section&nbsp;422 of the Code and relevant regulations and rulings of the Internal Revenue Service:  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Minimum
standards</U>:&nbsp;&nbsp;&nbsp;&nbsp;The ISO shall meet the minimum standards required of Non-Qualified Options, as described in
Paragraph&nbsp;6(A) above, except clause&nbsp;(a) and (e)&nbsp;thereunder.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Exercise
Price</U>:&nbsp;&nbsp;&nbsp;&nbsp;Immediately before the ISO is granted, if the Participant owns, directly or by reason of the applicable
attribution rules in Section&nbsp;424(d) of the Code:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>i.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ten
percent (10%) </FONT><FONT SIZE=2><I>or less</I></FONT><FONT SIZE=2> of the total combined voting power of all classes of stock of the Company or an Affiliate,
the exercise price per share of the Shares covered by each ISO shall not be less than the Fair Market Value per share of the Common Stock on the date of grant of the Option; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>ii.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>More
than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, the exercise price per share of the Shares
covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common Stock on the date of grant of the Option.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Term
of Option</U>:&nbsp;&nbsp;&nbsp;&nbsp;For Participants who own:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>i.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ten
percent (10%) </FONT><FONT SIZE=2><I>or less</I></FONT><FONT SIZE=2> of the total combined voting power of all classes of stock of the Company or an Affiliate,
each ISO shall terminate not more than ten (10)&nbsp;years from the date of the grant or at such earlier time as the Option Agreement may provide; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>ii.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>More
than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, each ISO shall terminate not more than five
(5)&nbsp;years from the date of the grant or at such earlier time as the Option Agreement may provide.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><U>Limitation
on Yearly Exercise</U>:&nbsp;&nbsp;&nbsp;&nbsp;The Option Agreements shall restrict the amount of ISOs which may become exercisable in any
calendar year (under this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined on the date each ISO is granted) of the stock with respect to which
ISOs are exercisable for the first time by the Participant in any calendar year does not exceed $100,000. </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=61,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=57705,FOLIO='A-7',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>TERMS AND CONDITIONS OF STOCK GRANTS</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Stock Grant to a Participant shall state the principal terms in an Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the
Participant. The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the
Company, subject to the following minimum standards: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
Agreement shall state the purchase price (per share), if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the
Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law, if any, on the date of the grant of the Stock Grant;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
Agreement shall state the number of Shares to which the Stock Grant pertains; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant, including the time period or
attainment of Performance Goals or such other performance criteria upon which such rights shall accrue and the purchase price therefor, if any. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>TERMS AND CONDITIONS OF OTHER STOCK-BASED AWARDS</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator shall have the right to grant other Stock-Based Awards based upon the Common Stock having such terms and conditions as the Administrator may determine, including,
without limitation, the grant of Shares based upon certain conditions, the grant of securities convertible into Shares and the grant of stock appreciation rights, phantom stock awards or stock units.
The principal terms of each Stock-Based Award shall be set forth in an Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant. The
Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company. Each
Agreement shall include the terms of any right of the Company including the right to terminate the Stock-Based Award without the issuance of Shares, the terms of any vesting conditions, Performance
Goals or events upon which Shares shall be issued. Under no circumstances may the Agreement covering stock appreciation rights (a)&nbsp;have an exercise price (per share) that is less than the Fair
Market Value per share of Common Stock on the date of grant or (b)&nbsp;expire more than ten years following the date of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company intends that the Plan and any Stock-Based Awards granted hereunder be exempt from the application of Section&nbsp;409A of the Code or meet the requirements of
paragraphs&nbsp;(2), (3)&nbsp;and (4)&nbsp;of subsection&nbsp;(a) of Section&nbsp;409A of the Code, to the extent applicable, and be operated in accordance with Section&nbsp;409A so that
any compensation deferred under any Stock-Based Award (and applicable investment earnings) shall not be included in income under Section&nbsp;409A of the Code. Any ambiguities in the Plan shall be
construed to effect the intent as described in this Paragraph&nbsp;8. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>PERFORMANCE-BASED AWARDS</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary herein, during any period when Section&nbsp;162(m) of the Code is applicable to the Company and the Plan, Stock Rights granted under
Paragraph&nbsp;7 and Paragraph&nbsp;8 may be granted by the Committee in a manner which is deductible by the Company under Section&nbsp;162(m) of the Code ("Performance-Based Awards"). A
Participant's Performance-Based Award shall be determined based on the attainment of written Performance Goals, which must be objective and approved by the Committee for a performance period of
between one and five years established by the
Committee (I)&nbsp;while the outcome for that performance period is substantially uncertain and (II)&nbsp;no more than 90&nbsp;days after the commencement of the performance period to which the
Performance Goal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=62,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=969725,FOLIO='A-8',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>relates
or, if less, the number of days which is equal to 25% of the relevant performance period. The Committee shall determine whether, with respect to a performance period, the applicable
Performance Goals have been met with respect to a given Participant and, if they have, to so certify and ascertain the amount of the applicable Performance-Based Award. No Performance-Based Awards
will be issued for such performance period until such certification is made by the Committee. The number of shares issued in respect of a Performance-Based Award to a given Participant may be less
than the amount determined by the applicable Performance Goal formula, at the discretion of the Committee. The number of shares issued in respect of a Performance-Based Award determined by the
Committee for a performance period shall be paid to the Participant at such time as determined by the Committee in its sole discretion after the end of such performance period. Nothing in this Section
shall prohibit the Company from granting Stock-Based Awards subject to performance criteria that do not comply with this Paragraph. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>10.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EXERCISE OF OPTIONS AND ISSUE OF SHARES</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
Option (or any part or installment thereof) shall be exercised by giving written notice to the Company or its designee (in a form acceptable to the Administrator, which may include
electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph for the Shares as to which the Option is being exercised, and upon compliance
with any other condition(s) set forth in the Option Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to
the Administrator), shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. Payment of
the exercise price for the Shares as to which such Option is being exercised shall be made (a)&nbsp;in United States dollars in cash or by check; or (b)&nbsp;at the discretion of the
Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a Fair Market Value equal as of the date of the
exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised; or (c)&nbsp;at the discretion of the Administrator, by having the Company retain
from the Shares otherwise issuable upon exercise of the Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number of Shares
as to which the Option is being exercised; or (d)&nbsp;at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and
approved by the Administrator; or (e)&nbsp;at the discretion of the Administrator, by any combination of (a), (b), (c)&nbsp;and (d)&nbsp;above or (f)&nbsp;at the discretion of the
Administrator, by payment of such other lawful consideration as the Administrator may determine. Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO
as is permitted by Section&nbsp;422 of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the Participant (or to the Participant's Survivors, as the case may be). In
determining what constitutes "reasonably promptly," it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation
(including, without limitation, state securities or "blue sky" laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The Shares shall, upon delivery,
be fully paid, non-assessable Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>11.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ACCEPTANCE OF STOCK GRANTS AND STOCK-BASED AWARDS AND ISSUE OF SHARES</I></FONT><FONT SIZE=2>. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Stock Grant or Stock-Based Award requiring payment of a purchase price for the Shares as to which such Stock Grant or Stock-Based Award is being granted shall be made (a)&nbsp;in
United States dollars in cash or by check; or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months (if required to avoid negative
accounting treatment) and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=63,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=208100,FOLIO='A-9',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>having
a Fair Market Value equal as of the date of payment to the purchase price of the Stock Grant or Stock-Based Award; or (c)&nbsp;at the discretion of the Administrator, by any combination of
(a)&nbsp;and (b)&nbsp;above; or (d)&nbsp;at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall when required by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant or Stock-Based Award was made to the Participant (or to
the Participant's Survivors, as the case may be), subject to any escrow provision set forth in the applicable Agreement. In determining what constitutes "reasonably promptly," it is expressly
understood that the issuance and delivery of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities or "blue sky" laws)
which requires the Company to take any action with respect to the Shares prior to their issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>12.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>RIGHTS AS A SHAREHOLDER</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Participant to whom a Stock Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock Right, except after due exercise of an Option or
issuance of Shares as set forth in any Agreement, tender of the aggregate exercise or purchase price, if any, for the
Shares being purchased and registration of the Shares in the Company's share register in the name of the Participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>13.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
its terms, a Stock Right granted to a Participant shall not be transferable by the Participant other than (i)&nbsp;by will or by the laws of descent and distribution, or
(ii)&nbsp;as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right may be transferred by a Participant for value. Notwithstanding the
foregoing, an ISO transferred except in compliance with clause&nbsp;(i) above shall no longer qualify as an ISO. The designation of a beneficiary of a Stock Right by a Participant, with the prior
approval of the Administrator and in such form as the Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above, during the Participant's
lifetime a Stock Right shall only be exercisable by or issued to such Participant (or his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by
operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right
or of any rights granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a Stock Right, shall be null and void. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>14.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE OR DEATH OR
DISABILITY</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Option Agreement in the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an
Affiliate before the Participant has exercised an Option, the following rules apply: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination for Cause, Disability, or
death for which events there are special rules in Paragraphs&nbsp;15, 16, and 17, respectively), may exercise any Option granted to him or her to the extent that the Option is exercisable on the
date of such termination of service, but only within such term as the Administrator has designated in a Participant's Option Agreement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Except
as provided in Subparagraph&nbsp;(c) below, or Paragraph&nbsp;16 or 17, in no event may an Option intended to be an ISO, be exercised later than three
(3)&nbsp;months after the Participant's termination of employment. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=64,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=370419,FOLIO='A-10',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_dq47801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
provisions of this Paragraph, and not the provisions of Paragraph&nbsp;16 or 17, shall apply to a Participant who subsequently becomes Disabled or dies after
the termination of employment, director status or consultancy; provided, however, in the case of a Participant's Disability or death within three (3)&nbsp;months after the termination of employment,
director status or consultancy, the Participant or the Participant's Survivors may exercise the Option within one (1)&nbsp;year after the date of the Participant's termination of service, but in no
event after the date of expiration of the term of the Option.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Notwithstanding
anything herein to the contrary, if subsequent to a Participant's termination of employment, termination of director status or termination of
consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent to the Participant's termination, the Participant engaged in conduct which would
constitute Cause, then such Participant shall forthwith cease to have any right to exercise any Option.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>e.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A
Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary disability (any disability other
than a Disability as defined in Paragraph&nbsp;1 hereof), or who is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone,
to have terminated such Participant's employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide; provided, however,
that for ISOs, any leave of absence granted by the Administrator of greater than ninety (90)&nbsp;days, unless pursuant to a contract or statute that guarantees the right to reemployment, shall
cause such ISO to become a Non-Qualified Option on the 181st&nbsp;day following such leave of absence.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>f.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Except
as required by law or as set forth in a Participant's Option Agreement, Options granted under the Plan shall not be affected by any change of a Participant's
status within or among the Company and any Affiliates, so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>15.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR CAUSE</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Option Agreement, the following rules apply if the Participant's service (whether as an Employee, director or Consultant) with the Company
or an Affiliate is terminated for Cause prior to the time that all his or her outstanding Options have been exercised: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause will immediately be forfeited.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Cause
is not limited to events which have occurred prior to a Participant's termination of service, nor is it necessary that the Administrator's finding of Cause
occur prior to termination. If the Administrator determines, subsequent to a Participant's termination of service but prior to the exercise of an Option, that either prior or subsequent to the
Participant's termination the Participant engaged in conduct which would constitute Cause, then the right to exercise any Option is forfeited. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=65,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=891153,FOLIO='A-11',FILE='DISK106:[17ZBJ1.17ZBJ47801]DQ47801A.;7',USER='CHE107324',CD='28-APR-2017;01:33' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds47801_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>16.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Option Agreement: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability may exercise any Option granted to such
Participant to the extent that the Option has become exercisable but has not been exercised on the date of the Participant's termination of service due to Disability;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of the Participant's termination of service due
to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days accrued in
the current vesting period prior to the date of the Participant's termination of service due to Disability;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>A
Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant's termination of service due to Disability,
notwithstanding that the Participant might have been able to exercise the Option as to some or all of the Shares on a later date if the Participant had not been terminated due to Disability and had
continued to be an Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is
set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by a
physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>17.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Option Agreement: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate, such Option may be
exercised by the Participant's Survivors to the extent that the Option has become exercisable but has not been exercised on the date of death;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of death of any additional vesting rights that
would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant's date of
death; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
the Participant's Survivors wish to exercise the Option, they must take all necessary steps to exercise the Option within one year after the date of death of such
Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the Shares on a later date if he or she had not died and had continued to be an
Employee, director or Consultant or, if earlier, within the originally prescribed term of the Option. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=380285,FOLIO='A-12',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>18.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS AND STOCK-BASED AWARDS.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a termination of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason before the Participant has accepted a Stock
Grant, or Stock-Based Award and paid the purchase price, if required, such grant shall terminate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Paragraph&nbsp;18 and Paragraph&nbsp;19 below, a Participant to whom a Stock Grant or a Stock-Based Award has been issued under the Plan who is absent from work
with the Company or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph&nbsp;1 hereof), or who is on leave of absence for any purpose,
shall not, during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant's employment, director status or consultancy with the Company or with
an Affiliate, except as the Administrator may otherwise expressly provide. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, for purposes of this Paragraph&nbsp;18 and Paragraph&nbsp;19 below, any change of employment or other service within or among the Company and any Affiliates shall not be
treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee, director or Consultant of the Company or any Affiliate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>19.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE OTHER THAN FOR CAUSE, DEATH OR
DISABILITY.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Agreement, in the event of a termination of service for any reason (whether as an Employee, director or Consultant), other than
termination for Cause, death or Disability for which there are special rules in Paragraphs&nbsp;20, 21, and 22 below, before all forfeiture
provisions or Company rights of repurchase shall have lapsed, then the Company shall have the right to cancel or repurchase that number of Shares subject to a Stock Grant or Stock-Based Award as to
which the Company's forfeiture or repurchase rights have not lapsed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>20.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE "FOR CAUSE".</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Agreement, the following rules apply if the Participant's service (whether as an Employee, director or Consultant) with the Company or an
Affiliate is terminated for Cause: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
Shares subject to any Stock Grant or Stock-Based Award that remain subject to forfeiture provisions or as to which the Company shall have a repurchase right shall
be immediately forfeited to the Company as of the time the Participant is notified his or her service is terminated for Cause.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Cause
is not limited to events which have occurred prior to a Participant's termination of service, nor is it necessary that the Administrator's finding of Cause
occur prior to termination. If the Administrator determines, subsequent to a Participant's termination of service, that either prior or subsequent to the Participant's termination the Participant
engaged in conduct which would constitute Cause, then all Shares subject to any Stock Grant or Stock-Based Award that remained subject to forfeiture provisions or as to which the Company had a
repurchase right on the date of termination shall be immediately forfeited to the Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>21.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF TERMINATION OF SERVICE FOR DISABILITY.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Agreement, the following rules apply if a Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate
by </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=67,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=718799,FOLIO='A-13',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_14"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reason
of Disability: to the extent the forfeiture provisions or the Company's rights of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the
event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to such Stock Grant or
Stock-Based Award through the date of Disability as would have lapsed had the Participant not become Disabled. The proration shall be based upon the number of days accrued prior to the date of
Disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator shall make the determination both as to whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is set forth in
another agreement between the Company and such Participant, in which case such procedure shall be used for such determination). If requested, the Participant shall be examined by a physician selected
or approved by the Administrator, the cost of which examination shall be paid for by the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>22.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EFFECT ON STOCK GRANTS AND STOCK-BASED AWARDS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR
CONSULTANT.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided in a Participant's Agreement, the following rules apply in the event of the death of a Participant while the Participant is an Employee, director or
Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or the Company's rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided,
however, that in the event such forfeiture provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the Shares subject to
such Stock Grant or Stock-Based Award through the date of death as would have lapsed had the Participant not died. The proration shall be based upon the number of days accrued prior to the
Participant's date of death. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>23.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>PURCHASE FOR INVESTMENT.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the offering and sale of the Shares shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue Shares under the Plan unless
and until the following conditions have been fulfilled: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
person who receives a Stock Right shall warrant to the Company, prior to the receipt of Shares, that such person is acquiring such Shares for his or her own
account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person acquiring such Shares shall be bound by the provisions
of the following legend (or a legend in substantially similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant: </FONT></DD></DL>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>"The
shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1)&nbsp;either (a)&nbsp;a
Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b)&nbsp;the Company shall have received an opinion of counsel satisfactory to
it that an exemption from registration under such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws."  </FONT></P>

</UL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>At
the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued in compliance with the Securities Act
without registration thereunder. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>24.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>DISSOLUTION OR LIQUIDATION OF THE COMPANY.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the dissolution or liquidation of the Company, all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants and Stock-Based Awards
which have </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=68,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=800757,FOLIO='A-14',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_15"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>not
been accepted, to the extent required under the applicable Agreement, will terminate and become null and void; provided, however, that if the rights of a Participant or a Participant's Survivors
have not otherwise terminated and expired, the Participant or the Participant's Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right
to the extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. Upon the dissolution or liquidation of the Company, any
outstanding Stock-Based Awards shall immediately terminate unless otherwise determined by the Administrator or specifically provided in the applicable Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>25.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ADJUSTMENTS.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of any of the following events, a Participant's rights with respect to any Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided,
unless otherwise specifically provided in a Participant's Agreement: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Stock Dividends and Stock Splits.</I></FONT><FONT SIZE=2> If (i)&nbsp;the shares of Common Stock shall be subdivided or combined into a greater
or smaller number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii)&nbsp;additional shares or new or different shares or
other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder
shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made including, in the exercise or purchase price per share to reflect such events. The number of
Shares subject to the limitations in Paragraphs&nbsp;3(a) and 4(c) shall also be proportionately adjusted upon the occurrence of such events and the Performance Goals applicable to outstanding
Performance-Based Awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Corporate Transactions.</I></FONT><FONT SIZE=2> If the Company is to be consolidated with or acquired by another entity in a merger,
consolidation, or sale of all or substantially all of the Company's assets other than a transaction to merely change the state of incorporation (a "Corporate Transaction"), the Administrator or the
board of directors of any entity assuming the obligations of the Company hereunder (the "Successor Board"), shall, as to outstanding Options, either (i)&nbsp;make appropriate provision for the
continuation of such Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock
in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii)&nbsp;upon written notice to the Participants, provide that such Options must be exercised
within a specified number of days of the date of such notice, at the end of which period such Options which have not yet been exercised shall terminate (all Options shall for purposes of this
clause&nbsp;(ii) be made fully vested and exercisable immediately prior to their termination); or (iii)&nbsp;terminate such Options in exchange for payment of an amount equal to the consideration
payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would have been exercisable (all Options shall for purposes of this
clause&nbsp;(iii) be made fully vested and immediately exercisable immediately prior to their termination) less the aggregate exercise price thereof. For purposes of determining the payments to be
made pursuant to Subclause&nbsp;(iii) above, in the case of a Corporate Transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be
valued at the fair value thereof as determined in good faith by the Board of Directors. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to outstanding Stock Grants, the Administrator or the Successor Board, shall either (i)&nbsp;make appropriate provision for the continuation of such Stock Grants on the
same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants the securities of any successor or acquiring entity in the Corporate Transaction or
(ii)&nbsp;provide that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=69,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=577285,FOLIO='A-15',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>exchange
for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock comprising such Stock Grant
(all forfeiture and repurchase rights being waived upon such Corporate Transaction). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
taking any of the actions permitted under this Paragraph&nbsp;25(B), the Administrator shall not be obligated by the Plan to treat all Stock Rights, all Stock Rights held by a
Participant, or all Stock Rights of the same type, identically. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Recapitalization or Reorganization.</I></FONT><FONT SIZE=2> In the event of a recapitalization or reorganization of the Company, other than a
Corporate Transaction, pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising an Option
or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the price paid upon such exercise or acceptance, if any, the number of replacement securities
which would have been received if such Option had been exercised or Stock Grant accepted prior to such recapitalization or reorganization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Adjustments to Stock-Based Awards.</I></FONT><FONT SIZE=2> Upon the happening of any of the events described in Subparagraphs&nbsp;A, B or C
above, any outstanding Stock-Based Award shall be appropriately adjusted to reflect the events described in such Subparagraphs. The Administrator or the Successor Board shall determine the specific
adjustments to be made under this Paragraph&nbsp;25, including, but not limited to the effect of any Corporate Transaction and Change of Control and, subject to Paragraph&nbsp;4, its determination
shall be conclusive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Modification of Options.</I></FONT><FONT SIZE=2> Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph&nbsp;A, B or C
above with respect to Options shall be made only after the Administrator determines whether such adjustments would (i)&nbsp;constitute a "modification" of any ISOs (as that term is defined in
Section&nbsp;424(h) of the Code) or (ii)&nbsp;cause any adverse tax consequences for the holders of Options, including, but not limited to, pursuant to Section&nbsp;409A of the Code. If the
Administrator determines that such adjustments made with respect to Options would constitute a modification or other adverse tax consequence, it may refrain from making such adjustments, unless the
holder of an Option specifically agrees in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of such "modification" on his or her
income tax treatment with respect to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion of the ISO to violate the annual vesting
limitation contained in Section&nbsp;422(d) of the Code, as described in Paragraph&nbsp;6(B)(d). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Modification of Performance-Based Awards.</I></FONT><FONT SIZE=2> Notwithstanding the foregoing, with respect to any Performance-Based Award that
is intended to comply as "performance based compensation" under Section&nbsp;162(m) of the Code, the Committee may adjust downwards, but not upwards, the number of Shares payable pursuant to a
Performance-Based Award, and the Committee may not waive the achievement of the applicable Performance Goals except in the case of death or disability of the Participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G.&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Change of Control.</I></FONT><FONT SIZE=2> In the event of either </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;a
Corporate Transaction that also constitutes a Change of Control, where outstanding Options are assumed or substituted in accordance with the first paragraph of
Subparagraph&nbsp;B clause&nbsp;(i) above and, with respect to Stock Grants, in accordance with the second paragraph of Subparagraph&nbsp;B clause&nbsp;(i); or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;a
Change of Control that does not also constitute a Corporate Transaction, </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>if
within six months after the date of such Change of Control, (i)&nbsp;a Participant's service is terminated by the Company or an Affiliate for any reason other than Cause; or (ii)&nbsp;a
Participant terminates his or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=70,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=745691,FOLIO='A-16',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>her
service as a result of being required to change the principal location where he or she renders services to a location more than 50 miles from his or her location of employment or consultancy
immediately prior to the Change of Control; or (iii)&nbsp;the Participant terminates his or her service after there occurs a material adverse change in a Participant's duties, authority or
responsibilities which causes such Participant's position with the Company to become of significantly less responsibility or authority than such Participant's position was immediately prior to the
Change of Control, </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>then</I></FONT><FONT SIZE=2> all of such Participant's (i)&nbsp;Options outstanding under the Plan shall become fully vested and immediately exercisable as of
the date of termination of such Participant, unless in any such case the Option has otherwise expired or been terminated pursuant to its terms or the terms of the Plan and (ii)&nbsp;any forfeiture
or repurchase rights of the Company with respect to outstanding Stock Grants that have not lapsed or expired prior to such Change of Control shall terminate as of the date of termination of such
Participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>26.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>ISSUANCES OF SECURITIES.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no
adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid
in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>27.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>FRACTIONAL SHARES.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
fractional shares shall be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market
Value thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>28.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>CONVERSION OF ISOs INTO NON-QUALIFIED OPTIONS; TERMINATION OF ISOs.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator, at the written request of any Participant, may in its discretion take such actions as may be necessary to convert such Participant's ISOs (or any portions thereof)
that have not been exercised on the date of conversion into Non-Qualified Options at any time prior to the expiration of such ISOs, regardless of whether the Participant is an Employee of the Company
or an Affiliate at the time of such conversion. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting
Non-Qualified Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any
Participant the right to have such Participant's ISOs converted into Non-Qualified Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The
Administrator, with the consent of the Participant, may also terminate any portion of any ISO that has not been exercised at the time of such conversion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>29.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>WITHHOLDING.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any federal, state, or local income taxes, employment taxes, Federal Insurance Contributions Act ("F.I.C.A.") withholdings or other amounts are required by applicable
law or governmental regulation to be withheld from the Participant's salary, wages or other remuneration in connection with the issuance of a Stock Right or Shares under the Plan or for any other
reason
required by law, the Company may withhold from the Participant's compensation, if any, or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which
employs or employed the Participant, the statutory minimum amount of such withholdings unless a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=71,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=812637,FOLIO='A-17',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>different
withholding arrangement, including the use of shares of the Company's Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the
fair market value of the shares withheld for purposes of payroll withholding shall be determined in the manner set forth under the definition of Fair Market Value provided in Paragraph&nbsp;1 above,
as of the most recent practicable date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount of payroll withholdings required, the Participant may be
required to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion may condition the exercise of an Option for less than the then Fair Market
Value on the Participant's payment of such additional withholding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>30.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Employee who receives an ISO must agree to notify the Company in writing immediately after the Employee makes a "Disqualifying Disposition" of any Shares acquired pursuant to the
exercise of an ISO. A Disqualifying Disposition is defined in Section&nbsp;424(c) of the Code and includes any disposition (including any sale or gift) of such Shares before the later of
(a)&nbsp;two years after the date the Employee was granted the ISO, or (b)&nbsp;one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in
Section&nbsp;424(c) of the Code. If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>31.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>TERMINATION OF THE PLAN.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan will terminate on April&nbsp;23, 2025 the date which is ten (10)&nbsp;years from the </FONT><FONT SIZE=2><I>earlier</I></FONT><FONT SIZE=2> of the date of its adoption by
the Board of Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders or the Board of Directors of the
Company; provided, however, that any such earlier termination shall not affect any Agreements executed prior to the effective date of such termination. Termination of the Plan shall not effect any
Stock Rights theretofore granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>32.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>AMENDMENT OF THE PLAN AND AGREEMENTS.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan may be amended by the shareholders of the Company. The Plan may also be amended by the Administrator, including, without limitation, to the extent necessary to qualify any or
all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal income tax treatment as may be afforded incentive stock options under
Section&nbsp;422 of the Code (including deferral of taxation upon exercise), and to the extent necessary to qualify the Shares issuable under the Plan for listing on any national securities exchange
or quotation in any national automated quotation system of securities dealers; and in order to continue to comply with Section&nbsp;162(m) of the Code; provided that any amendment approved by the
Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Other than as set forth in
Paragraph&nbsp;25 of the Plan, the Administrator may not without shareholder approval reduce the exercise price of an Option or cancel any outstanding Option in exchange for a replacement option
having a lower exercise price, any Stock Grant, any other Stock-Based Award or for cash. In addition, the Administrator not take any other action that is considered a direct or indirect "repricing"
for purposes of the shareholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Shares are listed, including any other action that is treated as a
repricing under generally accepted accounting principles. Any modification or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock
Right previously granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which may be adverse to the Participant but which
is not inconsistent with the Plan. In the discretion of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=72,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=429350,FOLIO='A-18',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<A NAME="page_ds47801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg47801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Administrator,
outstanding Agreements may be amended by the Administrator in a manner which is not adverse to the Participant. Nothing in this Paragraph&nbsp;32 shall limit the Administrator's
authority to take any action permitted pursuant to Paragraph&nbsp;25. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>33.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>EMPLOYMENT OR OTHER RELATIONSHIP.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
in this Plan or any Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a Participant, nor to
prevent a Participant from terminating his or her own employment, consultancy or director status or to give any Participant a right to be retained in employment or other service by the Company or any
Affiliate for any period of time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>34.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>SECTION&nbsp;409A.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Participant is a "specified employee" as defined in Section&nbsp;409A of the Code (and as applied according to procedures of the Company and its Affiliates) as of his separation
from service, to the extent any payment under this Plan or pursuant to the grant of a Stock-Based Award constitutes deferred compensation (after taking into account any applicable exemptions from
Section&nbsp;409A of the Code), and to the extent required by Section&nbsp;409A of the Code, no payments due under this Plan or pursuant to a Stock-Based Award may be made until the earlier of:
(i)&nbsp;the first day of the seventh month following the Participant's separation from service, or (ii)&nbsp;the Participant's date of death; provided, however, that any payments delayed during
this six-month period shall be paid in the aggregate in a lump sum, without interest, on the first day of the seventh month following the Participant's separation from service. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administrator shall administer the Plan with a view toward ensuring that Stock Rights under the Plan that are subject to Section&nbsp;409A of the Code comply with the requirements
thereof and that Options under the Plan be exempt from the requirements of Section&nbsp;409A of the Code, but neither the Administrator nor any member of the Board, nor the Company nor any of its
Affiliates, nor any other person acting hereunder on behalf of the Company, the Administrator or the Board shall be liable to a Participant or any Survivor by reason of the acceleration of any income,
or the imposition of any additional tax or penalty, with respect to a Stock Right, whether by reason of a failure to satisfy the requirements of Section&nbsp;409A of the Code or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>35.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>INDEMNITY.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Board nor the Administrator, nor any members of either, nor any employees of the Company or any parent, subsidiary, or other Affiliate, shall be liable for any act, omission,
interpretation, construction or determination made in good faith in connection with their responsibilities with respect to this Plan, and the Company hereby agrees to indemnify the members of the
Board, the members of the Committee, and the employees of the Company and its parent or subsidiaries in respect of any claim, loss, damage, or expense (including reasonable counsel fees) arising from
any such act, omission, interpretation, construction or determination to the full extent permitted by law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>36.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>CLAWBACK.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary contained in this Plan, the Company may recover from a Participant any compensation received from any Stock Right (whether or not settled) or
cause a Participant to forfeit any Stock Right (whether or not vested) in the event that the Company's Clawback Policy then in effect is triggered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>37.&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>GOVERNING LAW.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Plan shall be construed and enforced in accordance with the law of the State of Delaware. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=73,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=595200,FOLIO='A-19',FILE='DISK106:[17ZBJ1.17ZBJ47801]DS47801A.;6',USER='CHE107324',CD='28-APR-2017;01:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">NNNNNNNNNNNN .   NNNNNNNNNNNNNNN C123456789 000004 000000000.000000 ext 000000000.000000 ext   000000000.000000 ext 000000000.000000 ext 000000000.000000 ext   000000000.000000 ext ENDORSEMENT_LINE______________ SACKPACK_____________   Electronic Voting Instructions You can vote by Internet or telephone!   Available 24 hours a day, 7 days a week! Instead of mailing your proxy, you   may choose one of the two voting methods outlined below to vote your proxy.   VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. Proxies submitted by   the Internet or telephone must be received by 1:00 a.m., Eastern Daylight   Time, on June 29, 2017. Vote by Internet &#149; Go to www.envisionreports.com/MDGL   &#149; Or scan the QR code with your smartphone &#149; Follow the steps outlined on the   secure website MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5   ADD 6 Vote by telephone &#149; Call toll free 1-800-652-VOTE (8683) within the   USA, US territories &amp; Canada on a touch tone telephone &#149; Follow the   instructions provided by the recorded message Using a black ink pen, mark   your votes with an X as shown in this example. Please do not write outside   the designated areas. q IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE,   FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED   ENVELOPE. q Proposals &#151; The Board of Directors recommends a vote FOR the   nominees listed and FOR Proposals 2, 3, and 4. + 1. Election of Directors (or   if nominees are not available for election, such substitutes as the Board of   Directors may designate). For Withhold 01 - Paul A. Friedman, M.D. 02 -   Kenneth M. Bate For Against Abstain ForAgainst Abstain 2. Proposal to ratify   the election of Pricewaterhouse Cooper LLP as Madrigal&#146;s independent   registered public accounting firm for the fiscal year ending December 31,   2017. 4. Proposal to approve, on an advisory basis, the compensation of   Madrigal&#146;s named executive officers, as disclosed pursuant to the   compensation disclosure rules of the Securities and Exchange Commission. For   Against Abstain 3. Proposal to approve an amendment to Madrigal&#146;s 2015 Stock   Plan that would, among other things, increase the aggregate number of shares   for which share awards may be granted under the 2015 Stock Plan by 10,000,000   shares. Authorized Signatures &#151; This section must be completed for your vote   to be counted. &#151; Date and Sign Below Please sign exactly as name(s) appears   hereon. Joint owners should each sign. When signing as attorney, executor,   administrator, corporate officer, trustee, guardian, or custodian, please   give full title as such. Date (mm/dd/yyyy) &#151; Please print date below.   Signature 1 &#151; Please keep signature within the box. Signature 2 &#151; Please keep   signature within the box. NNNNNNNC 1234567890 J N T MR A SAMPLE (THIS AREA IS   SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A   SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR   A SAMPLE AND + 1 U P X3 2 9 7 5 0 1 02LSNA NNNNNNNNN B A Annual Meeting Proxy   Card1234 5678 9012 345 X IMPORTANT ANNUAL MEETING INFORMATION </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1247" height="1613" src="g116782bci001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=74,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=835845,FOLIO='',FILE="DISK108:[17ZBJ2.17ZBJ47802]11678-2-BC_ZBJ47802.CHC",USER="HYUNG",CD='Apr 28 14:00 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">. q IF YOU HAVE   NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH   AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q + Proxy &#151; MADRIGAL   PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN, PA   19428 PROXY FOR ANNUAL MEETING OF STOCKHOLDERS - JUNE 29, 2017 MADRIGAL   PHARMACEUTICALS, INC. BOARD OF DIRECTORS SOLICITS THIS PROXY The undersigned,   revoking any previous proxies relating to these shares, hereby acknowledges   receipt of the Notice and Proxy Statement in connection with the Annual   Meeting of Stockholders to be held at 9:00 a.m. EDT on Thursday, June 29,   2017 at Philadelphia Marriott West, 111 Crawford Avenue, Conshohocken, PA   19428 and hereby appoints Paul A. Friedman, M.D. and Marc R. Schneebaum (with   full power to act alone) the attorneys and proxies of the undersigned, with   power of substitution, to vote all shares of the Common Stock of Madrigal   Pharmaceuticals, Inc. registered in the name provided in this Proxy which the   undersigned is entitled to vote at the 2017 Annual Meeting of Stockholders,   and at any adjournments of the meeting, with all the powers the undersigned   would have if personally present at the meeting. Without limiting the general   authorization given by this Proxy, the proxy is instructed to vote or act as   follows on the proposals set forth in the Proxy. This Proxy, when executed,   will be voted in the manner directed herein. If you do not specify below how   you want your shares to be voted, this Proxy will be voted FOR the election   of the Directors and FOR Proposals 2, 3 and 4. In his discretion, the proxy   is authorized to vote upon such other business as may properly come before   the meeting. If you wish to vote in accordance with the Board of Directors&#146;   recommendations, just sign on the reverse side. You need not mark any boxes.   Mark, sign and date your proxy card and return it promptly in the enclosed   envelope. PLEASE CAST YOUR VOTE AS SOON AS POSSIBLE! Non-Voting Items Change   of Address &#151; Please print new address below. + IF VOTING BY MAIL, YOU MUST   COMPLETE SECTIONS A - C ON BOTH SIDES OF THIS CARD. C </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1247" height="1613" src="g116782bci002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=75,EFW="2231996",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=816979,FOLIO='',FILE="DISK108:[17ZBJ2.17ZBJ47802]11678-2-BC_ZBJ47802.CHC",USER="HYUNG",CD='Apr 28 14:00 2017' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g73532.jpg
<DESCRIPTION>G73532.JPG
<TEXT>
begin 644 g73532.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ O35),3%]'4D%02$E#4SI;4UE.5$%=
M34%$4DE'04Q?1E!/7S1#7TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 0P$L P$B  (1 0,1
M ?_$ !\   $#!0$! 0            H " D#! 4&!P(!"__$ $H0  $$ @$#
M P," P4#!PD)  ,! @0%!@<1  @2"1,A%#%!%5$*(F$6(S)Q@1>1L1@D)3.A
MP? G-SE"<W:RMM$H-#4V.%)E<N'_Q  = 0  !@,!               " P0%
M!@<  0@)_\0 .Q$  @(! P0! @0$ @@'     0(#! 4&$1( !Q,A,10B"#)!
M4146(V%"@212<7*1L='P%S,W9;/!PO_:  P# 0 "$0,1 #\ /XY3E$_?[?Z=
M>7/:U6HY>/)>$_S_ ,_LG5%R?+'JY/Y$Y5$3CR1%^Z+^$^?Q_5/\HN.^SU!J
M/MZ',USK58=_M^1&\#E>H9%7@C9+!DCS[<!P&#.L2C>Y(-5Y*BD\7S&?3M)T
MPZAU)B=*XR;+9NTM6I"  =N4T\I]"&O""&DE8[<5!]#DS%44L)IV_P"WVJ^Y
M^IJ&DM&XN7)YB^Q(53PJU*R%?->OVF'CITJZN#+-(3NQ2*)99Y889)-Y^0T=
M7*@PK&VKH4NS.L6NC29D<)YTE&N=]/%"\C2'-XM<OMB:YW"+\=,VWSW_ /;W
MV^YI8:\S>TR"1F%5#KY\^IIL>GV(H\>SB!FQ/.>-J1&%)%,POM.(CF\^+DY1
M>HJ?3>EYOM_N(V!W,;?R:POXVL\,R A\BO)*NB0+>[ C5KPA&YL.!"BT4B?-
MC1PA0(6B3VD1[6\1A[UV=8;BVYL+9MBXK/[5Y/,L0QS.1SX%=[JBJZQ%\6M:
MD&,,8!>#48]$Y:G"IQ1NJN]MNMI*AGL/1KTI\SE[E7&1Y)9+@EQ>.CVL7YHZ
M\M5H))+CQUXH2TB@1RGR2<E([A[5?@IP^8[N:HT%K/4E[+8O0NDL)>U9>TSX
ML5'5UCJ.3ZC'Z>I6LC7R!NU*^(AL7)[S5*DDLKPHT%10/,49HSU!-";^S6OU
M]@RYFN46$:=+%#G8A:LB@A0&L<:1-L@C+#ABX(U/.0]C$7E7N:G3PZ_,,6MK
M:WH:O(::PNL?*(%[50[*'(L*B0<(Y H]C$$9YHAW@,(J!.QA/;*-_CXD:JP0
M]G=%3=F?:?G_ ';9_7-!FV=USZG7M>9[@RI]1-B--BL>(I%*)W]HK-KK8)O;
M;X5[Q!*J<=1:ZJM]V;+[@**RU_D-Z#;N;YFR8Z\J3-BR@65I8-E6ED9K7, E
M?%1TB4<#FI'4 VQ&M:P@V*M'=O,8.CI&KG<56R6I-2R);GQ^+9J9HXJSQBH,
M5L26/)>M3/&4@9XQP+JY3CSZ;#^$32>NM0]VK?;[5=W2_;OMC7DQL&I=6&/-
M5L_JC&026\^D=NA5Q*T\-BHE6M9LQP7YXYFBFACNI*T<9I'N-X1>55%_*)RB
M+^RJGV5/V7YZ]^2<\?G_ /SGIK==W":[PW8V!]NF;Y[%MMPV6&1)DNQ?&971
MKBTA 9'D,(T3$B5]O=%CRYT*H<1AW11D<UCN.5<XCD\FHQ41&\JYG/+D7G\K
M\\?*?9?V7J\J64J9 3?2S0RR5)#7N0QRI)+4LA48P3HOM'568L"??$\.6QZX
M3RN#RF%:G_$J5JK#DJHR&*LSUYZ\&4QKRRPPY*BUF.%YZ4[PR"*4(N_$A@K
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M)$8JJR2&MRL2331*Y?:_E7E516M<OS]T^.5^/GE?^SH 'O.I,L[R_5 W;AV
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MUK0"#!BW,PA*<\*T%+B2HWO-^N,UQU>Q*C-I6K\QH]87\?'=@&P^WKL#R2\
M.ZC5.4K5%CX_:V\>R9*;:1XU@D>18)+8=\MC3*3S>]5Z!#T*R/?^KMA0]8*P
M,"3W86DBG;$1C@/AQ;:XF9"\/MHY"!E#BWA_<8JJ15<3GP1O1_9$11N<J)RB
MJYJH[CY15\7<_P!.?O\ *I]V_/'3-^(%C'G]'68$2M6FTO0NPX4Q1"MCF:U,
M7K)"D4:F.1EVFC<'DZN/M0@=.W9\,V(U'6F,DD]?4%NG+?D<^>XD=6NL4K2&
M21AXX61(VY;\55M@>@<\>]-[U1^^>^RC+]KW625D6MRZ\JWV^\,MO*H))X;
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MJ''[3Y76.P_W7!<M^_Q\_P!G['[_ (3JMN]&F\=ISN#!'BZRT:V3I8W+M10
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M=_=0&QHRCLCX;3G;R7:4FU[U.^S*DHM>6$D%Y%KK]#5D[8!XC5="KPPQ(&3
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M7:&;*L:ZN>,2.B0IL@ 328P58$I B<]BJ-O"Z71SS2LNQED("<0"[$!0O$*
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M ZJJJ/(QV4 #<@$G8;#<DDG]R=^O//\ -Q^%Y1?Z\*Y$ZI(U$7E.47^BK_\
M7_LZ72Z*3X_S_P#H='G]?]U?_P ]5F+RBJO[_P#<G7OI=+K:_E'^?_,]!Z72
6Z72Z%UG2Z72Z76=9TNETNEUG6=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g116782bci001.gif
<DESCRIPTION>G116782BCI001.GIF
<TEXT>
begin 644 g116782bci001.gif
M1TE&.#EAWP1-!G< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     + $   #>!$T&AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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MN_?OX,.+_Q]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]^_CSZ]_/O[___P &*."
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M!W17QF[Y9T/OUES^)X!JE6/V5D7X9G7+1E?5%FK_=CEO]5?)@GOBM62\YV1
M4CH+]VK%%V@$%''T-6/IE4M'.(?K,8)*:#P=%WU.-'TR0U,L"%K9QV8I5V'3
MEG=!%4FJA5WAITTX2'XZ_WA^OH=SR/=A["=H/?=^1$B'FKB)G(@BK?")K2 (
MG^@7H"B*H]B)J'B$5Q  K-B*N5,2:?.*4-&*M)B*MB@@K7 %NBB+$:&+NI@4
M+$"+K'@2K4"+5Q 5P2B,M[B,R.&+5\ "SJB+HI@2J\B*QT@1K<@"P"B, <"+
M("$(R9B-L\B-S%B.PU&-W&B,*1&. 4 1@D"+WB@4[#B,)3&/].@4]FB.^H@;
MH=B. E&,Z2B,@C 0TC@2PAB/#,&. WD4Z.B*)1&0U]@4Z;B/%"D;N=B* _&.
M 2F. J&1 0"-( &0K1B1$"&,)$D4^5B/Z;B039&2%?F2JG&1'(D-]LB-KSB/
M+/_ DAOAD1C9B_.(%/:(D!U1DT)I%!,)DTAI&N HD/^XD3/)D[28DQS1D*RH
MDPU!E=IX%"XY$B(YDRU)CDD9EJ'! D'9D4Y9E0-QEAQACR?)$.E8E#U!E=UH
M$CS9EDMQE&*9EYK1"C49D7(IC%F)#5!IDFN)EPTQF %@E?((EL1XBE"QE7H9
MF9/1E4R)#93YEO]8DZS( J\(EPS!EX;)$']IET!1EGP1FI*9FHV!F#TIF&?I
MET[)DL^HF!!QF=;X$!NIE8RY%Y"IFKZ)&+99BP)QEIR9EAL9F$M9G.X8D,JY
M$*#)C<TY%'+IF4$1G2J!FK^9G8+!FB/9E$X)F[DY$.'_2)H-H9ESR1#<29L-
M$8J"T)XCT9[36!"]*1'LJ9X= 9_Q*9]H&1'X29T),9_:&:!]89ZLF#O<>8]+
M&9"R:9+^61#?V1"Q69O/^)'92*'NF1%\B9,?N9"F:1"A6)_YZ9KA&(S!&(NB
MB)_P^:$/D8LC2J%2*1 *B9[@2*(5&HP7BIN[*: ZRIO$:9P;&9'F&9&(29X)
M\9SI&)A%:IY(6J0)>I;[Z8X$VHI-VIH&,9T=2:!I$Z5$FI%1NIER:9]32IP-
M"J [6J9R<:"WZ9K':: 1"J,!29]G"9=H*II.>J3VJ1!_6:<.>1!6FJ<<Z:=5
M"9> JJ<'$:9ZNJ4^*IQFNJAS_Q&<!RD0@'J-CAH 0,J<$H&F=XH-@UJ47=JF
M#C&I>NJ/?&J3@WJ>6KH0G?J@51JJZ8BH-)FCC!JK:V&DQYFHT$F0M6J6 =F@
M&=FC"A&E18FF3IJI!,&J3HF0<MFE@3FH=VJLK9H0SDJ8"X&=LEJM90&J:0JH
M;+J1N>.HQ'H072J4PIJIT1J5Z^FDT%BJ"5&J&TJ++'FJ",&=Z6JH4HJGY;JG
M_PFKUKJO8M&IN:.DF<FM 7ND ^&8SCF/7[JNW(B5"P&5N_B/@NFGGIFGT,B+
MDXJL3AF=@K"*!)&+&VNHZLF::%,0&WND0GF9-PJIFKFD!D&M_/JR6R&LE.J=
M)JNKS_\*J9;:JY^ZL R+$#C9L[^ZF9QZLPDAL@K!F@J;L[6YL CQE_99DW=:
MC2_:M+L:M,H(LUCK%9W*H3]*L]"YK2M9L&G:L#QKDP=QF5< E=9I$.#XK6^:
MI*TJJ)@YJ@1[J=Q(F[:YMF+KLL/IJHA9E'R;M8(;%7KZKP+[JE4[G I:K%2:
MM.Z*#7=;J.1XF9[IG[8IE*/I$&3ZERSK$(-IEW\IIW.+$&/*M/EZM8.;NE3!
MKEF9GC9[JXI;LVZ*KZ<KG%CIC0@;N_6Z$7))GG'K$%9*MX\Z$8,9HC@+F!!J
MMADQF)UKJ_>HNM#[%%NKN\AKF2N+J[*+N-V)JF YF!9KNCC_R1'%&Z]AJ[GZ
M>KSF2A%H*[R[NQ#)NA%\2Z;1.[]%4:<CRYHORIU@&[FOV[@>:KJ0*ZV]BKIR
MR1'KR[Z;"1$=6A"]6Q'CNZK#R[T"C!'A"ZWG2[\8'!0R>XV:*:F'&\#EJZ87
MW+\SB[X)3!! &[PK&HJ^F*XR^;@',;KE><$J;+<3+)[*Z[ZPN\+.6+&V:;6*
MFL%"+!0RZ[6HV[76"Y%<&KB6"<#>2Q"Y:\3G^9D9RJIV>;D04<,HG,,V#,,,
MS,6U.Y+4&8JIVKXM.\)#G,8W4:H<O+B:JK37B\/\"\2-.\>#Z:"5Z;YE[,4=
MN\/FB[H0#(\5<<!??,-4:\@>NL=\_ZR?@*S&CIP3I3J0M,J1^+N0^%NP3GN5
M7)S"$WR9S2NVBKR]C*R."@S&V"O(RYG'6UR]TVK*'<NN&VF?3/S(M-P24=JZ
MB:N9EGRX+TS*S@G )&RXBPRTDGNOB8G )?P0F^O*G@O, QR5HLO,26S,3XO&
MM7S-*L&L::/$O>S+L7S*QMB91>K,(-R=8<JV@!FRKPF-T*C$!L&6O<C,6@P1
MQ1N/OTNZ]OC)DPR8S_B,NFS!C8S- LT2!%J<G"O%8_O/"-V<?#G.ALRP#HO.
M$4P0W(DV%OO A>S+?QS$&4V[$4'(HZS1'2W*[\R<(]NQMEG- 3W0+'T2D3K-
M5^NH<CS'>?_;F<$8QL^[M[48Q7@LTM3KE?^+R/!<RA.]RJA,O'-,LA!IL9R+
ML=!)I/8HR];<TE0]E,<JPC"LF;E#L<\,S06;C([KT;,[DN?KQR8,U!*]R&>=
MS!OMO^!<H Y,SF^=C6G;GGZJGGE+KDD=TCE=U7X-$GZ:E36;IUM=D\I9TU_M
MUF.MV%B)R-I[PHG-R@[MTX\]ML KS]*,GGO-UU:,TQN:D)OMO*+ZUZ3M$>8Y
MD*';Q#?+U0MMTQRMTR3=QYXZTE.,U8JMU*H\U[4-VBN]UKQ:$""-S/:K$"%,
MW*&]V'U=VLI]$5R]SUR[L&DSH=#=VI&MV,'-N.&)S+*8L)\IUW__2]1'3=N_
M3='';=1U"I+&W=MGG-O8_=K+_=X3\<^?N]8E+-/4/;#N_<;LK=N6O=XD'=6'
M&=JVZ:HS?=OS_!#S3:?V&\WIZY;E+;_P'>$Z_+7EW).(69S[O)^(C=]H[=N3
M+==23)(0#MO]K=M9C-E%3<]W6Y382JD6K=G[#:[E/<L27N/F7:\)&YRQJ- ;
M#M-JC=R[S=EPC=-(NL!%>]Q#JLPTG-F_[-@^OID?>](J[N0]_>- _JTV;N.(
M^>227+,9_J(]GN%L3>(?6929:Z]YS-T*D>&DZ\:\'=XW'N0(7MX-F9/C'=3J
M#<7%7>6QG>5^#MQFBY/1C9EBOI ]3J_)_ZW:E"W;,3[7K\B\!_NVPGW,9+OD
M*3[GCDV9""G.R7OI>K[G<4[I?S[J[?V1BBZTE5WF3P[E]ZW?S!F/O0N7(T[(
M^_S)TNVR\FJPF)RX@2S6F&[EX1N+N:B+/*OKGQZ5>'W:1W[/I#[J#3F0\SCH
M9OOEAIZ]@TJ:!S[2B.K)QP[-L6B9PDJ>UYZVEGGK+IOMY^K8L+RFY/NLWX[H
M'8[0='WGS2[0TJV-5#F088KA?=FMUNZD"&GD9]OHI6[J9'ZDA>O9S GPAPSG
M4V[E+>ZDV'Z<Q@JF:EGO?NZ*M"K)9?GENAV1W5RW>.[P,N[KO3[D]"WQ(E_R
MQISHKF[R 9[I+?_?YZ<>JH2-SU>-\5J>F+VLC?N^X[\;\CPOVD3KWY ]X6/N
MV;+8CZR:I:#>[7HJ\!Z>RN[JU#./MWM\C'D*MY*N\Q+.ETR?P)/,[_=\YK;M
ME!]>XFW^I)7NTS)+J=T*X$>;JIRYS)Z>[HL.[NA*E@![MITZM>_+]8!)[UY_
MS5VIC=ULT$1YI8;Y]J+.MNQ,EN3^QROJS^Q\Q00JY?\(E<1*QDIZC?W,]YI/
MT9%?L0YL^;/IG+HH^F1YH@7+HBX+^T=JYR3+CI_\U3]9^#:.CEEII:RYR].]
MZKGZ$7Q)X/3)HJUO["B=H5ANF9Y/EJ!H%?L,E\^?MLK_^L7_J9_8SX3_K_N/
MK)&(3Y4CV]0JZ\19SY4WT?U;T<#K28S>;^,E^O(EW)?_F*P+RJJW[YP?:HKR
MJ;=<8;P @4W@0((%"5YA<<7@0H8-'0IL%4#B1(4/+5[$F%'C1HX=/7X$&5+D
M2)(E39Y$F5+E2I8M7;Z$&5/F3)HU;<ILA:W5E8D2!>5DT7.B()V"A$J\DE,@
MBZ!'G4Y4VM&H4!9$=4J,>M-F5FP\ W#ER),%S8A"*VI%FU;M6K9MW;Z%&U?N
M7+IU[=Z=ZQ4JMJE4E>KM:97O4\(^0?852K2L8+PB>9X5.!7L1K$@6U6E?'1R
M8\Z=/7\&'5KT:-*E39^VJU=A*\1#<PIJVI.%_]++A0DSEHJUZ,2K7U%?##JV
MH"#<'2M_;)KT(FNGOYT_AQY=^G3JU:U?]\Q4(>RCLW4"WBL0H>VGD#U./>AS
M,6OB!HD3Y]K^?2O6K]]#A%^0??N%[W\.GX^@_ ;*C[NJ_O-/OP 'V@^WX_ ;
MT*'6O&MH)Z?,PRY##3?DL$,//P0QQ)ER B\ S 8[ZK_>R'-*Q<-T@T@]I(1B
M,#:D&)0HMJH"  ^AV)1#<:(38Y3M+*:$% X;PR *BKG$L(F-0?"\&Z^G]))L
MK3B":NON"A79*PQ#$<<DLTPSST0S3375*E$Y+F6CS486 R,)O8&\^DFVIH0K
MR\2AB,SQ*\3DC,VJ/?^M!#2A&Z',42_AENR-OO$2\E))WG3ZL2D2 \WQ3A,!
MQ;-".9\:M;LU3T4U55579;75#573Z3(Y*Q6OU#FU/ _&/GOSSD+?^%+,T@
MU2FR3NF[U%(^5^MJ2:ARH@^H)7T5"%+)EOHTO6&;Y9'!_^K;+0"KQ'H-1C$)
MFI-%5]=EMUUWWX4W7I2N<+-$"KE-]ZAS<[VP-\&N%7!2(K.RLUIQ/4T2(B]O
M#%6_H"!;S%+!RE+JX8*."^XAUAH^KJR$);0U72#E);EDDT]&.>401Z45WWR%
MVNRCUA:E&,=?W[PT8@)AE'B@C,7C]&"C/DY4R!LAK=E2\[SRMZ&9*^JXT)C_
M!0RYL"%5QCIKK;?FNFNU?$4JJA)?[A:EJ>@5!&)K)4K4*SYY1A'=@X$63C6O
M%&+:H#Z=R@EI&"T6D.V>%]*+N[D?!/O>A]).]VJO'X<\<LDGI_P@J^BK>LZ1
M3P)8/YYK?I9;(AE+6FF?/YV*PJ"(&GHAG1=:^]>?/1VV+#%3'VC)!XO=<Z.T
MQ?(S."^GKKQXXX]'/GDTQR9[<[,%USMV:07K&.Z"!V]VK-(9AK3&LF&?.U)L
ME\YV]L"W-7C<;"^&7GGWWX<_?OG59"US4L4E?J3.M_Q<MT6%'=WYH@*IC %L
M*E8)W4ZDA;]8":93*U)*LH"VK;L12#&Z<1+43*28_V]Y)7_S V$(13A"$C9F
M8T>R6E4^6*?V\2]\=DH.8"[X*V.A#WN5Z5.5LM47196O44U1GXD 4[%&;<M.
M;ZJ2DQ+RHPE^Q6-1*F$4I3A%*E:1+ V$SWQPY9*A3:8V48E(KX(CQ(R%,2MF
MS-V0F"*<H?E)+*MI8W"2="3A*<5 )CI2G()'HJ!(*7@;[,H8URB[)MVQ259$
M9"(5N4A&FI ^%>+*(QD4K5C1)I*2A,@9,1DM2^J'DI[\Y)8DB<E*;O*2H2QE
M)L&X2E(VTI6OA&4L93E+6M;2EK?$92YUN4M>]M*7OP1F,(4Y3&(6TYC'1&8R
ME;E,9C;3F<^$9C2E.4UJ5O_3FM?$9C:UF1)I8*.; OFF-\49SFZ24YS@'(@Y
MT5G.<9XSG>]$YSKAV4YSUM.=\70G._$93GFRTY_Y?*<^VRG/?<[SG_\DB#WM
MB<]^#I2> "VH0@LB483>\Z$"Q:A! WK1B6ITFQ\%:4@7(@U@E)09V# &,+XI
M#5V<-*7>!(8N@.'2DAI#&B0]J4!*B@UFS!2E,06&-V6J4FSL5" ]/>E.21K3
MFP(UJ4$]*E%WVM.2=K.DNC &3ULZ$&!D%:E%K2E/KVI5J/[4JEX=JE5EZE6B
MPA2M:NVJ6&5ZUH&DM*ELG2LSTDK2K K$KGS5:DQUNE:S@M.G+R6I3&DZ5\#Z
M-:C_@$VI3&$:4YI^\ZN(E>E64ZI4G^KTL9H=ZF1]:E2MTA2FBF5I5<$ZD*]R
MEJDBA6ULLZD+VKI4%ZR-:U596EN4TC:H>NTK-B3+4F9(PQBTO:U>>3O7H^JB
MJ<E%;G&1J]:Z;G6XTRVJ;\6:4^&^-;&25:YURZK7IOX6N\A]JV&#>MR3HE>K
MM!5J676+U??>]KC,I:]?;[O4WM*VF^X]KF7I^]KH]G>_<?7L3>E[W_VZ5[5"
MM>UI!^Q;!7-7L,#-+F.Q*]BH/E7!_@UO>]M*WL36E[NR17&*F;G;K;ZVM-D5
M*F]C>ET+FS>IVF7QC5G;XL^"N,"DU:N.PZM6\&Y5($6^_W&1_2O<L@:8OT/.
M<%8##,X%._>[:%VR9/6K8"E/=\BIY:J5Z1O>(].VRRNM\H>KK.'@"I:E78:O
M<&5\V^;J.,?]-6^;;8SG&/-XQT*.[ITYW-NG]IF?*D9THH=9X./^&<9W9K!6
M@TMC/H<8K *F;HA93%W]>GC3&5ZOD;NKU><JV;E,WG%Y#?Q?,Y-:O;UE-5:E
M\672JG;,R,7S?X/;:/XR.-;%G;)8LTI@WD8:PPDFKH'[/.RV)IO7#J9PL@<K
M:5"K6<>=1O6F+<U<4I?8THH&=[AY*>@1M[C!<]:PA:&;Y![[N<ZKU7:!M>SJ
MJ?Y8NT&F\IYGC.53SWO*IB9RJ/]S^F981[F^NJZNJGW]Y7G/%\YT!O"IA=KE
M9>>:X-,F^'W;;5L!VYG1]\YOMD%[71F7&]"U);>CE8I=<;?<Y;3\.&Z9;6UE
M'UODP,;UMLO]7!-_>M#L%?F29RSP@12YU.9=[GBM7.\LMYJ\KP:Z>\D,9F3?
M&KX:1[A^)[MJ.8-6P,/N=[%QW=A+9WSL#FXV:/O,[@J'F=I#5S.G"5UV+\M[
MY]XN\,OUOG=%DKOCC[8WI3W[XJ&O'<;O7KF/2ZYRI)^Z\/@^LKY!GN4FM_3)
M&VYUL,U>:G[_M_)<7K6OJ9Y=T$>ZZU).^YE9#&>57ASP#R^SN55^[I'GF:N?
M9;?A@2S_>TW;N[J%_C3?A3_\*,8<\;2W+7QM3FF-FYC)F,8[RC'_>[H+7;M
M/[)-2?SX\RI=X>=UNL1[;5TSSWKLM2:JU>U+X>Y^D]<[]777.1Y5L/]:V:Z?
M+\[AN_I+4SG"_(<[:8,Q# M W\,VDG,NG8.^"\L[XG/ !WP?OSL^W8LV46/
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MEVJF4UJS*I^OXLW(XZ0)EJF\+Y)H4E"I#N:GPQ>P*=>D@H0BX?Z2Z5.=Q)9
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M(B$77QFOB1JBN<>&UFZ3R4\:)W/-%DS#>IC<6#,U83/#:)^>;*A. &^1&?&
MG',Q7__G#??)GP 5UA*SI9W$U,J:,H?2- _N-^^>. \O/4OI,4?2:>7S/#?S
MOMSP3L@S#B-%%_N<3T6T1$\T13,5XICNVMT5*F92' MPGP@6H^UR["XOX-A5
MU08K>2[SR6XM[\9$Q"YS*VL>NZ9LK046*"N5W;PT$J.'"KF60S[MY0Z>,)LF
MO\ 86>E<7^4<7L8F@3*900JUWNH<F$T9P='E4[M'M!8UPU U4DO9ZKXT'SN<
M.B?8>, 85X,MXG[U4D.EQ.U$A^KTS6YU:NF/^)CU7#=FO\%89V5QVV5?#28%
M]QF=,ET885-8G#:,Z8XS,MFNN#)@5V';IF4?\ZICX(8L?9[_\A&;!Y 6L?OR
M+D]X:]L==KM!Y"AG;FJB[\^6=>1U(K@6Y4G7Q"T/-8#\Y,IQV935<U,596G#
MMEP&&31#-DVH6+55I#,S&=F%)H>R)=*1V+;V( G3CVYB%2-[$CS7-M8&\)PH
M[T*G%5KF=';?Q)4197 G=U>>([!=MTO@MLS5"<&(='%/E02S*MP(M>45MGT;
M]D4'3N!$;241)S%#W/<P\3)K,5\+N%_KM_S8LG$J.*4A>&7V8Q$'!3L##HA5
M>"4ML8-G7MW\CV6RK6K3(_B$G(6K[B@:)Z&$N.;*]CJ7G#DF7#VO9@(*Y*2=
MV+"17$!FX_K,.+TI;><9I8N['(PW_]P />EL,F@)UFV!-!M7PMK&D:-Y>&^I
M@:/FRB/VF6)@*[EK,OF+LV-Y1!O(I3@D2E5FP@?%6=Y@W[=]B[:D/"NT#I6]
M=M"[$O.00UQV ] &-JF9?2O8DB:?QWF;0Q)Z_#$Z=U6ULE:>!+J?-W31X7F>
MX(\QBR\DI5+89I"Z^B^=K.C'J>B@JS@!ZB%]:V/A_: B/G8,HJ\BC;ILEJ(C
M+9ZI>V,Y*M[8?5X\^@OC\IJ)&JAJ_DELN\D??KH_UK2GPV"H/Z(>PGIPKJ,.
M9N.O4YW?L:/4Z5T!&8J@N31K)NBFJ]M%9KNV;SNI!EU8N]#1/; )6Z.XQ[<"
MIU*YSS<'G_^[AXE[NR.5ND-5O$<JNY\[5-D[4]5[N5LT?!.35A1KOM?ENE=E
M*A&\P.^[P2,5OB?\O2/\PMN[O*_[OM.I)?(A+SD;L7\</YY:(CK['@Z9__+@
M)"F?\S$?)I;RP3F2MZ*U=>(UH_C>#2Y[>:!B*79B[6FB)8)Y#"<[(]K\!RZ9
MZL6OSG\IP\V>5"LANL^WTIN[?(?N#4NLM4H%7T$]B%.]_!0PU(,5UI,\UL-'
MU\_5TQ?P_U"]5X6]Q'*XU9/]P7X]VF^]UDOLM2,VV?,/V=_:UYL]$ZO]U&/]
MB:<]V[\],0]6UP,^A7^]U]?]G!8@YNK8ZCG=X3DVZ\5@45G=\%W_HR=G.8HU
M-N4#S#4R'6O_O&R&H$]LUCG3):,LY-TAXNFYH. )^^)I?@0F7LQ_QPNN8..S
M?ES6X+,[;4 ^MAH#V5BG&[H./_'K:_1^.U(@/PH.A0./,.(TOPHW_=*O,/5+
M?WQ7__1;O_+W9<4/61^B8J\'(F -(NZ'(GD<(I!W?/</W+RA_/Z^Q+?"DN Y
MROH+XL6SFB;6?/35'MVAN@J>/T!@$R@0F+&!V(P!0ZAP(#-=V!Q*&RA-%S.*
MS X67'@P(41@$@52!)E1%S"3)QOJTC6RXT&7+V'&E#F39DV;-W'"E :L9$^>
M/WT&!0H48TZC1Y$F5;J4:5.G3Z%&E3J5_VI5JU>Q9M6ZE:O4G0P)*DS(\J/(
MB2MW&ARH4>/:CPX/BMQ9%!M%@VT)&I-F[&'*EQ'/UJTXD:W:O-+@^F4&C.Y<
M;(,'ZC(<V63"RB I?G3;M>E7CF(U"^0KS6Q(M'BQF4P-=B'IE6=),\YX=[))
MQ'T%)B8\N>/8@:-+"XY=FW;&M[@%PRQY,J%>TZ$W<I;.52+IZJ3K8K>>_?KU
MZ=_!AQ<_GGQY\^?1IU>O7O5:@[HW7DPI$?5@OL8AOLZM&;)@C"WKTNB^WUC+
M33^$7NO/K/;RRH\L_^9+S;"T7L)KI+ D(W ]F1B4,#^.'I+/0/HFLP^YCD1T
M\+$)[6--(\!$0_\NK-D^_"W$_@"SL,7/5(P1)HTN="M#'S<L\B72+$H2L265
M;))))HV,4LHIJ:S2RBNQS')#W1Q;C*XAAZP10"\]&@FR_EIB<#&)?(,PN XC
MHRM-L-9LS32,WE2(0M$TL\VT(%=CJ:B$F($1SBBY?%&VPU;T"\&&9(.QT<?D
M9&C,U]JD5+C-7$H4(S(9Q;&O2S\]\,Q*?X3.&(L\*E2_3+4L3Z59::W5UEO[
MBU7777GMU==?@0UV*1%':S"_05_;TZ%!P1H2QI:(U:\]8D.;%K(E^;QSQ!DA
MM',U;>U4%K)#CS70(,\\0Q#0(NW:]MMRU35V62(GG3<Z$0UE*%J0K"W_"MMV
MX_40WF+%938RM?(%M]-K,T2W/?B$I8X98RB>N&**5\78XHPOIGC=B$$.6>21
M22[99*-^XHLNARP#:R?)2AJ)N0-9K@Q2F)T3:#F>,./+,L,6*T@RD& ,FB_H
M=C[09YL-%)K%DW#;2S*3Z(IKZ?:*7:C47*/\6<&=7>;I:)DKHWEJ-<6.V2V3
MS/XY):>)?K7LQL F#&;H3N(Y);?W$QHZJY.6Z-G!'.+ZY,,13USQQ1EOW/&9
M+*O:(]3J:B[(R#MENB'+K?9SHJ EGQBUO482/>>0+ L2],P+NG OSU&G6B;$
M+A.MZE5%P[W*U>/2//;3^5P44LI-=SUUUD.O_SVWTWD??K+*6^]<^+Y#YUPF
MHW^[?5#='^_>^^_!#U_\\;?ZF*9US4]?)Z3,#XG]]6-2?Z;J2$8?_ON/Q!\G
M^_/OWR7^]1>7 ,YN?^0S8%)DMQ38+>9YYR,780KDP+;E)%TX2:!.]"83M47E
M@D%#V=_^!SN;-&=X'Y0<35@&0;(TT(0'=.$+81A#&<[P*J_+VPUQF,.\M2]6
M*F%A3DHBIY)0<(,P*9Q15"+$",ZOB#;AR0D/DL39J82'1U'964 XOPS&)(C[
MN^)SJFBW,-HH;"<*$_NV2$,UKI&-;71C^%Z&*SG*$8J\>B)3J&BC'\8OCS$Y
M8DZVZ#,BRJ@F=XR?(?^Y:#BFB"TEA*2)%/EX(">&J7!C)(@B92)(TQR(D0K$
MY!M!&4I1CI*45@*@ /T7K$XJ!9((6N(4L]A()*)IB/OKXTT0J9Q/4D22G4%D
M9BB8QI<TL29?%$PL#]E+FAS-;B#:HTU>5L=23I.:U;3F-9]B'6UNDYO=U&;$
M<HF46VKR)KPTGT->F<S2U;*<MYRD-*,Y$W<Z995_Q$DKCS1/FM23G;C\)$S(
M:<ZUG!$IX<3F01&:4(56,XX]L15/'GHK:>K*AW@4'C-MB<S\.%*>M$RG3HBY
MSW_B\W_Z7.37-'HD8;JDB^4T9F8L^3)+NK*9>AS62A>:4YWNE*?BX^4<@5K_
MJXG&RJ"S9 E!SV?23093:4AE(D<YM,NB1N:?!:6D2HPZ167.A)]0C<E48Q+0
M<3H5D%7MZ5G1FE:U\JJA00WJ4+6TRJ2T$J/MU*@];T+7?M9$H!8<Z2Z5FI1X
M/H>I[0LIY% :4YQFDITO<^9,*V36M4Z6LI6U['@*E5G-;I:SG665L,":UZ8^
M,Y];;5IAWS9(E$GUKY MY%6]JDMX!O9'L%TM7)UY%DZ2U:^XO>P:]P*\RG$O
M)!/[[.:$&]P@(8:XRSNA<O\WL?8Q]X3&/=*JEFO=3C47(MAM''2MQEWCJLYC
M_ZM8=,5+L>LF5[OQ*V]X)4==\B;WO'%I+V6?9!$D_SUIOTKJ+\@JNI26TC2C
MY\0J$#U*Q)1&=J(DC0MMD?+2PZI3GM,[GX07W#O3AK6Q/,FM4F3ZVVDFI"<C
MR4R *]>3TY%XBR<.T\O$)C.5>/AM UY,3^H(XZ$)B<9-LS%0:O,3UJ!SP$N9
MV)5NW&*?3.AH163Q@4YL(2"3I2<'(;+P=/S#)YMXR1-ILJJ PN64V2W&3ME+
M*'_JUK>"4[(=/2II2[IAO$[RS:HM*SQ#Z^"3 NW ]P3LAFO+9T S."=BW2V<
M1>I;$<<P+:0!D)^R%I';^*MA#%);UL8R:0/AJ2UVB0U8;".U=17+7O/:DZ>_
M A+?#*Y4:KG(IYT"H"E1Z/]U;A$<9$P]I'95$-*A(36N!W/JH;U.U9J1U%G.
M]6C-1#I9N@XV@UI'[!C=6M&(13-$U0S4:E>IGNHM+G3V<ER]NLS;^Z&;JKAG
M3^::>'KC]O*0N==7A,2[W*E1$'%;:3'=LOMV*Z;WA'[9S_IV%^!0QC=TVAM<
M$)V;)>DN=XA#,KWW$CA 9B1.PU?V\- NFH:Z(9-C=*867;=D0&5J59QTYB^2
M@\4W;3)+:?;$TL^NG$!L"LW+.<D0:"\[-,=&X$?54S39@%Q")'*4QXW=GU,5
MFUZKOGFSZ7(HH7]*>#O&RX \_AI[:8I23&\*K-J8;;=NFTJ(1"=)E!C%T>Y[
MH"S_VNW*^FGV#IO-96-UNXR?)F.XEW'O:C]JW=<.QK;+<J!]IVK:-UGGQ _^
MM(5/K>-CQ!J[L_V2=X=\?ES49HZ_4-8O.I&>1&5T;97\6\%IR8LQ%;;W*"V"
MIN</BVR^FQY%)_3OZM9?"K*RJB7IB:X%3^=7_Z 4Y:A$I>+1\/O$HO^X*/@:
M<@GP9X^BVM?G/\A1C>L_9C'=EXYV%?$]^)!4*,1P=OR;+;]F 4S)'D,<\U&\
MZ-R/RG#&;]1N<#^=NR,>^&/BG?"7/+?:$4\P]$_>N@KML,A,T(1!V"^%*"/J
M7FS], P!!4V,]@8! ]"Q;$KP*N]F*'#SWJC6-B-3,@W*_TZ#.&PO4."#(@*$
M;C "-00$.2!F]N""Z-K%!5?/RAYBZQPC5Y!*:O)FT\+B-A8K/4 P6T00+4AP
M./"C0Z2/RV*#;HK#/6K$0$*(-7I#59#0"6/.0UQ0(20E!E/L![ME+ HGPSPP
M2N0N\P+P,0;PEE:) +_&^D2EC!1/9]K0X@[P\M0M#0$P RNN#F%J_O J#1'P
M[R@/02QO PU$#@W/_\C([_Q0WLAI$.?0 ,_0C;HP.JA04EYM>@3$"D%#"R4I
M0U#C"G%0=1 N"Z-(+THQ%.<C.#JQ:J0.V(I"->Q%UJ2D%8O006!Q,'+E$W'0
MY.XD11JE%;UE]HS%"(=L)>I$6_]^\2Z641B1$0A/3EWVA/3:R(9T:!MUZ/O0
MT+;R;YWN+\'R[\/V3Q#[;+ PSP(?,1SU"#/<$!P=L6G8,?(.D0$%D/\6L?ZP
MR!(I;@'/R,G8":\B\/#Z#R!+Y/W*Z+$TT-XF\/(N48VVL",6B!E'T2(\42&B
MAT]NX\$T+>(,XAEW,093D!FQ3"-^\2-D306;<06YCE&,0V80IB!Z[('6HX(V
MHB)=XT*\SQAUL22?4/;.:"Q64D8F4B-3<2>C"".#;%(X$B@K!&^<(RT !!?;
M2(? !FIR:&?(;DKX\/+JB@T!,1X3T=X:T2P?[P_34A)13P[S3@_G[BS'"O#&
M$F_D$2W_&\\.+W#R%D\1Z0\NU; =[7 L#^T0Y8X1(_(J>0,T3I$3O>\93W Q
MI%$N+O(H-7$:6Y(R>3(*E;$Q21 C9;&!;".S&(0O6,]*C%'6(H(39<,3#4(U
M<Q#<'G,S!:8S(X1&- 0V9V\NB)$MALP5_R0JQ4]T;"0!1XE^D+,NE#,YF3/]
M'E(MZ;$!!1,#8^0M_7(/Y[ >_S&04,\NGQ,OCZD/[;$O$=$P[[(@]7(ZMP@?
M'T-XWA "$XNJGA,AM;.NJ+,\&[*>UF\($_. +%,$RT)&>K(I?Q(YY.(D0_+B
M='-A/#)%*"0C:2<8,U,V>+"!;N7I\ ;HT ,GKW"=E#).ME U_PJT05VS-E$0
M!HTR-;'P0X6#Z+YE1&%CF!X*'L%,E/;K1I<$1_4K1W,T8@@%4H*L=+I02 $.
MS!H#=GXTXD!Q97012&.20(KT,X[T=#I( 3.%@9Z43XJ4+([42$NHYIS4UL(T
M0!#N)+U423^#W1:328,44KITA2!(2F7/+;JR/Q_'!J?P47JQ!:LF0V2M([X0
M"?NT!9GO,JVR)0&#!PD5/XYP4_XD1$6S+'HT1HR3VPH5/F;P:UK0!/_4"\U&
M(A3U!&T1"RN$4U'T]HAO*0W5"Y,R*GGTJ&CIVAQ**&9E*&HU*.HT2NC'?9;K
M?WS5?W9U(GS5Q.XG6-U'@(@UE903E?]^=3F;]5B%55E[E5FAE5J7-5J%E5BG
M%5NK%5N-]5IYE5N]%5S)-5A/J5R'-5N?U4YE"$ HI"7;0U2@AS"6STS.I:D"
M!&AD(U."[?/R:9V2D4Q@Q_M44$-BSC=T!%!0X[,8J.1L<CT2I?F"\"4!PUWW
ME9/N%6!M;U[X5;_P]?FBQO/(!E3A+ELBKEZE,#C <'2THR"JT@PY#V-D=F9I
MMF8GCEUQ-F=UULCT S!$!&!V;MJHL%OD(^;:XF7=Q6?QPG",5BVJLB]*0VD-
M8UQ8CB$&!U"RYAIS$#*P$5$8!B1T[6BK=C_BICH8IA8-0VQ5#6I[]MFFMH&*
M1C\81BV"UEO_?/9L\U4*7R)KL08)$2:V=C9P!7=P+2N(/&W:)@8W&.AUO@2[
MPH1G/$A+&=<T5L5>4BUR5P,C>^Y5AB9)[<)5_&4T=TYSXR:S].-RR>5R"89J
M;4ZXC(1J&FW3$C=N]"))5\15<F8T$O<=/5<R0#<<,9=04FUHV],B=@Q!"J7D
M6&9R!:-RPT1W2\YR;%?#F*M?:W'9CI=PM7=[N;>G?@K<L.U"3/.,"B=[&TI\
M9V7W9F4R;JR(SA=28#57RG<RXNAOL.UVUM?*("J=VI=JD4T $<T\ZA=]W6E\
MV;=6V6U6"%A^\]=NFNA^;W. O4R!003%-JJ?)+@X60N2/ =@++A[_T$XA$6X
ME(YK(A!#)[#C+P %25!X74HX)%+X?V(X?F:X(<KUA%6X5_%$AH>*A:WUAZ5D
M.Z*KA7U5OXX$BH2X4VK8AV5X6V%XA9%XB2&BANLBBGF(B0'(&\&'&[DXAW)U
MA,$XC,5XC,F8<73,5M&85HFBC-FXC=WXC>$XCN5XCNFXCNWXLOHKO_3829KD
MCOWXCP$YD 59@\1.VP;YD!$YD15YA-NJD&WEBQ<YDB5YDBD9H=+,D1^YDC5Y
MDSFYDZ\I_#+K_$*YLT39DTWYE%$YE55YE5FYE5V9DU^G.6A2EFEYEFT9[%XY
MEW5YEWE9@#&9CGHYF(5YF(F9*AKYE_6LF/^5>9F9N9F[^)E/ I*;>9JIN9HG
MN3FQV5F3TYJYN9N]N9,]*YS%^86_N9S!N!70.9W5N14$(IVM!)V/0IUAPIV-
M@IZI0IYC!9[-F2F.&9FE>9\!>O,"@ 4&NJ )F@6N0" $8:#9N2GLN2JN@* ;
M&B=:8:!9X"46&J%O0I\KF@4$H2HZ^J*?HA4$8:)!^J/;>:!1.J"18IQ=VOQ8
M.J:UMZ(#H*9MVJ91>J$#P*23HA6N8*>QXJ>!VBALFJ<).@!66B9\>JAI.JFC
M@J83VBF6&BL$0:,5NJ:=6J:U>JLCV:8C^JL1.J=5NBDR.JNE(J)%VBB..JE;
MX:!Y&B9T&J7;^@K_S%JJ:SJMF>*G6>"MH:*M R"JL:&M/9JK+0B:G_F?"3NQ
M%XJF\?HEA)JOC>*QLP*R:T*G\9JQ;4*RM4*G 3NO:YJRG:*F.UNQRRF-35N-
M<8RT55N@!WHF='JB23JLX;JJZ7H@!$&HZ1J=!:&DJ[JD;3NB??L@=IN=KZ"X
M39JD1_NV/9JR&7NBA3JIBSNW?WN@I5NZ WNXL2&Z84*[2;JN,5NA?3NZ>=JG
M@7NBJYJZ/]JG/[JWT=FZL6&WG;JXEWL@(EJE&QJ[!X*\]]HE?)J=R7NTD=NX
M5WO "7S1OCLF7KN=C_JN74*HO5H@%ORSX[JH SO"D3J_L3K"5UJSL<'"_^NZ
MPS][(([ZOF^:H2&\Q-$9JZ\:J5$\OQ?<HU7\): ZI9$ZPIV[Q ?;KV\ZN[':
MID&<J0\:PV]ZOW7ZP>/:MG%\H@_:P5M;P4M\M L\RJ6<IXH:ODG:O,=ZJ>^:
MP06BOI_\Q^^:I),<S&UZL .[Q,N<OFM:Q-%\O^%:M >"RVEZS"-\KYMZQ=N<
MS0MZR_GZN^<<QVG\K\N<G9.<R?]ZJ=T<&[A<T=L\Q6\ZH>_\O='\T+M\SV\:
MI?6:!1;\PZ>\TSV]E/X<S=4<J"V[TH%:Q].;P;7<MXN<KM<[S'G<Q.<\U4-<
MTD\=UCD[)KX[UW_\"M!YK0/[N=GYR&V=U+G<LO^'':?G&<[/7,7GG+C7O-+W
M&]6A7;1W^\<;VJ]%&K?9>:T=W<YM':5Q^M=C_*CW&[<%@MEG7)G[:SC=/4G>
MO?QP^-/I':$F'=9MO=MKW:]I/:VU6]+=O-3U?*5'O-G3^JA'/=DO',)K.R9\
M/-;7FZ!]/<ZCO:QI7*S_FN(#P-0)OM;Y6\X7'>%YW*H#^R#TFL0S7LT3G<LU
M>Z[36^*%_-53WN YGL8ONKE+?IJ16:+JO>>MB;&C.^B1'*C=.IWAG-@=N]:1
MGM'Q.M?7/=8;6K(+_B:>^\=7/*D+ON5C'.G=&MN'WJS7_>DEN\C'^B!$'N+-
M?M^#G.EUG=G#'>W9?+__IW[=A[SAEQF47WJ<169;MYF YH>*T158G;5;PU6+
M?;Z3%_W-!_O>#WWIA;OLD=ZO._O(Q;[6A3K83?PF.'O=.=SKB3W2N7[-$?W&
MA_KCF[SRAWK2-SSSJ[Z=3Y[B;Q[FYUGVF_VC.U_D7S_=FYSL+?KP=46$6BYI
M]HAR'-C")K1 VH-M3J(Z0(C%V,;P?7^2#WR[/UO'#9K!.]_DE3[&:5[((9W[
M-3O!S_XF[IK8EUZRPW_K/?[UI_[M,5K=P7_]+3SJ+=_CK=[)13KQ7<+MC[SS
MI;[) 0);*Q8!KF [*(A@@(4!6!Q\"#&BQ(D4*UJ\B#&CQHT<.WK\"#(D1FG&
M_X"5/&DR)<J5*E-*$PDS)D9@NIA!U 7,IDEFTI@QTV5LHC2<+R4"Y5FRZ$%C
M-1\.!::4&<V#1WT"@SI48DF?7)7*_ HVK-BQ9,N:/8LVK=JU;-<N=%A1T,)6
MV!1&I(M-;L&'@@3AE<OB[T)!#P<VQ(OMRF"!"PT>5!S@(62ZB@/S;85X8F6&
M?!<_M)NW(6'& 4;K'5UWH<#*J!5F+OSV8*O&DE5#Q'Q%H>/*@@-DYOTP=FJX
MCS$+).B8-&'(J+%Q3GPX>,/" A.^?=TVN_;MW,'J^@X^O/CQY&UV1XL3F-.K
M+XT%?2AUHON<$J5!?6C2:4WU!^W3/R@5?TWUIXLT]O]YA<U_YRW(8(,./@AA
MA!).^-%LT\4U%W2^R7:%7Z01-YF&O67FVF<96HB:7GB%R)QL!!&G&4,7?@C;
MA2$JAU"&CT4'F6.&E3:1A3YZ)F)>5R0GY(Z1*4FBCGK!52)I!EE(W&DTYKC7
M<#5.>61K.E((9IAB5F0?>6:>"9YY8W[D$H!;)?@>@/=!9)]5]>E"IYI)_3=4
M2?C]=)""=6*#9T3NK8EHHHHNRFBCCE[$4&Z2LG!DCBP09MT5=$6I6RMZ+:F7
MIIX229IO@D &5Y),*BD;0W[U:)&%M-5VF'648BDJBEAZN:2L1RJTH414M@KD
MJK".FB5SN'VIH4'67?BIIRW_&G8I7;I2J^FSHP%W4&Q/6LOMH^*..]95YIZ+
M;KKJ*DBN44,5E5.!V!S:WU5W8G-@1/[QI%50?.9T7YT"JOENOA"99.!+"+;+
M<,,./PQQHK+*&.FJJ;TE7&@4%_NIJ:1J2#%>NEJLHI(AQPIL9C_*6*6,R)KV
M);>0,:10<UL2BUJ(G[*0LLF10191QPV]Z.+&Q 'KK&="9TQTT8XIQ'/%$4]-
M-;Y.7=T?UE9GS?74.1UZ('WIRFOH>P-"Q Q3[-WT4GSX%BCO@87BE/9/QAA8
M*$1JXP34PE7_#7C@@@].T<8L8XD8L*(5)K2'W;IJY6TS?ZFJAK2*/+EOV$4$
M]6O/_P[-N:LC1WYQ83.?RFR-J<YJ.4**!UNJQ[ ?I#BUA2EN&98%84;DYSQ#
M%"[3P-Y*>/&,\H1\3\HGS_SRSOO-<('QI9U@>U^O+1'")/%7GU0#2F7@3S8=
M>*@Q=A)Z[MWXSHF?^<I#;WS\\L]/OX2>WH^97X[G'_2ICM_6E__))H "\11%
M6M$AFQ40@(BYWUT2N#EA^65STNJ+!"U8G<(8AW&OP0Q=2A:D_1F0@P!,H+!,
MR#^)!-!:&^2+"8/6(19VT'\=;&$!54;#^NDP0F5"DP_%HR:(T0=/=QM4?M87
M)_W09(D(4LKVEL(WF@0E*VD[4%82-+Z(Y.TA]-JA%[\(QO\PBC%B ^G0Y<:(
MQC0Z:"@_;.-W@O@P>0'L)?+J(E,0E)2$L:N+V'!;31+F)RL"K(\#JP_[ @5'
M-2IRD8QLI"-%\B3]O2B"CZRD)3?20S?Z,)$-H\]\UJ<3]5$EB7!RBI_T4Y0G
M@F\]/,'3OO!&E41>46^DO*0M;XG+7!;/<%G2I2]]V;Q@.D^8/($?N>(VH/OP
M\2=.))N<O,*4^=21>X&ZFS+EY4=9XN0D_KH*2HSYRW"*<YSDW,[*6%?.="[2
MB5IC9]? V2[UD41AZC-?GM1$O8@<LB?F*HHHX1.4]Y"$BTOA9$ML(I65<%*=
M#&VH0Q^:D?S9$*(4G=]5TK/$BYK_"Z,<W2B[;@G/BHITI"0MJ4E/RLCM972E
M'=6H2VFR4)3*=*8TK:E-;XK3G.ITISSMJ4]_"M3SA&^81"7F\H**U*0J=:E,
M;>K?V*C)33IUJE2M*D@2<BF(8%6![9KH10:2NX\D)#E?;0LE87+6O/SNJFM%
M"UC3:M6V],1\=*U;7>]JU[S^,ZY\[6M<J868C#DL(5RUR,<X4IF,Y :N,D$@
M6;\RF[0"AK$3F:Q:#NO7S&IVLYRE4.1(YS""%/: !*%LC&!T0-ND13&/E8EH
M+P*8D,0V+18R;6='RA6?.+$GN4TE2>S9'WX%=R=.,9!3A(LOXP(HMS[!%W+Y
MV=S@>@6Y_\=-[G*9*Q3E.M<KQH6C\VX+7C7&QC":HDX'.T)!@52$DFFU5NAL
MEM;%M/>T0;I-=&ZSWKNH5UBA:ZU^#QBDTN)79?>E#H [8YGTLK>^K\%L>%$*
M'IH,"*K?L=>\TH,3 L''FU($T-D(U<SW>*_"W\%;47Z2DN]]V)E<1"A_F$+B
M6B;(F7UBFWV2Z*>]/GC'.CP-"-7:&,0LUG7^!=G_AK>B2WU+A<0[3NZ>E1Q4
M1?DM7#4,E!_39+!*)+&)4?)UCD/EU;A*,H%!3AFIU1Q4;>M%8=5JISY3YF)Q
MZ"V.N3*6^-(Y(@/64K;*C)VQC$!T_MG*/$Y+F988Q40C>M&)CO\IN8XXKX =
MDD"II,\J_;-AF\!X/4KY)-H"1DB%63C2"/W.P;Q;S_L@[") B=-/MMB45;Y-
MU(6N-?VHU30- 4LZ,&NSF&7D(:@)9S-0$];B0@,75(T7R1>KV40,1YC9Y(ZU
MK^$RL3G3,4Q1;#0O&LR3&A*=0*<LT%\.&L5RU^U>/LY;Z8:+9:DE'&F#.T.
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M9-@2+$&R(YN,505<V4$2A@JR+:M.LHB?C&0A+DNS9]$3W,&R-:NSOK1GY(1
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M?^=&;*Y%.N#;&3, -!SP>=.;T/GF.+-Y3G2F4YT3:1]83.<O.2KP=*7_!%W
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MEB$9)FR^"JT=XL36X3KVSGJE"_NPZP\'8T.$2\,R%'BR/_BH"_C7.+BR._A
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M]RTJP,Y'C%<U^N-1'P(N0?0B//1@+P* 52(,T2XH@RM:+P(>0[A&E/.W+I.
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MTYA87+[QK.KR[5!VB6"]QHMR?><_T=AWUC/\6$7_B(VZWN@>N96WRLBB):V
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MHY_-T$PZJX)9;SK_IIJCY6=1T\E-"I5GD!8JA&.JD48H]H,;D<7G/2C<H<Z
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M^"Y&O5#E-A9TQ>-2ND''ZO7(F&EKEVYG#L:*-B[#VBE=@]1)56S"QQ"QZ@X
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M:-G'W=LM)Y]WO:['V[UL:J\Z*;)VZ-[+1>$O;:$BB\(1'L@O?;I0Y32^W<X
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M@E&*6LL:TZ3\2)]VN>^$/>HC&"DH1M H"VC/NY"H7+C".?9P*@!3_^->S/5
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M(A'M'=AX0=W _=/OO=3FB%V+,-L=[<[TS1B)==3;BD 6&5OQ'5#D$)+_V47
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MSP9E9S!QY]04')+6.GZV%'KVZ/$XJ%,K5%-]"?BB:!%ZUG:)1#EJ%X^ KX8
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M4]@=[=]DD&/VG 0<XVXT0YD,VK)&D)'D9+!BO+,]VP1'(Z!)N""BE!$9'2!
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M>SF2$3FSL9_$;S0L;.#2]&8PCTCK+!_Z7Z00&+3,)2EB)_EA_VQRI#?ZD8B
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MH$.+'DVZM&FG;#'6O*N::\F7!5,GE TWX\I6@@#C[CB8;%S8!$>B96S1)E?
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M/BQ!S('$_JC"$=F/R(.6B&##6KF2R]J18SF6P<H+Y)'$G# 9K;B76-1"#BE
M1EP06;J,'&D7>4*+<U(M4=DP,@RF*$PP5)21*925A$$WW,O!::3&:B0II<+&
MG_]SB57IN]9BB)#X&Y/8,H(8"<,11X(8L[X#J=8JQY#0B!.R)I& #!J"QX 2
MQVXD1TE:" =*QY*("+L9"6$1B1KL"7S\1ZXZ"90(2#\+#K,QKG8L%X@D1Q4Y
MQ[,3EG()BGN\LG=DQY/X1ZVI"XF$(H1(&-\02=TX28MTQW^\EX1HGH5,R(^,
MH7PT28%TH'/$R) (M)8DR*")R/MP2/WP#8)DR(_$29C4CY&H0:34"'[<QKYS
MRIJ,B:8$R)3D1YX<RI,H2:3L2(,DRIOH.XW 29K$QZ DR9,TRN[PC95T#^:(
M1X,02"P[&\KB2'AL2) :RZ2<1\/927/LBJ^TQL 43!?_N\!L#,/!%,.I\T+$
M9,S&I)#%7#QT<\S)I$PBB2[4JLS,U,S-I(G&,TS(XTR>*!/>^,'0-,W&A,S$
M(RW /,W6S,P0PSC7E,W9#,R&F)/;Q,W<U$V#H,W.!!/6[,W@[#:B^S;0$\[C
MS$PP*2'D9,[F=,[!'(FH?,[I9#&ZRT&NI,[LM,'HG$GM],[O!,_P%,_Q),_R
M-,_S1,_T5,_U9,_V=,_WA,_XE,_YI,_ZM,_[Q,_\U,_]Y,_^],__!-  %= !
M)= "-= #1= $5= %9= &== 'A= (E= )I= *M= +Q= ,U= -Y= .]= /!=&Z
M"DM(0Q+@9#RZ&LN\K!\3#9)B_V/1^5%1F9@OH #.%S4AA(Q)"HE1<_1/HCP\
M&QU,L132T/S&XKS1R !2G'C1ND1(P-S1(TG2QA03U\"+**6).;'2G.!(7=LE
M^S.;6P+)D9&(;?3#[K2?S,@)]>J(Y:R),;U2-HT)-;5%^4!3,833CBC-%B6:
M+(71.P7+692,,^)2;Y0),\VE/"4]MUHTGS#4J?13)'FU>\.?1JT+K_F101T2
M3)U*>MG'62H7\]"/[D!4(EFZX)0(=70P3062)QT2KP"5N2J( ./3R%!3,0TN
M?SR862V[414E@'E4)P%4MJ1%F0F-S(A5'7527?7-0 4WWM318%71$I+47(75
M8.T/O/] QX*T5N7C52/AS5\%&6==F3#153<]$G M"M-R"*9:LRI)FFX-$G$U
M50!3#*] H7F\QWQ=3GJ,29191]WP,TBS3G<451P+V+C(UQDU2(+XQFX<6+LL
M"I+XUV/]5*PT(:\\RH0-U1/!TJ,<R;]L27I<V$>B*(V4)*\02'X]6'V$6+GD
M1I- TYGT2BA2+ZA<E;C\1_386,,1RB-UV"+[T8,:IG2-V8#52#-]6*STUW$L
M,HPT-7W-2(G%#4@:R8VTV(-]2I]ER4_56MO<VHN-6C\[B,Q8VFSE,HU$QYQ1
M'85DB*7#V*?=RXNEVKKX6'VL4X@%6-%X(*.EH;I$(=T0'*'_)%%X]-H<';.I
M;-A&.UP3DE@NZ<YU9-E'TEB"#8JU=->R7<MC9=N0M2:(/2B,C=NO]4M>\UF<
M]%H2Q5(N?36Z>#4U59V&O%K*#8ZM?356U<Q3-4 WU8NU ;P[A)0UD=3,X!FS
M&BV.XI/9T8J[4*](Y8WC@!3V.]5&BA;AW;G2VI;0HUZH4XSH2UZIBIJR(<VG
M0EZ:P92IDY@Y!3S%K+S>S5X/$5ZM.![XU8\%:0C]X\&<V=[2/-7TA<&CJ!C!
M*M7=B%3S(."*.1I1F5];W-Y[V[_0(AKK==5];,H">5X#"PT1D3%;](KC=0_>
M>%>VL<6""%]9G=\ZO8KW[2#[Y>!U_ZF@I+E?$1Y>OMA>RBHM=GT819M3 W0-
M4EG%D;!>&?X]^Q4+OJ"-:>U=X@55>'FJ,BKBW7@6!)Z33Z._HF"1*5G@]UV+
MIAQ C4E>Z#O?L[BQNYNY_@+B.]K=N:$;/KEBT3!#M^%!_UTT]I-##UZ6L D3
M'AR/"EH0/>2S*CX.%];@^*E@T3NC]W6P].'-95D+Y##D$1J/WXGBA!MC/3:?
MP?BJ\$'CD=BF!0::Y'T>XL6X\BW3-=9=2#&H.9UAS#)E31FM!K%7T0!AE7!B
MS9T2CO(]H[B[-7.-.1:[[O6]R_MC*E;@!9G6TWSE*O'?L]A'T[@+!XM5E"5;
M9;:(OK-BE/]5LI8).P\A8YI3M--5C )Y5[)M&<>5#,?BB,_Q&H5TYEKC"+)8
M9R3^9J\5Y]I].&T^9XZZ8ZS0WM--U;XS"["S37?M8!?&,7\^BZ.HUVY&T_HM
M$"1V$@O9YO4 "1.1"(Y2B?V5"]S-Z/EM&9#Z9[I1"[E0RJNYVP+91TT>V[;)
M&UN6#!G>8'"F#'_N9H46C'HE"]R5#[JK96NFGHHFEA4ZRW&V5Y%6YH3698^^
M19UV7)XF"[*0"QF&$9)DY@=*&"Q5M%<M7+SP&H<6#)#&BNH*.XL&YSJ-X M!
MZH"NZ:WNZ >RYOF5Y\\)Z7_^%IE.Z$7S"$%[Z3XFZ'&NW3LFEG+_)(NU1F=D
M!KRQ?&JT-FBVJU\7Q@^D!FBC#NE\+A!*%(RGCN;_N^H-QN@I6=W90>8O"A\?
M%NA8-=;)CN:2KBI0'N= ]6;3>+6;=F>V9FNPFVEN)>QZI:%UOEO>5(L&6>J,
M_NF.[2]775WFQ8N;Q8Q:FVDL7;.FJ6S.7F1U]B&##8U(S9M[B56KMM?4U92Q
M-8VQ_2JD_I"UX#.OR>WK1N0G1N8YG;K9_)+[Y6OTP$<TU6YR!I5;-+= DYDO
M IK<5@T>D5^)M>*AU!B3?N6#A&HRIFQ,]K/4W;R<.?"8A96H"6VZ3=>6.8YG
M^=X(7X_0UNCT\9!O?M7=]N$+QX^VMM<(_SYPDCUP5]5OS*J3$$<FZ)FY&,?I
MJY!3$=;;(YUI4!WQ(UR4ISJ+LBY5$5]JM[!OL:S#\S:A.;G;$^;=8D[PR\7L
M5UVZKH9P5#0W)Y<9:1YJ#=?;1CH3DQA3<38N/,56+I'F!"\4&"]K+&UAP$5S
MX4WG,%<-D8#EILGQ6F7+[?Y>J ;TIHEL^;!R"E=S<6[P&$]RM2C5(:.-K(9R
M6#[QW0YR7"WS*B=B]YAQ5^5TB/Y+.65HTCON*HU81%]D0%?S*[>; X?S_@Y5
M6!:<=0-MCD19%;_5T(A>84$0T&9M7,]T52]6S#8)YW9U.2_G7 ^+NH1S<U-U
M-+_OH2:/CUY33?_G:&Q=U^[FZ,\I<1/WR/M6<%\U(43&"MJ@<9.FS0W>" CW
MY+LF21-C;UNYZPX.;-S,<',]L/'CW<5Z7_LF"-RHTK)NK?!];_<%7Q6A7OXF
M=93U9+U1+S*3HHN&'A,1<S5_JOS]W8..[>Z!C)JUD-6@GD ;X^W=Z$D'WQH\
MU<\=](,"9FHG6O_5;X,-U!J>(6+M[+#0X+NU$-=M*TQV\K^05X^GK$AN:T)G
MUO"!W[4H]X%TLD).9B)N&IQOF87G=0P?LJ-WW*FK=2?+=(Y?;7-/[5"Q^DK]
M79#?-N) T_1YN/-=X*5N="6[$MF(\O*E"*8J5K-2]'3E\Y!L7A O;Q/_C]60
MWO!Q=O@JO5LP[A68/^ZV+V>6E^%C%5<<'Z1*;W=KX>SRQ:&EBU2L9O00A_=M
M*Z%71A"5/PA&[O>0A]\JCG=1^N^NKWO>H/@WYW7#GV!2WPXME]?)CI#/ .1[
M'OJ=+WU.I]ZF1_5*17,+@:TYA>'*;V=/)L8B-M@4S_F%GUXP-VGN;DN3UF.@
M'QO;I)D=-K ZAVHG"O;>Q&F+Z.B '/T9$O&S:$3T[T[H.PL2=].AAV:8C+T8
M^^9:[?1REE? P^6N H@ K; 1;,6B((M6!ED($G3E"K8 !",.Q,8P0,.,V!Y.
M;'6%A4""#"=N9''%X16#$QUN%(10$,:,@A:>_V2HLJ @D!!7[FPE\:',5CE%
MGLSHLZ)!A0<)AB19L*# A!,3.DQ*D*/4B2>UIDSH5>5-BRB#<N098"?)G!C+
M^L3&DF#.FTD=#KWJDFO0G$4E-D4X]:[9@P_+BJUKU2G4NF/=]DQX5B8VN5D#
MMR3,T'!"CF5A'JX+]S%,LV@MFD09>6EFM%CO9@5ZN>' JDN=YI3ITF!(GWEG
MVX4KV.5(D:81G[[L]:[*K1MW8A7:4V+;R!\3JL1L'*+ PQ:U.^W;$B]SM*EY
MWH2YUZW@US-)!A<+]J!*[Z6-$D8L-6OKNVHA:BX*6_UZ3H7UT&%;?7321U9Y
MMA5T+!C7T%)'$=?75_^T\1;15!4YY*!'+E'(F5]Q.8@@=G\1]Y9[?/DWTX$;
MPG5%  ?-!YM6@%%WGVD?!4421V^U=5)85T'$TDBNV986:!))!U)%'4U7('"
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M([(865<Q'7@TA?=ES?<7Q;1?)])/*QAH#?AKR?9MO5* ;559_?99>]5U5Y=
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MQWNA[GU*:EGBZF= 9P'N1-Q)E?>\)S_P$;)Q3[)5Q'!EELZ];#0NPQOF+ /
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MSN*5YJ.R=$;?[6-295I&5=[(DD=-J?>N&R0K\[2^1**O0AS6Z*$BC*BSRZ_
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@01YD0BYD0SYD1$YD15YD1FYD1WYD2(YD29[DJ T( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g116782bci002.gif
<DESCRIPTION>G116782BCI002.GIF
<TEXT>
begin 644 g116782bci002.gif
M1TE&.#EAWP1-!G< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     + $   #>!$T&AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
M_YDS )DS,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF9
M9IF9F9F9S)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G_
M_\P  ,P ,\P 9LP F<P S,P _\PS ,PS,\PS9LPSF<PSS,PS_\QF ,QF,\QF
M9LQFF<QFS,QF_\R9 ,R9,\R99LR9F<R9S,R9_\S, ,S,,\S,9LS,F<S,S,S,
M_\S_ ,S_,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\S /\S,_\S
M9O\SF?\SS/\S__]F /]F,_]F9O]FF?]FS/]F__^9 /^9,_^99O^9F?^9S/^9
M___, /_,,__,9O_,F?_,S/_,____ /__,___9O__F?__S/___P$" P$" P$"
M P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$"
M P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$"
M P$" P$" P$" P$" P$" P$" PC_ +$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O8,.*'4NV
MK-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_@ ,+'DRXL.'#B!,K7LRX
ML>/'D"-+GDRYLN7+F#-KWLRYL^?/H$.+'DVZM.G3J%.K7LVZM>O7L&/+GDV[
MMNW;N'/KWLV[M^_?P(,+'TZ\N/'CR),K7\Z\N?/GT*-+GTZ]NO7KV+-KW\Z]
MN_?OX,.+_Q]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]^_CSZ]_/O[___P &*."
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M( VI2$=*TI*:]*0H3:E*5\K2EKKTI3"-J4QG2M.:VO2F.,VI3G?*TY[Z]*=
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M?_[UOW_^]]___P?  !3  23  C3  T3 !%3 !63 !G3 !X3 ")3 ":3 "K3
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M\M'B_2FNMTCX0=U<ZD,(SC>96M#+RS+C^4FE(5:JP2V5M4.72C1KM4DT'!C
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M46YU;9*K[__I2:\^!,DB9]F6=C>Z9GTEXTO4:BM;E)F4X\_ @V<3=8B;_>4
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M">:OP>:RD4A+(61)8F<$&B<PFJ*90F?[S-@W-AN_H9Y1)&D%)J:-NJ9 [26
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MGEVR_Y(<I48&S4B9JKGRO Y9*-J$>I8#W;A;!7+F>,^[WO?.]R2O^RS9^0P
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M_?=_ ?CHQG=X\7>SSC> $3B!%7B!&;B!(Q?UB+> &TI_';B"+?B",3B#^W>
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:>J$9NJ$=^J$A.J(E>J(INJ(M^J)+."   #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
